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5Preface
Those who know me the longest, know that my interest in prosthetic joint infections was born 
many years ago when I was still taking my first steps as an orthopedic resident. As many things 
in life, I think it happened by accident… 
I was confronted with a series of patients suffering with infected total joint replacements and 
I witnessed my colleagues struggling hard to try and treat them and not often succeeding. 
Then I operated on D. Natalia, a very nice but extremely obese patient that I followed on the 
outpatient clinic after her total knee replacement. She presented persistent wound leakage and 
despite being prescribed antibiotic therapy she progressively worsened. I closely witnessed 
as she went through a long calvary of surgical debridements and prolonged periods of IV 
antibiotics followed by removal of the implant, a few more debridements and then ultimately 
a knee fusion! This patient really opened my eyes to this problem as I witnessed her downfall 
from being an active working women to a disabled woman struggling to walk with crutches…
I started reading and researching and I reached a point where I was able to identify a lot of 
common mistakes that were being made on a daily basis. 
In order to systematically address this problem, I retrospectively looked at our institution’s 
experience in dealing with prosthetic joint infections between 2001 and 2007. Out of 69 cases, 
only 30 were successfully treated! I undertook an extensive literature review and proposed a 
number of changes to our practice. I was lucky enough to see my work acknowledged and I 
continued to make clinical research on this topic throughout the years.
When I finished my residency, I had already set the scene for continued clinical research and 
transforming it into a PhD dissertation was but a natural event. My only condition was that I 
wanted it to be all about clinical research. At the end of the day, what I am really interested 
about is what can I do to improve the outcome of patients afflicted by prosthetic joint infections. 
Now that it ends, I am sure the work must continue. There are still a lot of gray or even black 
areas in our current knowledge. Much of this needed understanding will certainly be born out 
of present and future cooperation with basic science researchers. Whereas our diagnostic 
accuracy and treatment results improved significantly in the past few years, the search for 
reliable diagnostic and treatment alternatives while providing a more comfortable and less 
disturbing experience to the patient is the next priority.
6Acknowledgments
Naturally, a work of this span would not have been feasible without the help of many people 
that I must thank.
First and foremost, I would like to thank Professor António Oliveira. Long before I was even 
considering a PhD he had the vision to acknowledge me. I imagine it was not easy for a Head 
of Department to have a “kid” point out to an existing problem in such a sturdy way. I always felt 
encouraged to question the status quo and pursue the search for further know-how even if it 
meant leaving abroad. If there are conditions in our department to advance scientific research 
regardless of classic beliefs and traditions, it is greatly thanks to him. I also think I could not 
have made a better choice for my supervisor. I thank him deeply for helping me keep things in 
perspective whenever I got lost in the fine print. Lastly, I cannot thank him enough for all the 
times he proved his belief in me and my work and for all the occasions he helped promote it.
I would also like to deeply thank Professor Alex Soriano. We have come a long way since we 
met in 2010 and I had the chance to learn a lot about PJI management visiting his Bone and 
Joint Infection Unit. Not only is he a never-ending source of knowledge regarding prosthetic 
joint infections but he is also always glad to share his love for scientific research in this field. 
Thank you for greatly contributing for the success of the work we have been performing.
To Professor Maria Pia Ferraz I would like to thank her for introducing me to the world of basic 
science research, especially in the field of infection resistant implant surfaces. I hope we can 
further improve our cooperation and bring new developments to the clinical setting.
I also need to thank all those within my department that have endured me throughout the years. 
To Dr. Seabra Lopes a special thank you for always believing and trusting me and my work. 
I know he was fearful of taking on this endeavor within his group, because tradition implied 
these were difficult to treat cases that one would be better of avoiding. He always knew how to 
give me just the right amount of autonomy while always being there for support when I needed. 
To Dr. Costa e Castro for being a most helpful reviewer of all my papers since the beginning. 
Thank you for your always pertinent comments and insights.  
To Dr. Joaquim Ramos for being there to help me in more complex hip surgeries whenever I 
asked him. Results would not have been the same without him.
To Dr. Alexandre Pereira, a colleague and a real friend of many battles.
7To all other colleagues that were kind enough to cooperate and accommodate my requests as 
well as those who trusted me to treat their cases. Without them I could not have gained much 
needed experience.
To all my junior colleagues that so willingly helped me collect, organize and process data. 
Without their help, it would not have been possible to perform the same amount of scientific 
output over the last few years.
To all the nurses of the Orthopedic Department, especially those in our outpatient clinic, for 
gladly embracing the added work load with a smile.
Although the main focus of this work was in the Orthopedic Department, it would not have been 
possible without the cooperation of several others. 
To Dra. Inês Amorim from the Nuclear Medicine Department who believed and encouraged 
since early on.
To Dra. Maria Helena Ramos, Dra. Ana Paula Casto, Dra. Claudia Santos, Dr. Paulo Pereira, 
Dra. Virgínia Lopes and all other staff of the Microbiology Department for always seeking to 
accommodate our relentless and increasing demands.
To Dr. José Carlos Oliveira and his staff of Clinical Chemistry in the Clinical Pathology 
Department for your huge cooperation and help in evaluating synovial fluid biomarkers.
I would also like to sincerely thank Dra Joana Dias for all her statistical work over the years. 
If it wasn’t for her support, know-how, thoroughness, patience, perseverance, and most of all 
endless hours spend with this research, our findings would certainly not have been as 
respectable.
Last but certainly not least, a few words to my loving family. I could not have made it here 
without their great sacrifice over the years. Thank you for everything! To my brother, a friend 
for every occasion. To my mother who never ceases to take care of me even when I am at my 
worst. To my father: Wherever you are, I am sure you can be proud of me now…
They say behind every great man there’s a great woman and I am sure that whatever degree 
of greatness there might be in me, I owe it all to the women in my life. Ana, I cannot thank you 
enough for patience, encouragement, help, understanding, etc. In a word, love! Thank you, 
Clara, Joana and Teresa for being the sunshine of my life!
8Abstract
Prosthetic joint infection is probably the most dreadful complication after total joint arthroplasty.
It is indisputably a source of significant deleterious impact on a patient’s health status and 
quality of life.
Prophylaxis is challenging because the implant greatly reduces the number of bacteria needed
to cause a clinically relevant infection. There is no single measure able to completely 
eradicate it. Despite modern operating room environment and rigorous aseptic procedures 
there is still a growing rate of infection after elective total hip or knee arthroplasty. The patient
itself as a source of bacterial endogenous contamination has become focus of attention 
recently. A positive co-relation between being S. aureus carrier and risk of infection as well as 
a positive impact of preoperative decolonization has been shown in different fields of surgery. 
Less information is available about asymptomatic bacteriuria and its possible influence on 
surgical site infection rates. We further studied these questions by analyzing the real impact 
in reducing prosthetic joint infection rates of preoperatively screening and treating S. aureus 
carriers and/or patients with asymptomatic bacteriuria.
Regardless of every progress made on prophylaxis, there will always be a small proportion 
of total joint arthroplasties that will need revision surgery. Distinguishing between septic and 
aseptic prosthesis failure is often difficult. There is no 100% accurate diagnostic modality. 
Definitive diagnosis relies on the combined interpretation of several different parameters and 
often it may only become clear after surgery.  Notwithstanding, correct preoperative diagnosis 
is critical as treatment differs significantly. Despite its known limitations, arthrocentesis and 
subsequent synovial fluid examination is probably the most informative test currently available. 
We proposed to further refine the diagnostic accuracy of preoperative joint aspiration by more 
exhaustively studying synovial fluid biomarkers. In addition to leukocyte count and differential, 
we focused on simple, readily available and inexpensive molecules that could easily make the 
transition into clinical practice such as synovial C-reactive protein and Adenosine Deaminase.
Once a proper diagnosis is reached, correct treatment is mandatory. Managing prosthetic
joint infections is fastidious and often unrewarding as the results have been traditionally 
unfavorable. Although some centers of excellence are able to show reasonably satisfying 
success rates, that is not often true in day-to-day practice of many other institutions as was 
previously our own case. We sought to validate a rational and evidence-based approach 
by treating infected cases strictly according to a predetermined protocol that proved to offer 
significant improvements in treatment success rates.
9Resumo
A infeção é provavelmente a complicação mais terrível após a realização de uma artroplastia. 
É indiscutivelmente fonte de significativo impacto sobre o estado de saúde do doente e sua 
qualidade de vida.
A profilaxia é um desafio porque a presença do implante reduz significativamente o número 
de bactérias necessário para causar infeção clinicamente relevante. Não existe nenhuma 
medida isolada capaz de erradicá-la completamente. Apesar do moderno ambiente do bloco e 
procedimentos de assepsia rigorosos, existe ainda uma taxa crescente de infeção após 
artroplastia eletiva da anca ou joelho. O próprio doente como fonte de contaminação 
bacteriana endógena tornou-se foco de redobrada atenção recentemente. Uma correlação 
positiva entre ser portador de S. aureus e risco de infeção, bem como um impacto positivo da 
descolonização pré-operatória tem sido demonstrada em diferentes campos cirúrgicos. Menos 
informação está disponível sobre bacteriúria assintomática e sua possível influência nas taxas
de infeção do local cirúrgico. Estudámos estas questões, analisando o impacto real na 
redução das taxas de infeção protésica do rastreio e tratamento pré-operatório de portadores
de S. aureus e/ou doentes com bacteriúria assintomática.
Independentemente do progresso feito na profilaxia, haverá sempre uma pequena proporção
de próteses que necessitarão de cirurgia de revisão. Distinguir entre falência séptica e 
asséptica é muitas vezes difícil. Não há nenhuma modalidade de diagnóstico 100% exata. 
O diagnóstico definitivo baseia-se na interpretação conjunta de vários diferentes parâmetros 
e muitas vezes só após a cirurgia de revisão fica claro. Não obstante, o correto diagnóstico
pré-operatório é fundamental, uma vez que o tratamento é significativamente diferente. Apesar 
de todas as limitações conhecidas, a artrocentese e subsequente exame do líquido sinovial
é provavelmente o exame mais informativo atualmente disponível. Propusemo-nos refinar 
ainda mais a sua capacidade diagnóstica, estudando exaustivamente os biomarcadores 
existentes no líquido sinovial. Além da contagem diferencial de leucócitos, concentramo-nos em 
moléculas simples, generalizadamente disponíveis e baratas que poderiam facilmente fazer a 
transição para a prática clínica, como a proteína C-reativa sinovial e a Adenosina-deaminase.
Uma vez feito o diagnóstico, é necessário passar ao tratamento. Lidar com infeções 
periprotésicas é trabalhoso e muitas vezes pouco gratificante dado que os resultados têm sido 
tradicionalmente desfavoráveis. Embora alguns centros de excelência sejam capazes de 
mostrar taxas de sucesso razoavelmente satisfatórias, isso não é frequentemente o caso na 
prática quotidiana de muitas outras instituições como era anteriormente o nosso próprio caso. 
Procuramos validar uma abordagem racional e baseada na evidência, tratando os casos 
infetados estritamente de acordo com um protocolo pré-determinado que provou oferecer 
melhorias significativas nas taxas de sucesso do tratamento.
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I.  BACKGROUND
Burden of Infection
Prosthetic join infection (PJI) widely acknowledged as the most feared complication after total 
joint replacement. In addition to significant medical implications for the patient it is also the 
source of substantial burden for the health care systems.
Epidemiology
PJI is fortunately, a relatively uncommon event. Despite all the attention that has been 
dedicated to this topic over the last few years, it is still very challenging to offer an undispu-
table estimate of its real incidence. Traditionally, contemporary PJI rates vary between 1-3% 
for primary total hip (THA) or knee arthroplasty (TKA) and higher, around 3-6% for revision 
surgery1. The rate of surgical site infection after joint replacement is of course, highly variable 
and institution specific. Since 2009, we established a prospective department surgical site 
infection (SSI) surveillance program focusing on infection rate after primary total hip or knee 
arthroplasty (Fig. 1).
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We adopted the Center for Disease Control (CDC) recommendation to extend the surveillance
period to 365 days following procedures that involve implantation of prosthesis to define 
our surgical site infection rate. We registered a trend towards increasing number of primary 
total joint arthroplasties (TJA) being performed each year and found that the overall infection 
rate during this six years’ time period was 2.0% (44/2213). THA presented a somewhat lower 
infection rate compared to TKA, 1.5% (15/979) and 2.4% (29/1234) respectively. Revision 
Fig. 1 Volume of primary arthroplasties (THA and TKA) and one year infection rate of our institution between 2009 and 2014.
17
arthroplasty infection rate was calculated for the 2012-2014 period, and it was 6.4% (6/98) 
overall. Interestingly, revision THA infection rate was higher than revision TKA, 7.8% (5/64) vs. 
2.9% (1/34) respectively. None of these differences reached statistical significance.
Conventional institutional surgical site infection surveillance, focuses chiefly on infections 
detected at the hospital where the operation was performed. Infections diagnosed and treated 
elsewhere can consequently be missed. A paper by Yokoe et al.2 determined a statewide PJI 
infection rate using data submitted from every acute care hospitals in California. Out of a total 
of 91,121 THA and 121,640 TKA procedures, and using ICD-9-CM diagnosis codes predictive 
of SSI, they found 2214 (2.3%) THA and 2465 (2.0%) TKA presented with infection in the first 
postoperative year. They further found that seventeen percent of SSI would have been missed 
by operative hospital surveillance alone2. Registries might theoretically be a way to more 
accurately report infection rates but that does not seem to be the case3-5. In a recent study from 
Denmark by Gundtoft et al.3 the authors’ found that using several available data sources, the 
estimated “true” 1- and 5-year incidence of PJI following primary THA was 0.86% and 1.03% 
respectively. They found that based solely on national registries, incidence of infection was 
consistently 40% lower. 
Notwithstanding these limitations and despite the increased awareness and prophylaxis 
efforts, the incidence of infection seems to be on the rise. On a study based on the Nordic 
Arthroplasty Register Association (NARA) dataset of 432,168 primary THA from 1995 to 2009, 
Dale et al.6 found an increasing risk of revision due to infection over time that could not be 
explained by change in registered risk factors. On the American side, the same phenomenon 
seems to be happening. Kurtz et al.7 found 159,360 procedures for infected hip (54,292) 
and knee (105,068) replacements in United States (US) hospitals between 2001 and 2009. 
They confirmed there was a significant year-to-year increase in the risk of both hip and knee 
infection over the study period even after adjusting for patient demographic factors.
In addition, it is well established that prosthetic joints are at risk for infection during their entire 
lifespan. Late infections occurring many years after index surgery are becoming more common
as the number of people living with some kind of total joint arthroplasty is on the rise. Ong 
et al.8 determined the risk of PJI in a cohort of 39,929 primary total hip arthroplasty patients 
identified between 1997 and 2006. The incidence of infection was 1.6% within 2 years and 
0.6% between 2 and 10 years. A recent Finnish study by Huotari et al.9 including 112,708 
primary hip and knee replacements, found that the rate of late infections (i.e. occurring over 
24 months after index surgery) was approximately 0.1% per prosthesis-year. Moreover, the 
incidence rate of late and very late PJI also seems to be increasing over time9. 
As the requirements for total joint arthroplasty have been and are expected to continue steadily 
increasing so will the burden of infection10,11. Even though infection rate is relatively low, the 
increasing prevalence of population living with some kind of total joint arthroplasty equates to 
a sizeable number of infections.
Prophylaxis, Diagnosis and Treatment of Prosthetic Joint Infections  Burden of Infection
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Patient Quality of Life
PJI is traditionally depicted as a devastating complication, that may potentially inflict signifi-
cant morbidity in the patient’s quality of life or even cause death in some instances. There is 
however scarce information in the literature regarding quantity and quality of life in these patients. 
Berend et al.12 studied 205 infected THA treated with a two-stage protocol. They found that 
despite a high rate of infection control there was a high mortality rate. Fourteen patients (7%) 
died before reimplantation and two (1%) were not candidates because of medical comorbidities.
The 90-day mortality rate after the first-stage was 4% (eight patients). Overall, 91 patients 
(48%) died during the study period that extended between 1996 and 2009. Choi et al.13 in-
vestigated mortality rates after revision total hip arthroplasty in 93 infected patients and 93 
matched control patients. They found the mortality rate was 33% (31/93) in the septic group 
and 22% (20/93) in the aseptic group at 5- and 6-year follow-up, respectively. The same authors 
performed a similar study focusing on 88 infected TKA patients and controls14. They found 
the overall mortality after revision TKA was 10.7% at a median of 4 years of follow-up. Most 
importantly, mortality after septic revision (18% - 16/88) was six times higher than that of 
aseptic revision (3% - 3/88)14. In a study by Zmistowski et al.15 the authors compared the 
outcome of 436 PJI patients with 2342 patients undergoing revision arthroplasty for aseptic
failure and aimed to determine the effect of periprosthetic joint infection on mortality. PJI 
was associated with a fivefold increase in mortality even after controlling for other variables. 
Mortality in the PJI cohort was 3.7% at ninety days, 10.6% at one year and 25.9% at five years. 
These figures compare unfavorably to some of the most frequently dreaded cancers such as 
female breast and uterus and male prostate cancer16. Of course, this increased risk of mortality 
is not only due to direct adverse effect of infection and treatment, but also the fact that PJI often 
reflects decreased health status. Nevertheless, these figures should raise awareness among 
surgeons to the systemic impact of infection and the need to address PJI in two dimensions 
that are tightly interconnected: infection eradication and general health status. 
There is extensive evidence that successful total joint arthroplasty greatly increases the 
patients’ quality of life regarding function, pain and mobility17. However, quality of life studies 
after PJI are surprisingly scant in the literature. Cahill et al.18 were among the first to 
address this issue. They compared 62 uncomplicated TJA with 34 PJI cases and naturally, 
found that infection reduces patient satisfaction and seriously impairs functional health status
and health-related quality of life. Unfortunately, no information regarding infection control 
status was given. Helwig et al.19 were able to evaluate 58 patients with PJI and applied 
the Short Form Health Survey 12 (SF-12) as to their overall quality of life. They did find a 
significant disadvantage in the physical scale but not the mental scale in this cohort compared 
to the general German population. Surprisingly they found no significant difference in either 
scale when comparing successful vs. unsuccessful therapy19. The authors did not differentiate
between those treated with debridement and implant retention and one- and two-stage 
revision protocols. Patil et al.20 compared clinical outcomes and patient satisfaction rates of 
aseptic (30) versus septic (15) revision TKA. Interestingly, patients operated for infection had 
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better post-operative Knee Society Scores (KSS), Function Scores and SF-36 Mental Scores 
than aseptic group but there were no significant differences in the satisfaction rates. Just 
recently, Aboltins et al.21 prospectively collected pre- and post-arthroplasty data of 2,134 TJA 
patients, of which PJI occurred in 41. PJI cases treated with debridement and retention had a 
similar improvement from pre-arthroplasty to 12-months post-arthroplasty as patients without 
PJI in quality of life according to the SF-12 survey. The analysis however did not evaluate 
the potential influence of the infecting pathogen. Núñez et al.22 evaluated 24 patients who 
underwent debridement and retention of the prosthesis due to an acute knee PJI and were 
in remission after 12 months’ follow-up. Health-related quality of life was measured using 
WOMAC and SF-36 at baseline (before TKA), 12 and 24 months after antibiotic treatment 
discontinuation. There was a significant improvement in all items from baseline to 48 months 
except for patients infected by Staphylococcus aureus who had significantly worse outcomes. 
Our own experience reflects these observations. In a retrospective case-control study we 
focused on patients that underwent debridement with implant retention for suspected acute 
postoperative infection of total hip or knee arthroplasty between 2010-2014. Using validated 
patient reported outcome measures, Hip disability and Osteoarthritis Outcome Score (HOOS) 
or Knee injury and Osteoarthritis Outcome Score (KOOS), that include a joint related quality of 
life subscale, we were able to show no difference between 19 successfully treated cases and 
38 uncomplicated TJA controls available for functional evaluation after 12 months’ minimum
follow-up. Regarding revision surgery, we studied 11 patients undergoing TKA two-stage 
exchange for infection and also found that function and quality of life as measured by the 
KOOS questionnaire was not inferior to a control group of five one-stage revisions for aseptic
failures and four complex primary TKA using the same condylar constrained prosthesis. 
However, our own previously published paper on recalcitrant TKA infection salvage 
procedures shows inferior results in all KOOS sub-scales including quality-of-life23. 
Although more studies are needed to fully clarify the extent of the impact of PJI on patients’ 
quality of life it is undeniable that it must be a concern for surgeons. It would seem that early
detection of infection and successful treatment with debridement and implant retention is 
perhaps the more advantageous course of treatment. Revision surgery (regardless of the 
cause of failure) seems to have a more significant impact. Failure in eradicating infection or 
salvage procedures naturally leads to more deleterious effect on health-related quality of life.
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Economics
In addition to the clinical implications, PJI management also represents a substantial 
economic burden for hospitals, health-care systems and most importantly, patients. Infection 
is consistently one of the leading causes for total joint revision surgery all over the world24-32. It 
is often the first or second most common indication for revision total knee arthroplasty24,28,29,31 
and the third most common in revision total hip arthroplasty after aseptic loosening and 
dislocation27,29,33,34. It is also a leading cause for failure of other prosthesis, specifically 
shoulder, elbow and ankle33,35.
The real cost of treating an infected joint is not easy to ascertain. Naturally, it depends on a lot 
of variables such as the specific type of treatment, patient co-morbidities and even bacteria
related factors such as antibiotic susceptibility profile. The full spectrum of economic impact 
comprises the more commonly reported direct in-hospital costs, but also outpatient direct 
costs (follow-up visits, rehabilitation, pharmacy, etc.)  and even indirect costs that are virtually 
impossible to accurately assess such as productivity loss and absenteeism from work of the 
patient or even his caregivers.
Kurtz et al.7 including over 150,000 PJI cases, found that the average total hospital costs for 
infected hip revision were $72,700 United States dollars (USD) in 2001 and $93,600 USD in 
2009. The average charges for infected knee revision were $58 700 USD in 2001 and $74 900 
USD in 2009. More recent studies from the US include not only inpatient but also outpatient 
services costs. In 2014, Kapadia et al.36identified 21 infected TKA and matched them to 21 
non-infected patients who underwent uncomplicated primary surgery. Naturally, patients with 
PJI had significantly longer hospitalizations, more readmissions and more clinic visits. The 
mean total episode cost (fixed- and variable-direct costs) for patients with a surgical site 
infection was $116,383 USD (range, $44,416 to $269,914) which was significantly higher than 
a mean $28,249 USD (range, $20,454 to $47,957) in the matched group. Just recently the 
same authors, studied 16 consecutive infected THA and matched them to 32 non-infected 
patients. Similarly, the mean episode cost was significantly higher in the infected group, 
$88,623 USD (range, $44,043-$158,202) when compared to the matched cohort, $25,659 
USD (range, $13,595-$48,631). Naturally, specific cost varies dramatically from one setting 
to another depending on the type of healthcare system and the corresponding economic 
standards. Fernandez-Fairen et al.37 performed a systematic review of the literature and found 
huge discrepancies in absolute values between publications according to its country of origin. 
Nonetheless, the cost for septic revision was consistently around 2-4 times more expensive 
than primary surgery. It was also 1.5-3 times more expensive than aseptic revision surgery. 
Early acute and hematogenous PJI cases can be treated effectively without revision surgery. 
An Australian study by Peel et al.38, aimed specifically to calculate the cost associated with 
debridement and implant retention treatment. For that, they focused on 21 prosthetic joint 
infections (12 THA and 9 TKA) and matched them to 42 control patients with uneventful 
primary joint replacements. For patients with infection the total cost, including index operation 
and costs of PJI management was 3.1 times the cost of primary arthroplasty. The mean cost 
for cases was Australian dollars (AUD) $69,414 compared with $22,085.
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We performed a similar economic analysis in our own institution, focusing exclusively on 
inpatient costs. Variables included were Hospital Bed costs, Pharmacy including antibiotics, 
Laboratory, Radiology, Blood products, etc. and Operating Room costs including orthopedic,
anesthesia and nursing personnel as well as costs with implants, medications, surgical 
supplies and post-operative recovery bed. Unfortunately, we were not able to collect data for 
outpatient and emergency department visits as well as other outpatient direct and indirect
costs. During the study period (January/2014 – December/2015), our mean total cost on 
uneventful 459 TKA and 256 THA was 3,618€ and 3,230€ respectively. Debridement and 
implant retention was the chosen method of treatment in 16 patients (8 TKA, 8THA) and their 
mean cost was 4,009€ and 5,431€ respectively which is around 2-2.5 times higher when 
compared to uneventful knee and hip joint replacement. 
We also determined the mean cost for aseptic revision and compared it to two-stage revision
for infected joints. Overall aseptic hip revision mean costs were 6,324€. Aseptic partial hip 
revisions were performed in 17 cases and averaged 5,994€ and total (both components) 
revision was performed in 4 cases with a mean cost of 7,730€. There were 13 aseptic total 
knee revision cases costing a mean 7,985€ each. Two stage revision is the preferred method 
in our department and it was performed in eight infected TKA and six infected THA during the 
study period. Taking into account both admissions, the overall mean cost was 12.551€ for 
knees and 11.415€ for hips. These costs are around 3.5 times higher than primary uneventful 
arthroplasty and 1.5 times the cost of revision for causes other than infection. To the best of our 
knowledge this is the only such study performed on the cost of PJI treatment in the Portuguese 
National Health System. 
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Biofilm	and	its	Implications
Lastly, it is not possible to discuss all the nuances and difficulties surrounding prosthetic 
joint infections without first examining the role of microbial biofilms. In order to comprehend 
implant-related infections, one has to acknowledge a new microbiology paradigm. The classical
view that bacteria grow as rapidly replicating free-floating individuals in a planktonic form 
causing vigorous host inflammatory response does not apply. It has been extensively shown 
that in most environments, including the human body, microbes grow predominantly in 
biofilms. Over 65% of all human infections are estimated to be biofilm-related39. Although 
bacterial growth on surfaces has been described earlier, it was not until the extensive research
performed by J.W. Costerton that it gained prominence in the scientific community39. More 
than three decades ago, Gristina & Costerton40 promoted the idea that microbial biofilms 
were responsible for increased susceptibility to infection in the presence of biomaterials and 
constitute a significant factor in the persistence of such infections until the removal of the 
prosthetic device. Since then, a considerable amount of research has supported this concept41.
Biofilms are highly structured usually adherent communities of microbial cells (of one or several
different species) that express different phenotypes than its planktonic counterparts. They 
further produce extracellular matrices consisting mainly of exopolysaccharides, proteins, 
teichoic acids and lipids that surround them allowing for cell-to-cell communication and 
creating a protected environment42. In their fully mature form, biofilms act almost as multicellular 
organisms with each cell assuming a specific role and communicating with each other - the 
so called “quorum sensing” - thus combining efforts to protect themselves against the hostile 
environment around them43.  
Accordingly, the development of a biofilm onto an orthopedic implant can be described as a 
four stage process44: 1) cell adhesion - starts immediately during surgery with the bacteria
reaching the implant surface. This process is mediated by factors such as implant surface 
charge, hydrophobicity and topography as well as interaction between bacterial and host 
proteins; 2) cellular aggregation - in this stage, there is bacterial proliferation as well as cell-to-cell
 adhesion that ultimately lead to the formation of bacterial micro colonies. These organized 
structures are then surrounded by self-produced extracellular matrix or slime. At this point, the 
biofilm is still relatively unstable and susceptible to eradication; 3) biofilm maturation - during 
the maturation process, physiologic changes occur within the biofilm and bacteria express
altered phenotypes beneficial to microbial survival with distinct gene expression patterns 
and metabolic activity according to its specific location within the biofilm structure. When the 
biofilm is mature, it assumes a sessile form which is more resistant to eradication; and 4) cellular 
detachment - large mature biofilms may release planktonic forms (or small pieces of biofilm) 
of their surfaces which then disperse to cause further local invasion or seeding to distant sites. 
The presence of microbial biofilms in orthopedic implants are a real game-changer and 
understanding this microbial biofilm paradigm is critical in developing an accurate PJI 
management concept. 
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Prophylaxis
Prevention remains the best way to avoid the dire health-related and economic consequences 
of infection after TJA. Still, there is no isolated preventive measure that can fully eradicate 
PJI. The presence of the implant greatly reduces the minimal inoculum of bacteria required to 
cause relevant infection and as such, effective prophylaxis must rely on the combined action of 
numerous strategies. Various different events that ultimately lead to clinically relevant infections
such as surgical field contamination, adhesion and proliferation of bacteria on the implant 
and host-pathogen interaction need to be addressed. The operating theatre is the primordial 
moment along this process but prevention of PJI must start before and continues well after. 
Reviewing the whole body of literature concerning the prevention of surgical site infection is 
perhaps beyond the scope of this thesis. We will focus on current and relevant evidence and try 
to provide concise clinical practice oriented information on various preoperative, intraoperative
and postoperative factors regarding the prevention of PJI specifically. 
Ultimately, it is not possible for the orthopedic surgeon to manage all these variables on 
its own, patients should be advised and a multidisciplinary team should seek to optimize 
conditions before elective joint replacement surgery. It has been proven that such a team is 
able to implement strategies that effectively reduce PJI rates45. Meanwhile, every surgeon 
must keep in mind that despite all the recent progresses in prophylaxis, there is no substitute 
for careful surgical technique.
Preoperative Considerations
The first step towards effective prevention of PJI is preoperative risk stratification. Knowing 
each patient’s specific risk of infection would be ideal in terms of preoperative decision making 
and counselling. Several epidemiological and intrinsic patient factors closely relate to the risk of 
infection. Males for instances have been shown to be at greater risk in a recent meta-analysis46.
 Revision surgery or simply previous joint surgery (e.g. posttraumatic situations), previous 
history of joint infection, prior steroid injection into the joint or history of bone cancer are also 
known risk factors that are simply not influenced47-51. While it is not possible to sway such 
factors, they are helpful in establishing a specific risk of infection for each patient that ultimately 
allows for better preoperative decision making, resource allocation, and enable more effective 
patient counselling52,53. 
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Prevention efforts should focus on those known yet modifiable patient risk factors. Some are 
straightforward such as treating active or potential septic focus (e.g. pneumonia, infected 
leg ulcers) before surgery, but others require considerable commitment such as nutritional 
optimization and management of medical comorbidities. Screening for potential sources for 
endogenous contamination such as Staphylococcus aureus colonization or unrecognized 
bacteriuria has also been advocated. We will further elaborate on these topics elsewhere as 
they were the subject of our research.
MEDICAL RISK FACTORS
Countless patient-related factors have been implicated in the increased risk of PJI. Associated
chronic co-morbidities such as heart failure, pulmonary disease, renal or liver disease, 
coagulopathies, rheumatologic arthropathy, etc. cannot be eliminated preoperatively but can 
and should be optimized in order to mitigate the risk of postoperative complications47,54-56. There 
is strong evidence that overall health status and greater illness severity is an independent risk 
factor for infection46,55,57. 
Diabetes 
It is well-established that diabetic patients often present delayed wound-healing and a 
disordered inflammatory/immune response. It is therefore not surprising that they are at 
increased risk for infection after TJA48,54,55. Recently, it has been shown that the current status
of glycemic control is more predictive than simply having a diabetes diagnosis. Marchant et 
al.58 found not only a twofold greater risk of infection in patients with uncontrolled diabetes
compared with nondiabetics but more interestingly an identical risk of infection between 
patients with controlled diabetes compared to the nondiabetic population.
Ideally one should strive to reach a good consistent glycemic control as measured by glycated 
hemoglobin below 7-8%. Several papers have confirmed the increased risk of infection above 
that threshold58-63. Nevertheless, in clinical practice some patients are simply unable to reach 
such a good control59 and a risk-benefit decision should be made on an individual basis. As will 
be discussed ahead, proper close postoperative glucose control may be just as important and 
should not be disregarded especially in diabetic patients. Perioperative hyperglycemia is also 
associated with increased risk for infection even in patients without diabetes61,62.
Obesity
Although it is not easily influenced, obesity is very common in total joint arthroplasty candidates
and some considerations are mandatory. Not only has it been repeatedly found to be an 
independent risk factor for infection48,49,54-57,64 but it is also associated with increased risk of 
other comorbid conditions such as diabetes and cardiovascular disease. A somewhat linear 
relation seems to exist between increased body mass index (BMI) and the risk of infection. A 
few papers have shown, that more elevated BMI categories seem to have increasingly higher 
risk of PJI46,48,55,65. Lubbeke et al.66 clearly illustrate this trend. In their recent study including 
over 9,000 primary hip and knee arthroplasties, infection rates were similar in the first three 
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BMI categories (< 35), but they were twice as high with BMI 35-39.9 and four times higher with 
BMI ≥ 4066.
It therefore seems logical that patients should be strongly advised to lose weight before TJA. 
There are some reports showing more favorable outcomes if bariatric surgery is performed 
before TJA, especially if more than two years have passed67-69. Notwithstanding, there is no 
clear evidence to support or refute the use of bariatric surgery prior to arthroplasty has a 
positive effect on postoperative complications such as PJI or even on the long-term clinical 
outcome and quality of life is yet to be proven70. Naturally it is important that both the patient 
and the surgeon discuss infection as a possible outcome when weight loss is not feasible. 
Malnutrition 
From a nutritional perspective, it is desirable that patients presenting for total joint arthroplasty 
have a lymphocyte count of >1500 cells/mL, an albumin level of >3.5 g/dL and a transferrin 
level of >200 mg/dL. The negative influence of preoperative malnutrition below these thresholds
has long been recognized71,72. There is enough evidence to show multiple nutrient-enhanced 
formulas can be used to prevent surgical site infections in adult patients undergoing major 
surgery73. However, the use of enhanced nutrition support is expensive and requires additional 
expertise from nutritionist and/or pharmacists. Except for elderly patients with femoral neck 
fractures, such debilitated patients are extremely rare in the total joint arthroplasty setting.
Preoperative anemia is also often associated with poor nutritional status and it has also been 
shown to be an independent risk factor for infection54,56. Prior studies have also shown that 
these patients are more likely to require blood transfusions postoperatively74,75  which are 
associated with an increased risk of infection as will be discussed later. Although prospective 
studies are still missing to confirm the real benefit of improving hemoglobin before surgery we 
believe it is a reasonable recommendation.
Tobacco use
Cigarette smoking increases the risk for perioperative complications, soft-tissue and 
wound-healing complications and ultimately musculoskeletal infection76. Singh et al.77 analyzed
data from over 33,000 patients who underwent elective primary lower limb joint replacement. 
They found that current smokers at the time of elective surgery were more likely to have 
postoperative complications, especially surgical site infections and pneumonia and suggested 
preoperative smoking cessation programs should be considered. Although cessation is easier 
said than done, the effects of smoking on the skeleton may be (at least partially) reversible and 
that should encourage patients. Immune function appears to recover after two to six weeks 
of abstinence and wound-healing after three to four weeks76,78,79. The benefits of preoperative
smoking cessation interventions in reducing postoperative complications have been well 
established with each week of cessation prior to surgery increasing the magnitude of effect80-82. 
Moller et al.83 conducted a randomized trial specifically before hip and knee replacement. They 
found a decrease in overall complication rate, especially wound-related complications after a 
preoperative  6-8 weeks smoking cessation intervention83. 
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Alcohol Abuse
Patients who consume alcohol on a frequent basis may have a significantly increased risk 
for postoperative complications after arthroplasty84. Although the benefit of alcohol cessation 
programs before surgery is not well established in the literature, it is reasonable to expect 
patients to reduce alcohol consumption prior to surgery and to delay elective arthroplasty in 
alcoholic patients until the issue has been addressed85.
Immunosuppression
Immunosuppressive therapy is becoming increasingly common among TJA candidates. 
End stage inflammatory arthritis (rheumatoid arthritis being the most frequent) is a common 
indication for joint replacement. These patients are fundamentally different from osteoarthritis
in terms of pathogenesis and it is therefore natural to expect these patients would have 
increased infection rates. In fact, many have found rheumatologic disease to be an independent
risk factor for PJI for both the THA and TKA46,54,56,86,87. Organ transplant recipients are also 
becoming more common candidates to TJA due to degenerative osteoarthritis or osteoporotic-
related disease (e.g. hip fractures) as survival rates after transplant surgery are improving. 
Naturally these patients have increased risk of infection and other perioperative complications
due to inherent medical co-morbidities and immunosuppressive medication51,53,88. This risk 
however seems to be much more significant in knees rather than hips although the reason for 
such a discrepancy remains unclear88.
Immunosuppressive medical therapy with corticosteroids, disease-modifying anti-rheumatic 
drugs and other drug(s) are often blamed for this risk. Still, evidence regarding the benefits
of therapy discontinuation before surgery is conflicting89,90 and recommendations are also 
contradictory. Considering the scarce evidence to support discontinuation of treatment and 
even potential harm it may cause such as the risk of flare-up of the underlying condition, 
recently issued World Health Organization (WHO) guidelines on preoperative measures 
for surgical site infection prevention state immunosuppressive medication should not be 
discontinued routinely73. On the other hand, the International Consensus Meeting (ICM) on PJI 
advocates disease-modifying agents should be stopped prior to elective joint replacement85. 
Decision to discontinue immunosuppressive medication should be made on an individual basis 
and involve the prescribing physician.
Human Immunodeficiency Virus (HIV) carriers constitute another group of patients with 
compromised immune system that, given their increasing long-term survival and high rates 
of osteonecrosis are increasingly being considered for TJA as symptom relief and functional
outcome seem to overlap those found in general population91. As HIV medical management, 
together with educational strategies continues to improve, the risk of PJI seems to be much 
lower than earlier studies stated. More recent studies suggest that HIV-positive patients without
medical comorbidities or other risk factors (e.g. intravenous drug users or hemophiliacs) may 
have postoperative complication rates similar or only slightly higher than uninfected patients91-94. 
Appropriate candidates must have CD4 T lymphocytes counts greater than 400 cells/ml and 
undetectable viral load85.
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Oral Hygiene
Although it is well established that seeding from a remote source of infection can lead to PJI 
there is still much debate regarding the use of active preoperative screening and treatment
of dental pathology to ensure adequate oral hygiene as an effective measure to prevent 
postoperative bacteremia and PJI in all patients undergoing TJA. Barrington et al.95 showed 
23% of TJA candidates had dental issues requiring treatment preoperatively. However, there is 
no evidence to support routine screening and treating all patients for every dental abnormality.
Still, signs and symptoms of active dental infection should be sought and treated before 
elective joint replacements85.
STAPHYLOCOCCUS AUREUS SCREENING
Staphylococcus aureus is a major pathogen implicated in PJI all over the world. In our own 
experience it was involved  in around half the cases96. About 20-30% of the general orthopedic 
population is S. aureus carrier and the anterior nasal cavity is the main site of colonization97,98. 
It has been extensively shown that patients who carry it in their nasal flora are at increased 
risk for infection in a multitude of clinical scenarios including orthopedic surgery97,99-103. There is 
also evidence that among carriers who develop S. aureus surgical site infection there is great 
individual concordance between nose and surgical site isolates confirming for the importance 
of the endogenous contamination pathway103. This apparently modifiable risk factor has driven 
a recent trend on preoperatively screening and treating carriers to potentially reduce infection 
rates also in total joint arthroplasty surgery.  Although there is convincing data favoring this 
approach in overall SSI, data on arthroplasty surgery specifically is not so convincing104. 
In a paramount prospective randomized controlled study by Bode et al.105, the number of S. 
aureus deep SSI was significantly lower in the treatment than in the placebo group. Still, further 
analysis of Bode et al. paper shows only 172 out of 808 surgical patients were orthopedics 
and no information is given regarding how many of those were total joint replacements. In this 
specific subgroup of patients there was no significant difference regarding S. aureus infections 
between treated and untreated carriers. In 2010, Kim and co-workers106 enrolled over 7,000 
patients before elective orthopedic surgery including arthroplasty but also spine and sports 
medicine cases. Non-carriers showed the lowest infection rate and MRSA carriers showed a 
significantly higher infection rate. MSSA carriers showed a not significant difference compared 
to non-carriers. Unfortunately, also in this paper, no information regarding specifically total joint 
replacement patients was given. A year later, Rao et al.107 reported their results on a cohort 
study of 3,724 total joint arthroplasty patients. Infection rate in the carriers group was reported 
to be 0.0% and the authors conclude preoperative screening/selective decolonization was 
associated with fewer SSI after elective TJA.  However, more detailed scrutiny showsthere 
were 17 cases of PJI among the 1,440 patients of the intervention group and 19 infections in 
the concurrent control group of 2,284 patients operated by non-participating surgeons107. Only 
when assuming that all infections of the control group occurred in the subgroup of expected to 
be S. aureus nasal carriers could the authors find a significant reduction of infection between 
treated and untreated carriers. This raises methodological issues that hamper this paper’s 
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conclusions as it is incorrect to assume that non-carriers in the control group would have zero 
infections. A major multicenter study performed in American hospitals involving over 30,000 
hip or knee arthroplasties was published in 2015108. Patients were screened in the outpatient
setting and carriers were treated using intranasal mupirocin twice daily and bathed with 
chlorhexidine gluconate once daily for up to 5 days immediately before their operations. A 
statistically significant decrease in S. aureus infections among hip or knee arthroplasties was 
found (difference per 10,000 operations, -17 [95% CI, -39 to 0]; RR, 0.48 [95% CI, 0.29 to 
0.80])108. However, patients during the intervention period were younger, had lower Charlson 
comorbidity index scores, and were less likely to have a history of MRSA carriage (all of which 
known risk factors for infection) than those during the pre-intervention period. Furthermore, 
and perhaps the major limitation of this finding is that patients were followed up for no more 
than 90 days after their operations which is admittedly a short period for PJI. Although the 
endogenous route of contamination in nasal carriers is clearly supported by the evidence, 
the exogenous S. aureus contamination pathway may still be preponderant in some settings. 
A French multicenter study including almost 4,000 joint replacements found that most cases 
of S. aureus surgical site infections, either an endogenous origin could not be demonstrated
or preoperative nasal colonization retrieved a strain that was different from the infecting 
pathogen102. Of the 22 documented S. aureus infections, 13 occurred in patients classified as 
nasal non-carriers and nine in nasal carriers. Among nine carriers that developed infection, six 
were due to similar strains and three were different. 
This controversy has lead us to perform research on this topic and detailed results will be 
presented ahead in this dissertation. We found a significant proportion of methicilin-sensitive 
S. aureus carriers (22%) but MRSA colonization was under 1%109. 
There was a higher infection rate among carriers 
but no clear benefit of the preoperative treatment 
protocol could be demonstrated109. We also 
showed that patients carrying S. aureus are 
significantly diiferent from non-carriers regarding 
other variables that addmitedly influence infection
rates such as the presence of inflamatory arthritis109.
Maoz et al.49 analyzing data from 3,672 primary 
and 406 revision hip arthroplasties, also found S. 
aureus colonization to be associated with higher
infection rate but it was not proven to be an 
independent risk factor as it was not significant 
in multivariate analysis. Although treating known 
nasal carriers with intranasal applications of 
mupirocin 2% ointment with or without a combi-
nation of chlorhexidine gluconate body wash is 
currently recommended to prevent surgical site 
infection by the WHO73, the ICM on PJI did not 
recommend universal screening of all patients 
undergoing joint arthroplasty85.
Fig. 2 Example of patient being screened for S. aureus 
colonization.
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URINE SCREENING
Concern with the genitourinary tract as a possible source of hematogenous seeding has been 
present as far back as the 1970’s when a few case reports 110-112 and a retrospective study113 
found a relation between patients with deep joint infection and perioperative urinary tract 
infection (UTI). Although there seems to be enough evidence supporting a relation between 
postoperative symptomatic UTI and PJI 47,57,113-115, literature studying the correlation between 
asymptomatic bacteriuria (ASB) and surgical site infection after joint arthroplasty is scarce115-119 
Nevertheless urine screening before total joint replacement has found its way into clinical 
practice among the orthopedic community. A recent survey in the United Kingdom revealed 
that two-thirds of surgeons would treat ASB prior to knee arthroplasty, although 70% would not 
have any evidence to cite evidence in favor of this practice120.  
This controversy has lead us to perform research on this topic. The hypothesis was that a 
preoperative screening and treatment program of ASB would potentially have an impact on 
prosthetic joint infection rates. Our results will be presented with further detail ahead in this 
dissertation. We found a significant proportion of elective total joint arthroplasty candidates 
present with ASB121. While ASB proved to be an independent risk factor for infection, the 
organisms found in the urine preoperatively were different from those causing PJI121. 
Furthermore, preoperative antibiotic treatment of ASB did not show any benefit121. 
As such, testing for and treating asymptomatic urinary tract colonization before joint 
replacement is unwarranted85. This statement should be interpreted cautiously and it should 
not be extrapolated for those showing signs and symptoms of active urinary tract infection. It 
is reasonable to treat symptomatic UTI before surgery85.
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Perioperative Considerations 
Before surgery, every patient should be educated about the importance of skin problems and 
a thorough examination should be performed at admission. If any skin irregularity over the 
surgical site or the lower leg is present, a thorough assessment should be made regarding 
potential wound healing complications. Such skin problems may include simple conditions 
such as abrasions, scratches from pets, contact dermatitis, eczema, psoriasis, skin ulcers or 
even cellulitis and postponing surgery may be indicated (Fig. 3). 
PATIENT PREPARATION
Preoperative bathing is recommended in order to wash gross contamination and reduce 
bacterial load. Chlorhexidine is commonly used although there is no evidence to show a clear 
benefit for preoperative showering or bathing with chlorhexidine over other wash products73,122.
Chlorhexidine gluconate-impregnated cloths have also been advocated as a possible
improvement over simple bathing. They are used by the patient at home during the morning 
of or the evening prior to surgery. There are scarce yet favorable results including a small 
prospective randomized trial, suggesting they are effective in decreasing the rate of infection 
in lower extremity TJA and surgeons may wish to consider using them123-125.
Hair removal is also a classic concern. Although theoretically the patient’s hair may be a source 
of contamination, it has been shown that there is no difference in infection rate among patients 
who have had hair removed prior to surgery and those who have not73,126. Therefore, removing
hair is not necessary unless the hair at or around the incision site will interfere with the 
operation, dressings or wound care. When hair removal is performed, concern over shaving
has been raised because abrasions formed from the shaving process can become sites of 
bacterial growth. In fact, clipping as opposed to shaving, is the preferred method for hair 
removal as it has been shown to lead to inferior infection rates73,126. It is also consensual that 
hair removal should be performed as close to the time of the surgical procedure as possible73,85.
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problems that had surgery postponed. A: second toe diabetic foot ulcer 
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SKIN DISINFECTION
The human skin is home to a large number of resident bacteria. Although a small proportion 
are restricted to deeper layers and hair follicles and are not accessible to standard antiseptic 
formulations, most bacteria are located in superficial layers127. The aim of skin disinfection is 
to reduce the microbial load as much as possible before surgery both within the patient’s own 
skin and the medical staff hands.
Surgical Site Skin Preparation
To date, no clear difference between various skin preparation agents has been established 
regarding the prevention of deep infection in total joint arthroplasty. Directly comparing 
chlorhexidine to povidone-iodine regarding skin antisepsis and rate of surgical site infection
offers conflicting evidence. Darouiche et al.128 showed that chlorhexidine-alcohol was 
significantly more protective than povidone-iodine against both superficial and deep infections 
after clean-contaminated surgery. However, iodine preparation used in this study was aqueous
and not alcohol based. This is a major issue as evidence suggests that combining alcohol
with antiseptics may be critical. Two recent meta-analysis, showed that alcohol-based 
antiseptic solutions are more effective than aqueous solutions in reducing the risk of surgical site 
infection73,129. Swenson et al.130 found that when alcohol was used (either as a solvent or a 
scrub following iodine paint), iodophor-based compounds may be superior to chlorhexidine. 
Other studies were unable to show a clear advantage of one agent over the other131,132. 
Theoretically chlorhexidine would be more advantageous in a long-lasting surgery such as 
total joint arthroplasty, since its bactericidal effect is sustained over a longer period of time 
than iodophor-based compounds133,134. A recent prospective randomized trial comparing 
chlorhexidine–alcohol combination to iodine-alcohol combination skin antisepsis before 
cesarean delivery confirmed this theoretical advantage135. With almost 600 patients in each 
arm, surgical site infections were significantly lower in the chlorhexidine-alcohol group135. In 
fact, current recommendations are to use alcohol-based chlorhexidine gluconate antiseptic 
solutions as pooled results seem to suggest it is more effective than povidone-iodine73,129. 
Staff should be trained and informed about the potential harms of alcohol-based solutions. 
They should not come into contact with mucosa and caution should be exercised to allow time 
for adequate drying as operating room fire is a real possibility.
As a final part of the surgical skin preparation, plastic adhesive drapes have been advocated 
as a way to protect the wound from organisms that may be present on the skin surrounding
the incision. A recent Cochrane review136 showed a significantly higher proportion of patients 
in the adhesive drape group developed a surgical site infection when compared with no 
drapes. Even the newer iodine-impregnated adhesive drapes had no effect on the surgical site 
infection rate136. As such their use is not recommended73.
Surgical Team Hand Wash
Surgical team hand preparation is of vital importance to minimize surgical field contamination
especially in the case of glove puncture that is not uncommon in arthroplasty surgery. 
However, much as for patient skin preparation, no consensus exists as to the optimum agent 
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or duration of the wash. A 1997 study by Pereira et al.137 showed chlorhexidine and povidone-
iodine aqueous scrubs to be equally effective in reducing skin contamination. The same study 
offered evidence that alcohol-based antiseptics could be just as effective137. A subsequent 
large, prospective multicenter equivalence-cluster, randomized crossover study showed 
similar findings. Traditional (5 minutes) scrubbing methods with aqueous agents (4% 
chlorhexidine or 4% povidone-iodine) were equally effective at reducing the incidence of 
infection compared to a single hand wash for 1 min with non-antiseptic soap at the start of the 
day followed by alcohol-only rubs138. A Cochrane systematic review139 found that chlorhexidine
gluconate scrubs may reduce the number of colony forming units (CFU) on hands compared 
with povidone iodine scrubs. They also found that alcohol rubs with additional antiseptic 
ingredients may reduce CFU compared with aqueous scrubs139. However, just how much clinical
relevance this surrogate endpoint is at predicting surgical site infection is unknown and no firm 
evidence that one type of hand antisepsis is better than another. In their systematic review, 
Allegranzi et al.73 found a limited number of studies with surgical site infection as primary 
outcome and they were also unable to find a difference between the use of alcohol-based 
solutions and povidone-iodine or chlorhexidine gluconate antimicrobial soap.
As such, alcohol hand rubs are effective and no more damaging to the skin than more time-
consuming, conventional methods using detergent-based antiseptic wash. Although no evidence
exists regarding this specific topic, we believe alcohol hand wash seems to ensure more 
adequate compliance. Despite the variability present in the literature a reasonable 
recommendation is to perform either a scrub or soap-and-water wash for the first case of the 
day (or whenever there is gross contamination) followed by surgical hand antisepsis using an 
alcohol based product for a minimum of 2 minutes before each case.
PROPHYLACTIC ANTIBIOTICS
Surgical prophylactic antibiotic therapy refers to administering antimicrobial drug(s) to the 
operative site in effective concentrations to lessen the consequences of bacterial contamination
thus reducing the number of clinically relevant infections. Its efficacy is currently indisputable 
and it is widely endorsed as one of the most powerful tools used to reduce infection rate after 
TJA73,85,140,141. 
Systemic Antibiotics
The goal is to reach optimal surgical site tissue concentrations of antibiotic(s) when the 
procedure begins. Therefore, it is usually recommended that they should be given within
60 minutes of the incision or the use of a tourniquet85,141. There is evidence proving the 
administration of antibiotics after incision is associated with a significantly higher incidence 
of infection compared with administering them before incision73,142. There is also enough 
evidence to support that administration earlier than 120 minutes is less effective73. In a large 
multicenter collaborative study, Steinberg et al.143 found that infection risk increased as the 
time interval between antibiotic infusion and the incision increased. They found a not quite 
significant trend towards reduced infection rate when antibiotics were infused within 30 minutes 
of incision (1.6%) compared to 31-60 minutes (2.4%). A Dutch multicenter study found a similar 
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non-significant trend to reduced infection rates when prophylaxis was given in the preceding
30 minutes142. However, the authors of a recent systematic review did not find significant 
differences in time intervals under 120 minutes73. They do however recommend administration 
should occur closer to the incision time (<60 minutes) for antibiotics with a short half-life such 
as commonly used cephalosporins73. When a tourniquet is used, it should be inflated at least 
5-10 minutes after antibiotic infusion in order to allow for adequate tissue concentrations85,144. 
It has also been suggested that giving prophylactic antibiotics before tourniquet deflation may 
be just as effective145.
In some circumstances, there is the need for repeat antibiotic dosing during surgery. The goal 
is to maintain adequate antibiotic concentrations throughout the procedure and redosing is 
indicated if the procedure lasts longer than two half-life of the chosen drug(s) or when there 
is increased blood loss and/or fluid resuscitation (>2,000 mL)73,85,141. It is also agreed upon 
that the duration of antibiotic prophylaxis should not exceed twenty-four hours postoperatively
and there is extensive evidence that a single preoperative dose (and possible additional
intraoperative redosing) might not be inferior85,141,146-148. Longer regimens offer no added benefit 
and are associated with increased risk of development of resistance, increased risk of toxicity 
and even higher costs141. There is also no evidence to support continuing therapy while urinary 
catheter or surgical drains are in place85. 
While proof of its worth is overwhelming, specific antibiotic(s) regimen selection remains 
controversial. Level I evidence studies in this setting are difficult to perform. For example, 
to demonstrate a reduction in infection rate from 2% to 1% with a power of 90%, at the 95% 
confidence interval, a study would need over 3,000 patients per group. For that reason, it is 
not a surprise that no hard evidence favoring any drug(s) over another exists and therefore 
many different regimens may be adopted141,149. Prophylactic antibiotics need to be effective 
against the most common organisms responsible for PJI. Given the varying levels of antibiotic 
resistance between institutions, it is often imperative to customize prophylaxis based on local 
trends. They should also have adequate pharmacokinetics and (ideally) reduced toxicity and 
side effects profile.
Cephalosporins (first or second generation) are still widely recommended as first choice in 
orthopedic surgery and TJA specifically85,141,148. This is due to their safety profile, broad 
spectrum and good tissue penetration, low cost and proven effectiveness. Cefazolin tissue 
distribution reduces with increasing body weight and is lower in morbidly obese patients150. 
Dose adjustments are therefore required and doses up to 3g in patients over 120 kg are 
recommended151. In patients with documented or suspected allergy, clindamycin is a good 
choice. It has good bioavailability, and shortly after infusion reaches effective bactericidal bone 
concentrations152. A 900mg dose is recommended141 but it should be noted that clindamycin 
has no activity against Gram negative bacilli.
Vancomycin is another alternative in patients with documented beta-lactam allergy but the lack 
of activity against Gram negative bacilli should also be acknowledged. There is increasing
interest in vancomycin and other drugs effective against MRSA such as teicoplanin due to 
its significant prevalence in PJI also in Europe96,153. In this regard, it has been shown that the 
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standard 1g dose may lead to suboptimal concentrations in a significant proportion of patients,
thus recommending adopting a 15mg/kg weight base dose154. A small trial focusing on 
total joint replacement specifically with little over 100 patients in each group in an institution, 
where MRSA and methicillin-resistant S. epidermidis prevalence exceeds 25% of orthopedic 
infections showed no advantage of vancomycin compared to cefuroxime or fusidic acid155. 
Merrer et al.156 conducted a prospective observational study comparing the incidence of 
infection after vancomycin or cefazolin prophylaxis in femoral neck fracture and found no 
significant difference. Finkelstein et al.157 in a study with slightly over 800 patients who 
underwent cardiac surgery requiring sternotomy, showed an overall surgical site infection rate 
similar in both groups. There was a not significant trend towards lower proportion of MRSA in 
the vancomycin group157. In contrast, surgical site infections caused by methicillin-susceptible
staphylococci were significantly more common in the vancomycin group157. Smith et al.158 
retrospectively analyzed data comparing two historical cohorts after switching routine 
prophylaxis before TJA from cefazolin to vancomycin. Overall infection rate dropped from 1% 
(23/2221 primary TJA) during the earlier 29-months cefazolin period, to 0.5% (14/2815 primary
TJA) during the later 31-months vancomycin period158. The most significant improvement 
seen was a decrease in the number of coagulase-negative staphylococci infections. MRSA 
infections also decreased but the difference was not statistically significant. There was also 
a not significant increase in the number of methicillin-sensitive S. aureus and Streptococcus
species infections158. Of course, the historical control group introduces a major bias in 
interpreting these results. In order to try and overcome this apparent limitation and also the 
lack of Gram negative coverage, dual antibiotic regimens have been investigated159,160. 
Table I Common antibiotics used for total joint arthroplasty prophylaxis.
Drug Recommended Initial Dose Redosing Schedule
Cefazolin
1g (<80 kg body weight)
2-5 hours2g (80-120 kg body weight)
3g (>120 kg body weight)
Cefuroxime 1.5g 3-4 hours
Clindamycin 600-900mg 3-6 hours
Vancomycin 1g or 10-15mg/kg 6-12 hours
Teicoplanin 600-800mg or 10mg/kg none*
* very long half-life precludes the need for redosing during surgery.
Sewick et al.160 compared dual prophylaxis with cefazolin and vancomycin versus cefazolin 
alone. In their retrospective analysis of 1,828 primary THA/TKA, with 1-year follow-up, the 
authors found that the rates of infection did not significantly differ (1.1% and 1.4% respectively)
 Although the prevalence of MRSA infections was significantly lower in the dual-antibiotic group 
(0.02% and 0.08% respectively), these infections were very rare and therefore, the number 
needed to treat to prevent one MRSA infection was very high160. Courtney et al.159 on the 
other hand looked at 500 primary THA/TKA performed with cefazolin prophylaxis and 1,328 
with cefazolin and vancomycin and found patients receiving dual antibiotics were more likely
to develop acute kidney injury159. The lack of clear evidence of efficacy and safety along with 
the concern of promoting bacterial vancomycin resistance advises against routine vancomycin
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use. In the United States of America, there seems to be an increasing frequency of 
vancomycin-intermediate and resistant Staphylococcus aureus isolates identified in clinical 
practice161 but the problem is already present also in Europe with the first case being recently 
identified in Portugal162. 
As such, vancomycin prophylaxis is best reserved for cases of documented MRSA colonization
or previous infection85 or other cases with increased risk of methicillin-resistant infections 
such as institutionalized patients, healthcare workers or revision surgery85,163. In addition, 
vancomycin administration is more cumbersome than other antibiotics. If administered too 
rapidly, vancomycin can cause histamine release, resulting in hypotension and a skin reaction 
called red man syndrome; therefore, infusion of vancomycin should take place over a longer 
period of time (60 to 120 minutes)141. Teicoplanin is an alternative that offers high and rapid soft 
tissue and bone penetration and is more easy and practical to administer than vancomycin. 
There are some favorable reports on the use of teicoplanin in total joint replacement showing 
that teicoplanin is at least as effective as traditional prophylaxis with the added advantage of 
addressing MRSA164-166. Nevertheless, like vancomycin, the lack of Gram negatives activity
is also a limitation with the use of teicoplanin. Recently, Tornero et al.167 compared dual 
prophylaxis with cefuroxime and teicoplanin versus cefuroxime alone in patients undergoing 
primary lower limb arthroplasty. A significantly lower PJI rate was found in the dual-antibiotic 
group than in patients in the cefuroxime group, 1.3% (10/791) and 3.5% (35/995) respectively167. 
There was also a significant reduction of S. aureus infections with no cases of S. aureus PJI in 
the combined prophylaxis group167.
Antibiotic-loaded Bone Cement
Routine use of local antibiotic prophylaxis using antibiotic-loaded bone cement (ALBC) is still 
a matter of open debate. Classical evidence of its efficacy come from large studies of the 
Scandinavian hip registries168,169. Malchau et al.169 reported on 92,675 THA from the Swedish 
database performed from 1978 to 1990. They found significantly decreased rates of revision 
for infection with the use of gentamicin-containing cement169. Engesaeter et al.168 presented
the results of 22,170 THA procedures out of the Norwegian registry. They showed lower 
revision rates when antibiotic prophylaxis was given both systemically and in cement versus 
systemic or cement alone168. Information regarding total knee arthroplasty (TKA) is meagre 
and not as compelling. Earlier studies that suggest its efficacy are clearly underpowered170,171. 
More recent studies by Namba et al.172 and Hinarejos et al.173 involving 2030 and 2948 total
knee replacements performed with ALBC respectively, failed to demonstrate superiority in 
reducing infection rates. This lack of effectiveness regarding infection as an endpoint is also 
shown by Bohm et al.174 in a larger retrospective study including 20,016 TKA with plane cement 
and 16,665 with ALBC from the Canadian registry. Notwithstanding, they did find a significantly 
higher proportion of revision for aseptic loosening in the non- ALBC group174. Tayton et al.50 
recently presented the results of 64,566 TKA from the New Zealand joint registry. At the 12 
months’ follow-up, there was no advantage in the infection rate among the 42,038 patients 
where ALBC was used (0.29%) compared to the 22,528 cases where plane cement as used 
(0.25%)50. Currently no conclusive evidence exists regarding the real efficacy of routinely using 
ALBC in preventing PJI after primary total joint replacement175-177.
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There are also questions regarding mechanical issues. A classical concern is that adding 
antibiotic(s) to bone cement may have a negative impact on its mechanical strength. However,
it has been proven that the doses required for prophylaxis (< 2 g antibiotic per 40g cement) 
do not compromise fixation which is critical to achieve a functional and painless joint177. 
This statement is further reinforced by the fact that a lower incidence of aseptic loosening is 
consistently found using ALBC168,174. A more relevant concern is that routine use of ALBC may 
select for antibiotic-resistant microorganisms’ infections. An in vitro study by Thomes et al.178 
showed a lower overall rate of infection in the gentamicin-loaded cement group, but also a 
significantly higher rate of gentamicin-resistant microorganisms in this group. Hope et al.179 on 
a study of 91 patients with deep infection of a cemented total hip arthroplasty demonstrated the 
use of gentamicin-loaded cement was significantly associated with the higher prevalence of 
gentamicin-resistant coagulase-negative staphylococci. This concern is further reinforced by 
recent clinical studies that have found an increasing prevalence of gentamicin resistant micro-
organisms, especially coagulase-negative staphylococci180,181. It is only logical to expect such 
a phenomenon. Gentamicin loaded bone cement is by far the most widely used and while it is 
effectively preventing infections by gentamicin-sensitive microorganisms, the relative weight 
but not necessarily the absolute numbers of gentamicin-resistant infections grows.
To this date, data on the use of ABLC in primary uncomplicated arthroplasty is mostly 
retrospective and it is possible surgeons are using it in patients with higher baseline risk 
of infection. It is not entirely clear whether a potential advantage of using ABLC outweighs 
the potential disadvantage of its routine use such as selecting resistant microorganisms. 
Therefore, a clear recommendation for or against its use in the general population cannot be 
made. One common recommendation is to use it only in patients with a high risk of infection in 
primary arthroplasty (e.g. patients with diabetes mellitus, morbid obesity, prior history of PJI) 
and whenever cemented fixation is used for revision surgery 85,141.
OPERATING ROOM CONDITIONS
Despite all the recent advances in surgical site infection prophylaxis, respecting the rules of 
good conduit in the operating room (OR) may never be disregarded. Traffic in and out the OR 
increases air bacterial counts by two methods, bacterial shedding from the additional personnel
and air exchange between the OR and the hallway. Unwarranted traffic should therefore be 
avoided and doors should be kept closed throughout surgery85,182,183. Optimizing OR conditions 
should be considered a team work including the surgeon as well as the rest of the surgical 
team and even hospital administrations whenever necessary.
Surgical Team Equipment
Over the years, surgical attire has remained relatively unchanged. This uniform has traditionally
been thought to play two roles: to protect scrubbed personnel from exposure to body fluids 
and to maintain the sterile surgical field. Health care personnel is admittedly one of the major 
sources of bacterial contamination. However, many of our time-honored practices have limited 
literature support.
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The use of scrubs, masks and some kind of head covering has become universally 
recommended. Despite the absence of clear evidence-based proofs of efficacy, wearing them 
should be considered in the best interest of both patients and medical staff pending evidence 
of advantage to not wearing them. Sterilized surgical gowns are demonstrably relevant and 
impervious gowns seem to be superior although no clear advantage of disposable non-woven 
versus reusable woven gowns has been shown146,184. The use of sterilized gloves is absolutely 
critical and is introduction resulted in a dramatic reduction of surgical site infections184. Many 
orthopedic surgeons prefer double gloving, but there is no direct evidence that additional glove 
protection reduces surgical site infections184,185. Nevertheless, the addition of a second pair of 
surgical gloves significantly reduces perforations to innermost gloves and blood stains on the 
skin, indicating a decrease in percutaneous exposure incidents185. In addition to perforation, 
gloves are also at risk for bacterial contamination during the procedure. It is recommended that 
they are changed whenever they are perforated, before prosthesis implantation, after handling 
bone cement as it has been shown to affect permeability or at least every 90 minutes in longer 
surgeries85.
In order to minimize bacterial shedding, body exhaust suits were initially described and 
popularized by Sir John Charnley in the 1970’s186. Despite the initial enthusiasm around these 
suits in arthroplasty, their use remains controversial. In fact, modern day’s data shows that 
compared with conventional clothing, the use of body exhaust suits could not be proven to 
provide more protection against microbial contamination187,188. Recent data out of the New 
Zealand Joint Registry by Hooper et al.189 also calls into question its efficacy. Their retrospective
review included more than 50,000 primary THA and 30,000 primary TKA and showed that the 
use of space suits was actually associated with a significant increased rate of surgical site 
infections compared with traditional head coverings regardless of the type of operating-room 
ventilation for both THA and TKA189. As such their use in routine joint replacement seems to be 
unjustified especially considering the added costs they represent.
Laminar Air Flow and Ultraviolet Lighting
Laminar air flow was also first introduced in THA surgery by Sir Jonh Charnley186. In his 
paramount study, the use of laminar air flow and body exhaust suits showed an impressive 
(9% to 1%) reduction in the rate of infection. However, this study was undertaken before the 
implementation of routine antibiotic prophylaxis. 
More recent studies question the real value of this methodology, especially considering its high 
cost. The first indication that antibiotic prophylaxis could reduce the impact of laminar air flow is 
brought by Lidwell et al.190. Although the infection rate in rooms with laminar air flow was 0.6% 
as opposed to 1.5% in rooms without it, they also found a significantly lower rate of infection 
(0.6%) in patients with preoperative antibiotics regardless of the laminar air flow. More recent 
data, reflecting modern OR air filtration and routine antibiotic prophylaxis is not able to show an 
advantage in the use of laminar air flow. A study including over 8,000 total knee replacements
in over 250 hospitals in the United States showed no significant advantage in laminar air 
flow191. Another major multicenter German study involving almost 100,000 surgeries and 
controlling for many patient and hospital-based confounders, also found a lack of benefit in 
OR ventilation with laminar airflow192. They found it was even associated with a significantly 
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higher risk for severe infection after hip prosthesis192. The same deleterious impact was noted
by Tayton et al.50 in their analysis of 64,566 primary TKA recorded on the New Zealand joint 
registry between 1999 and 2012. This seemingly paradoxical effect may be explained by 
several factors that influence air flow such as specific architectonic OR characteristics, 
equipment positioning, pressure and ventilation conditions or even lack of adequate protective 
clothing (i.e. body exhaust suits). As such, current recommendations state that laminar air flow 
should not be used to reduce infection rate in TJA surgery146.
An alternative to laminar air flow could be the use of ultra-violet (UV) lighting. Ritter et al.193 
found a statistically significant reduction of infection in total joint arthroplasty with and without 
UV light. In their study with almost 6,000 joint replacements, the infection rate with the use 
of laminar airflow and no UV lighting was 1.8%, and the infection rate with UV lighting only 
was 0.6%. Although the costs of its use are 100 times lower than laminar air flow, UV lighting 
throughout surgery is not without dangers that ultimately limit its use. It requires appropriate 
safety precautions and staff protective equipment to minimize the risk of cutaneous and ocular 
injuries that may still occur.
PATIENT HOMEOSTASIS
Despite the indisputable importance of enhancing operating room background, optimizing 
the host environment must not be overlooked. Patient homeostasis in the intraoperative and 
immediate postoperative period is also critical to reduce the risk of infection and surgeons 
must articulate with anesthesia staff and other operating room personnel.
Supplemental oxygen should be provided both intraoperatively and for 2-6 hours in the 
immediate postoperative period146. Tissue oxygenation benefits are maximized when 
normothermia and normovolaemia are also maintained146. Warming devices should be used 
to avoid hypothermia that commonly occurs in prolonged surgical procedures because of 
impairment of thermoregulation by anesthesia combined with body exposure to the cold 
environment in the operating room146. Adequate intravascular volume is an essential part of 
tissue perfusion and subsequent oxygenation. Intraoperative goal-directed fluid therapy has 
also been shown to reduce the risk of surgical site infection146.
DURATION OF SURGERY
Prolonged surgical time is consistently associated with increased risk of infection and there 
seems to be a direct linear association47,49,57,64,121,172.  Naturally some surgeries are particularly
complex and will require more time to perform. Still, some time-consuming variables are 
modifiable and staff education in how to operate efficiently and follow systematically defined 
and predictable steps might decrease the risk of PJI. It is also important to stress the need 
for antibiotic re-dosing when the surgery prolongs for more than two times the half-life of the 
prophylactic antibiotic administered before surgery as was discussed earlier.
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Postoperative Considerations 
It is thought that most surgical site infections occur as a consequence of intraoperative 
surgical field contamination. However, some may occur in the immediate or even in the late 
postoperative period and there are a number of contributing factors that can be influenced.
DRAINS AND BLOOD MANAGEMENT
Surgical wound drains are a widespread tradition after orthopedic surgery and total joint 
arthroplasty specifically. The rationale behind its use is to reduce the formation of hematoma
and subsequent need for re-intervention or over infection. However, several studies have 
demonstrated they can be colonized by bacteria194. The risk of bacterial colonization is directly
time related and increases dramatically after the first 24 hours195,196. It has also been 
suggested that the use of a surgical drain for more than one day may be associated with MRSA 
infection197. As such when choosing to use a drain in uncomplicated primary TJA the authors 
believe it should be discontinued in the first 24 hours. Notwithstanding, the main controversy 
is whether to use drains at all. Two recent meta-analysis on orthopedic surgery198 and total 
joint replacement specifically199 both reached the same conclusion. No significant difference 
between the wounds treated with a drain and those treated without a drain was found with 
respect to the occurrence of wound infection, wound hematoma or reoperations for wound 
complications. On the other hand, a drained wound was significantly associated with a greater 
need for blood transfusion 198,199.
Moreover there is increasing evidence that allogeneic blood transfusions, though required in 
some circumstances after joint replacement surgery, are not innocuous200. A retrospective 1999 
study201, found transfusion of allogeneic blood after total joint replacement was significantly 
associated with infection, fluid overload and increased duration of hospitalization. These 
findings have consistently been confirmed in more recent studies57,202-204. Although the clear 
etiology is not fully understood it seems that some kind of adverse immunomodulation occurs. 
On one hand, autologous blood transfusion does not seem to increase the risk so clearly85. 
Friedman et al.202 looked at data from more than 12,000 patients after primary total hip or 
knee arthroplasty. Most of them received no transfusion (n=6,313) and among those requiring
it, most received allogeneic blood (n=3,962) and some received autologous blood only 
(n=1,902). Infection rates in patients receiving no transfusion or autologous blood transfusion
were similar. All kinds of infections, including wound infection, were significantly higher in 
patients receiving allogeneic blood transfusion202. On the other hand, allogeneic blood seems 
to be associated with a lower infection rate when it is depleted of leukocytes prior to transfusion
although the real value of such practice in the total joint arthroplasty setting has not been 
established205.
As such, orthopedic surgeons should make an effort to reduce the need for perioperative 
allogeneic blood transfusions during total knee and total hip joint arthroplasty. A more restrictive
hemoglobin threshold strategy is currently advisable with no evidence that it impacts 
mortality or morbidity after elective surgery206. Decision should be based on clinical and not just 
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laboratory criteria. A discussion regarding preoperative hemoglobin optimization, cell salvage 
technology, the use of tranexamic acid or other strategies is beyond the scope of this paper 
but surgeons should be aware of this predicament when deciding whether or not to implement 
them or even whether or not to use a drain.   
WOUND CARE
Careful hemostasis and meticulous closure of the joint capsule and subcutaneous tissue at 
the end of the procedure to avoid dead space is crucial in obtaining good wound healing. 
Persistent wound drainage or wound dehiscence has been shown to be a significant risk factor for 
PJI55,207,208. Antimicrobial, specifically triclosan-coated sutures seem to be effectively protective
against infection146.   
The goal of wound dressings applied after closure is to provide physical support, protection 
and absorb exudate. The traditional approach to wound care after TJA consists of gauze 
bandages that are usually removed after 1 or 2 days with the idea that the wound 
re-epithelializes during that time and can then be left with a simple dressing. There is 
nonetheless no evidence that early removal of dressings (<48h) has detrimental effect on 
outcomes209. In a further effort to prevent surgical site infection, commercial dressings have 
been developed to optimize wound healing, seal wound drainage and have antimicrobial 
properties. Occlusive dressings with hydrofiber have shown favorable results after total joint 
arthroplasty and its use was recommended in the latest ICM on PJI85. Ravenscroft et al.210 in 
prospective randomized trial compared it against an absorbent perforated dressing and found 
that new hydrofiber occlusive dressing was 5.8 times more likely to result in a wound with 
no complications. A similar advantage regarding skin blisters, wound leakage and number 
of dressing changes has been repeatedly noted since211,212.  More recently, Cai et al.213 retro-
spectively looked at a single institution experience of 903 consecutive total joint arthroplasty 
cases who received the occlusive hydrofiber dressing and 875 consecutive cases who 
received standard gauze dressing. The incidence of infection was significantly lower in the new 
dressing group and multivariate analysis showed it was an independent protective. Grosso
et al.214 also confirmed the favorable impact of such dressings. Analyzing the charts of more 
that 1,100 patients, they found a 4-fold decrease in acute PJI with the use of occlusive 
silver-impregnated hydrofiber dressing. Body of evidence is not enough to make a strong 
recommendation regarding the additive value of silver and aspects such as costs should be 
taken into consideration215. The addition of topical antibiotics is also probably beneficial in 
reducing the risk of infection in surgical wounds healing by primary intention compared with no 
topical antibiotic, although the specific role of different antibiotic(s) or even its role in promoting 
antibiotic resistance or possible adverse reactions such as contact dermatitis are unclear216.
URINARY CATHETER
Indwelling urinary catheterization is often used to facilitate patient care in the first postoperative
hours and days after TJA and it has been shown to reduce the incidence of urinary retention217. 
However, urinary tract infection is a frequent minor complication after TJA especially in older 
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females218 and, as previously discussed postoperative symptomatic UTI is an established risk 
factor for PJI57,119,121.
Wald et al.219 confirmed the empirical awareness that prolonged catheterization increases the 
risk of UTI and defined a threshold at two days.  As such, surgeons must keep in mind that 
urinary catheterization is not without risks and efforts should be made to avoid it or minimize its 
length of stay. Stephan et al. 220 showed that a multifaceted prevention strategy can dramatically
decrease both the frequency and duration of urinary catheterization thus decreasing urinary 
tract infection after surgery.
DURATION OF HOSPITAL STAY 
Prolonged hospital stay is an important risk factor for the occurrence of infection after hip 
replacement8,49,57,64. Not only do these patients tend to have more medical comorbidities as 
they are also more exposed to nosocomial usually more virulent microorganisms. Decreasing
the duration of hospital stay depends on many factors. Of course preoperative optimization
of patient comorbidities is paramount but also proper patient education, optimal pain 
management, blood-sparing strategies, adequate anticoagulation and early ambulation 
collectively known as “fast-track” surgery seems to play a major role in diminishing length of 
stay without increasing complications221.
PREVENTION OF LATE HEMATOGENOUS INFECTIONS 
Even after successful procedures with uneventful wound healing and rehabilitation, patients 
with any kind of joint arthroplasty are at risk of developing late infections8,9. They most often 
arise as a result of bacteremia episodes and should be distinguished from those that result of 
intraoperative contamination. 
The strongest evidence for an extra-articular source of PJI would be to culture the same pathogen
both in the joint and the extra-articular site. Notwithstanding, that is not possible in a significant 
proportion of cases and presumed etiology is therefore assumed222. Most late hematogenous 
infections are sequelae of Staphylococcus aureus sepsis, skin infection, or urosepsis223-226. 
It has been shown that the risk of developing PJI after a documented S. aureus bacteremia 
may be as high as 30-40%224,225.  Naturally, other conditions such as infective endocarditis, 
pneumonia, gastrointestinal system inflammatory conditions, IV drug users and even dental
abscesses have also been implicated47,227-229. Any active bacterial infections in a patient 
bearing prosthetic joint(s) should be promptly diagnosed and treated to prevent bacterial seeding.
Extra-articular sources that contribute to late PJI should be identified by obtaining clinical 
history and performing a thorough physical exam, laboratory testing, adequate imaging, and 
examination by specialists whenever required.
Although cases described in the literature are exceptional, it is hypothetically believable that 
a small portion of these cases are caused by transient bacteremia during invasive medical 
procedures. The question whether patients undergoing such procedures (e.g. dental, urologic 
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or gastrointestinal) should undergo specific antibiotic prophylaxis is still matter of open debate. 
The recent ICM on PJI85 acknowledged the conflicting evidence available and recommended 
the use of antibiotic prophylaxis on an individual basis, according to patient risk factors and the 
type and invasiveness of the procedure to be performed85. The risk of bacteremia is, of course, 
directly related to the invasiveness of the procedure. Techniques such as dental extraction
or scaling230, esophageal dilation or variceal sclerotherapy231 and transurethral prostate 
resection232 or transrectal prostate biopsy233 pose higher risks than simple endodontic 
treatment, flexible colonoscopies, esophagogastroduodenoscopies or simple cystoscopy. 
Regarding dental procedures, the consensus recommends one dose of antibiotics be given 
about one hour prior to the procedure in all patients within the first two years after surgery85. 
High risk patients (e.g. previous prosthetic joint infection, inflammatory arthropathies, 
immunosuppression, diabetes, etc.) should consider doing it during their entire lifetime85. In 
gastrointestinal endoscopic procedures, prophylaxis is recommended routinely especially in 
high-risk patients85. The same is true for genito-urinary procedures, especially in patients with 
bacteriuria that has been shown to significantly increase the risk of bacteraemia234. 
However, this recommendation is not consensual and this is not surprising given the paucity 
of strong clinical evidence. The lack of clear evidence and the potential risks of antibiotic use 
such as toxicity, allergy and the promotion of microbial resistance have lead other experts 
to advise against routine antibiotic prophylaxis235,236. Ultimately the decision relies on clinical 
judgment of the treating physician taking into consideration an individual patient risk/benefit 
analysis.
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Diagnosis 
From an abstract standpoint, PJI is somewhat plainly defined as failure of the implant caused 
by pathogenic microorganisms (most often bacteria). This definition is however sometimes 
very difficult to translate into clinical practice.
As the improvement of microorganism detection methods continues, more and more bacteria
are being found at or around failed implants. Not only that, but such improvements are 
consistently finding bacteria traditionally considered to be nonpathogenic. The findings of two 
independent research groups clearly illustrate this. In addition to finding that culture of the 
sonication fluid of the explanted prosthesis increased sensitivity over traditional tissue cultures, 
Portillo et al.237 also determined that multiplex polymerase chain reaction (PCR) of sonication 
fluid further increased sensitivity. In a larger cohort of patients that included with 272 knee and 
162 hip prostheses, Cazanave et al.238 also determined that a PCR panel performed on implant 
sonicate fluid is more sensitive and more rapid than tissue culture for the diagnosis of PJI. 
Both these studies demonstrate using more powerful microbial investigation tools allowed for 
some cases who would otherwise be classified as aseptic failures to be classified as infections. 
Furthermore, they also reiterate that there is a significant proportion of cases that are 
ultimately classified as aseptic failures where some kind of bacterial positivity was found 
(though not sufficient to safely classified them as infections according to current accepted 
criteria). These advances are blurring the frontiers between PJI and aseptic failures making a 
bullet proof diagnosis of absence of infection extremely hard.
Another hint to the same phenomenon can be found in ALBC studies. While searching for 
the additional effectiveness of adding ALBC to the standard systemic antibiotic prophylaxis 
regimen, researchers from the Norwegian Arthroplasty Register came across an interesting 
finding. In their 2003 study comprising over 22,000 primary hip replacements, Engesaeter et 
al.239 found not only a decreased risk of revision for infection when ALBC was used, but also 
a significantly decreased risk of revision for aseptic loosening. More recently, Bohm et al.240 
in large retrospective study including 20,016 primary total knee arthroplasties with non-ALBC 
and 16,665 with ALBC, were unable to show an advantage in using ALBC with respect to 
infection rates but found significantly more revisions for aseptic loosening in the group treated 
with non-ALBC. These figures raise the question of whether some so-called aseptic loosening 
cases are really misdiagnosed subclinical low grade infections that are being prevented by the 
use of ALBC.
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These recent advances in our knowledge tend to challenge the traditional limits between 
clinically relevant infection, bacterial contamination and unquestionable aseptic loosening. It is 
becoming harder to determine where microorganisms are truly the cause of the failed implant 
or just happen to be found around it by increasingly sensitive methodologies and are really not 
causing an adverse reaction. 
It is therefore no surprise that up until recently, there was no universally adopted clinical 
definition of PJI. There is a multitude of several different definitions that have been proposed 
over time. In 2011, during the annual meeting of the american Musculoskeletal Infection 
Society (MSIS) a first attempt at creating a ‘‘gold standard’’ definition for PJI was made241. A 
couple of years later, an international consensus meeting, promoted by Dr. Javad Parvizi and 
Dr. Thorsten Gehrke was held and this worldwide collective effort resulted in a further refinement
of the previously proposed definition85. One of the major changes was the elimination of 
purulence as a diagnostic criterion. This was due to the recognition that despite intraoperative 
purulence is commonly encountered in patients with PJI, the presence of purulent-appearing 
or turbid synovial fluid is also frequently reported in non-infected prosthetic joints242,243. 
Table II ICM definition of Periprosthetic Joint Infection85.
1) Two positive periprosthetic cultures with phenotypically identical organisms, or
2) A sinus tract communicating with the joint, or
3) Having three of the following minor criteria:
Elevated serum CRP and ESR
Elevated synovial fluid WBC count OR ++ change on leukocyte esterase test strip
Elevated synovial fluid PMN percentage
A single positive culture
Positive histological analysis of periprosthetic tissue
CRP C-reactive protein; ESR erythrocyte sedimentation rate, WBC white blood cell; PMN polymorphonuclear neutrophil.
Currently, in the absence of a perfect gold standard, PJI diagnosis must rely on a combination
of microbiological and non-microbiological PJI criterion (see table II). However, the same 
document states that PJI may be present without meeting these criteria, specifically in the case 
of less virulent organisms thus illustrating that we have not yet reached a perfect definition85. 
They also acknowledge that numerous other tests, including sonication of explanted prosthesis,
synovial fluid biomarkers or molecular techniques may ultimately offer convincing results that 
might command modification of the proposed definition.
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History, Physical Examination and X-ray
PJI can manifest itself as a myriad of different clinical scenarios. Only by understanding the 
previously discussed etiology and pathophysiology is one able to grasp the full spectrum of 
PJI presentations. Patients’ symptoms may vary from acute, rapid-onset joint pain along with 
frank inflammatory signs and wound purulence with or without systemic features of infection, 
to chronic pain or discomfort, decreased range of motion with or without sinus formation and 
subtle discharge. 
The mode of presentation relates to the pathogenesis and microbial etiology of the infection. 
Acute joint arthritis reflects the presence of numerous microorganisms in planktonic phase. It 
often occurs in the early postoperative period. In a multicenter study performed in Australia244 
comprising PJI that occurred within 365 days of implantation, purulent discharge from surgical
wound was the most common clinical finding (72%) followed by pain and erythema at the 
affected joint (42% each). Fever >37.5°C was present in 38% of cases. This clinical scenario 
is also a common presentation of late infections following hematogenous seeding of bacteria 
from another body site into a previously asymptomatic total joint replacement245. It should 
be emphasized that not all early infections are that manifest. They often present as delayed 
wound healing or persistent (macroscopically seemingly innocent) leakage. A high level of 
suspicion should be maintained in these cases as persistent wound drainage has been found 
to be a major predictor of PJI207,208,246.
In contrast, chronic and more indolent symptoms reflect the presence of a lower number of 
adherent microorganisms (often less virulent species) in a slow growth phase, protected 
against host defenses by the ability to persist intracellularly or coalesce to form biofilm. It is 
the chronic feeble inflammatory host response at the prosthesis interface that causes pain 
and promotes tissue destruction that eventually leads to loosening of the prosthesis247. This is 
supported by studies that confirm the interface membrane is the best specimen for diagnosis 
of PJI both microbiologically (as it contains higher bacterial load) and histologically 248,249.
Realistically speaking, the only physical finding that is considered pathognomonic of infection 
is a sinus tract communicating with the joint85. Other findings such as wound dehiscence, joint 
warmth, erythema or swelling should increase the clinical suspicion but are not specific for PJI. 
It should be stressed that a normal physical examination is not enough to dismiss infection as 
a possible cause of a painful TJA.
Getting to know the patients’ medical history is also a crucial part of the initial exam. Chronic 
comorbidities that predispose patients to an immunocompromised state (e.g. diabetes mellitus,
inflammatory arthropathy, malignancies) are not only known risk factors for infection as 
was previously discussed but also greatly influence the host’s ability to fight off the infection 
during a hypothetical treatment. Host status is of major importance in the final outcome and 
unsurprisingly is taken into account in a number of PJI classification systems250-252. Prior history 
of periprosthetic joint infection, superficial surgical site infection, recent bacteremia/infections at 
other body sites or even an history of multiple surgeries on the same joint should also raise the 
suspicion. Patients with factors that increase risk of skin barrier penetration (e.g. intravenous
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drug use, poor wound conditions, psoriasis, chronic venous stasis or skin ulceration) should be 
considered to have a higher probability of infection.
Plain radiographs are always a first line imaging modality in orthopedics and naturally also 
when evaluating a painful arthroplasty. It is important to note that plain radiographs are 
generally normal in the setting of PJI. Nevertheless, serial radiographic evaluation over time 
can be very informative to detect subtle changes plus they are also important in evaluating 
many other possible causes of prosthesis failure and joint pain as well as allowing for planning 
of a possible revision surgery. 
Signs of loosening of previously well fixed components, osteolysis or bone resorption around 
the prosthesis, especially if they occur in the first years after surgery should be considered 
suspicious. There is evidence that a significant proportion of cases revised for supposed 
aseptic loosening are found to be infected253,254. There is an inverse correlation between 
microbiology and prosthesis-age as early loosening is more often caused by hidden PJI than 
late loosening255. Periosteal reaction with new bone formation or the presence of a transcortical 
sinus tract are more specific features of bone infection but are rarely present247.
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Serology
Serological inflammatory markers, more commonly erythrocyte sedimentation rate (ESR) and 
C-reactive protein (CRP), are often used as an initial screening test in a variety of suspected 
implant related or otherwise musculoskeletal infections256. They are inexpensive and can be 
performed with minimal inconvenience.
ESR is a nonspecific hematological test routinely used as an indirect parameter of increased 
acute phase reactants. CRP is a major acute phase reactant that is produced by the liver in 
response to inflammation, infection, malignancy and tissue damage. It responds quickly to the 
inflammatory process257. As such, they are nonspecific and are affected by countless factors.
They can be altered in non-infectious arthroplasty problems such as taper corrosion of 
modular stems or metal-on-metal bearings258,259 and they can be influenced by extra-articular 
infections, non-infectious inflammatory diseases or even underlying medications or medical 
conditions257,260. 
Despite all of its inherent limitations, ESR and CRP are widely considered to be valuable tools 
and are even accepted as a criterion for the diagnosis of PJI in recent consensus definitions85,241.
In the setting of chronic PJI (i.e. more than six weeks from the latest surgery), suggested 
thresholds are ESR>30mm/h and CRP> 10mg/L. Since they are traditionally used as screening
tools, sensitivity was privileged over specificity. Still, these thresholds were determined 
somewhat arbitrarily taking into account traditionally accepted values.
In 2007, Greidanus et al.261 tried to determine optimal cutoff values for determining infection 
among 151 TKA presenting for revision. They found ESR>22.5mm/h or CRP >13.5mg/L were 
the best performing. These results were later on confirmed by Piper et al.256 in their study 
including 297 knees (ESR>19 mm/h or CRP>14.5 mg/L). On the other hand, they also studied 
221 THA and found ideal cutoff values for differentiating infected from non-infected hips to be 
ESR>13mm/h or CRP >10.3 mg/L. On the contrary, CRP and ESR showed poor sensitivity for 
the diagnosis of implant infection in their cohort of 64 shoulder arthroplasties. A similar study 
focusing on 479 THA presenting for revision262 found different optimal cutoffs at 31 mm/h for 
ESR and 20.5 mg/L for CRP. More recently, using the already mentioned consensus definition 
of PJI, Alijanipour et al.263 reviewed 1962 patients (1203 THA and 759 TKA). For chronic cases, 
they found ESR >48.5 mm/h and CRP > 13.5mg/L for hips and ESR > 46.5mm/h and CRP > 
23.5mg/dL for knees were the optimal values.
Another typical concern regards the specific subgroup of patients with an history of 
inflammatory arthropathy. Patients with this underlying condition are known to be at a higher
risk for infection and although there is evidence of limited sensitivity and sensitivity of 
measuring inflammatory markers to monitor rheumatic disease activity264, theoretically elevated
ESR and/or CRP may represent either disease exacerbation or PJI. Most studies exclude this 
subgroup of patients or do not separately analyze them. Cipriano et al.265, approaching this 
question specifically found no significant differences in the ideal cutoff or respective diagnostic 
performance in patients with inflammatory arthritis.
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Despite the wide range of proposed thresholds illustrated previously, there are some common 
and relevant findings in the volume of literature256,259-263,265-267: 1) “optimal” cutoffs in each paper 
perform very similarly to traditional thresholds in excluding infection with negative predictive 
values consistently around or over 95%; 2) interpreting both markers together is helpful by 
increasing specificity when both are positive and sensitivity when either one is elevated.
All things considered it is important to emphasize that these tests alone should not be used to 
rule out infection in a suspicious clinical scenario. There is a small but constant proportion of 
so-called seronegative PJI. There seems to be a high prevalence of low virulence pathogens
in this group and in some cases, previous antibiotic therapy may be the culprit. In other 
cases, patients just seem to be unable to mount a sufficient immune response to be above the 
threshold but nevertheless treatment results seem to be comparable to patients with positive 
serology267. 
BEYOND ESR AND CRP
In trying to overcome these limitations, many other serum markers have been researched for 
the diagnosis of PJI but they have failed to show an unequivocal superiority. 
Procalcitonin (PCT) is a precursor of calcitonin and elevated levels have been noted in 
patients with systemic bacterial infections268. Bottner et al.269 measured serum levels of 
different markers including PCT, CRP and ESR in 78 subjects undergoing revision total knee 
or hip replacement. PCT levels >0.3 ng/mL were very specific (98%) but had a low sensitivity 
(33%). More recently, Glehr et al.270 studied 124 revision arthroplasties and found that PCT 
>0.35 ng/mL revealed a sensitivity of 89% and specificity of 37%. In both studies, procalcitonin 
was outperformed by traditional CRP measurements. Furthermore, Worthington et al.271 as 
well as Drago et al.272 found that PCT levels were not significantly higher among PJI subjects 
when compared to aseptic failures of TJA.
Interleukin(IL)-6 is another often-proposed marker for PJI that has repeatedly been shown 
to be significantly higher in infected cases269-272. IL-6 is secreted by different immune cells, 
such as monocytes, macrophages, fibroblasts and T2 lymphocytes. Because IL-6 triggers the 
release of CRP in liver cells, it can react much faster than CRP. There is evidence that the 
peak and return to base levels after uncomplicated TJA surgery is even faster than CRP271,273. 
Bottner et al.269 proposed that IL-6 <12 pg/mL had a 95% sensitivity and 85% specificity. Glehr 
et al.270 stated that an IL-6 <2.55 pg/mL had a sensitivity of 92% and specificity of 59%. Ettinger
et al.274 analyzed data from 98 patients, 57 with aseptic joint failure, 20 low-grade infections
and 21 high-grade infections. They found a IL-6 cutoff of 5.12 pg/mL had a sensitivity of 80% 
and specificity of 87.7% for predicting a low-grade infection. The classification tree method
showed that the combination of CRP and IL-6 was the most suitable combination for 
discriminating aseptic loosening from low-grade infection. A patient with IL-6 >5.12 pg/mL and 
CRP >0.3 mg/dL could be categorized as very likely (high-risk) to have a low-grade infection274.
Notwithstanding, these papers show that sensitivity gains compared to CRP are only marginal
and come at the expense of decreased specificity. Focusing specifically in shoulder 
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arthroplasty, Grosso et al.275 found serum IL-6 is not an effective marker for diagnosis of 
infection. Additionally, laboratory requirements for IL-6 measurement is much more complex 
and not as widely available as CRP.
The search for a more favorable serum marker of PJI continues with other molecules such as 
tumor necrosis factor-alfa and soluble intercellular adhesin molecule-1 under scrutiny. There is 
already limited evidence of its ability in distinguishing PJI from aseptic failures269,271,272. 
For the time being, ESR and CRP are still the more practical serum markers and they should 
be ordered in virtually all cases of painful total joint arthroplasty requiring revision. It has been 
demonstrated that their use before arthrocentesis is the best diagnostic strategy for PJI (hip 
and knee)276. Whether different ESR and CRP thresholds should be adopted according to 
anatomic site is not completely defined. It also seems clear that joints other than hip or knee 
lack more extensive research as to their specific diagnostic accuracy.
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Arthrocentesis
Synovial fluid analysis is most probably the best venture for preoperative diagnosis of PJI. The 
enormous amount of research being performed worldwide on this topic is the natural response 
of such a belief.  Furthermore, both the 2010 American Academy of Orthopedic Surgeons 
(AAOS) guidelines277 and the 2013 ICM on PJI85, recommend joint aspiration for synovial fluid 
testing when there is a clinical or laboratory suspicion of infection. 
Traditionally, TKA and THA aspirations were performed to obtain fluid for direct Gram 
examination and bacterial culture. As results of synovial fluid leukocyte count’s diagnostic 
accuracy for differentiating PJI from aseptic failure became known it gained increasing 
popularity. Nowadays, several other investigations can (and perhaps should) be performed 
when the joint is aspirated and fluid is available for testing as will be discussed further.
There is nevertheless a major practical limitation of such tests that is seldom discussed in 
the literature. It relates to the technical difficulties in performing the arthrocentesis, especially
in the hip. Because of its superficial location, the knee is usually readily available for 
aspiration in the outpatient setting. The hip however, presents different challenges. Because 
of its distance from the skin, adjacent anatomic neurovascular structures, and poor probability
of blindly reaching the joint space, most clinicians hesitate to attempt aspiration of the hip 
joint without fluoroscopic or ultrasound guidance278. Sometimes, even despite confirmed 
appropriate anatomic location within the joint at the time of aspiration, fluid is not recoverable 
the so called “dry tap”. There is a paucity of information in the literature regarding the exact 
rate of “dry taps” in joint aspirations.  In our empirical experience, it is more common in hips 
but it can also happen in TKA.
It is critical to emphasize that absence of recoverable fluid within the joint does not imply 
that periprosthetic joint infection is not present. Ali et al.279 while investigating the utility of hip 
aspiration in 73 patients with moderate to high risk of infection, found a dry tap to be present in 
32% of THA and the volume of fluid recovered from infected (4.1mL) and aseptic (4.7mL) was 
nearly identical279. Corona et al.280 described a technique for percutaneous interface biopsy in 
dry-aspiration cases (ten hips and 14 knees) and found that 17 (71%) patients were ultimately 
found to be infected after revision surgery. Most studies, recommend washing these “dry” joints 
with saline in order to increase the chance of recovering fluid for culture. However apart from 
culture, most other tests deal with some kind of fluid concentration measurement and therefore 
this methodology would hamper the results.  
One other major issue that the treating clinician must be aware in interpreting the results and 
deciding when to perform an arthrocentesis is the negative impact of systemic antibiotics in 
most synovial fluid test’s accuracy. Shahi et al.281 have shown that premature antibiotic therapy
may compromise the diagnosis of PJI. The median laboratory values of 53 patients that 
were on antibiotics showed significantly lower serum ESR and CRP as well as synovial fluid 
leukocyte count, polymorphonuclear neutrophil (PMN) percentage and naturally higher rates 
of negative cultures and false-negative cases falling below proposed diagnostic thresholds281.
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While serum ESR and CRP are easily available for repeat measurement, joint aspiration 
(especially hip) is not as easy and consideration should be given to allow for an antibiotic-free 
period of at least two weeks before arthrocentesis is performed85,277. It is critical that systemic 
antibiotics not be administered to the patient suspected of PJI until deep sampling has been 
obtained. Only risk of sepsis should supersede this axiom. Unfortunately, in clinical practice 
many patients are started on antibiotics before a definitive diagnosis is made.
GRAM STAINING AND CULTURE
Gram staining is a long held tradition among clinicians whenever there is a suspicion of 
infection. There is however extensive evidence showing that in the context of PJI specifically,
the sensitivity of the test is extremely low282,283. Notwithstanding, apart some reports on false 
positive results284, its overall specificity is considered extremely high 282,283. Although it is 
perhaps expendable, if performed it should never be used to rule out PJI.
Traditional cultures of aspirated joint fluid remain an important feature of preoperative diagnosis
and should not be disregarded. Obtaining a causative pathogen is not only indicative of 
infection but it also may help guide treatment choices. If the study is used as a confirmatory 
test for patients with clinical and/or laboratory suspicion of infection and not as a universal 
screening test, the predictive value of a positive result is high. Nevertheless, it is far from 
being the ideal diagnostic tool to exclude infection. Many studies have demonstrated the 
failure of culture of the aspirated fluid to provide accurate diagnosis of PJI, especially low 
sensitivity279,285-287. 
The reason for such limitations will become obvious as the correct methodology for intra-
operative microbiological sampling is discussed further ahead. As previously noted, especially 
in chronic low-grade infections, there are but few planktonic bacteria floating around in the 
synovial fluid. Multiple tissue sampling and even some kind of biofilm disruption technique of 
the extracted implants greatly enhances both sensitivity and specificity of cultures. Additionally, 
in a proportion of cases microorganisms identified in the preoperative aspiration fluid may not 
have a total correspondence with those ultimately identified in intraoperative samples288,289. 
Holleyman et al.289 showed that only 37 out of 75 cases (49%) matched for both microorganism
and antimicrobial sensitivity comparing preoperative joint sampling obtained by either 
aspiration or tissue biopsy and intra-operative findings.
In summary, a negative aspirate culture often represents a false-negative (especially in cases 
of chronic infection by low virulence microorganisms) and even culture growth may constitute 
a false-positive that must be interpreted in conjunction with other diagnostic tests.
LEUKOCYTE COUNT AND DIFFERENTIAL
Synovial fluid leukocyte counts and neutrophil differential has become an important tool in 
the past few years as different papers have consistently shown good diagnostic accuracy. 
Nevertheless, proposed thresholds vary significantly in the literature 290-295 according to the 
definition used for PJI (see table III). 
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Because the hip is not as easily aspirated in the clinic, these values are more often studied in the 
knee. Schinsky et al.293 studied 201 total hip arthroplasties (55 infected and 146 noninfected)
and found the optimal cutoff to be around 4,000 leucocyte/μL which is higher than most other 
studies that focus on TKA. However, other authors that studied THA and TKA simultaneously 
did not find such a significant difference. 
Dinnem et al.290 studied a total of a total of 75 patients including 48 TKA and 27 THA. They 
found similar optimal cutoffs for hips (1,425 cells/μL) and knees (1,715 cells/μL). In our own 
cohort (results will be discussed further ahead in this thesis), we also did not detect a higher 
synovial fluid leukocyte count amongst infected hips. 
Much as for serum inflammatory markers, there is the question of how reliable are these 
conventional thresholds in patients with inflammatory arthropathy. Based on limited evidence 
presented by Cipriano et al. (27), no change from the above thresholds are recommended85.
Their data on 871 revision joint arthroplasties (TKA and THA) including 61 cases with 
inflammatory arthritis found very similar optimal cutoffs in both groups. Total leucocyte 
counts over 3,450 cells/μL (91% sensitivity; 93% specificity) and PMN proportion >78% (96% 
sensitivity; 87% specificity) for the non-inflammatory group compared to > 3,444 cells/μL (88% 
sensitivity; 80% specificity) and PMN proportion >75% (100% sensitivity; 82% specificity) for 
the non-inflammatory group.
Despite this wide range of proposed thresholds for chronic infections, delegates to the ICM 
on PJI were able to reach a strong consensus that leukocyte counts >3,000 cells/μL and 
proportion of PMN > 80% are indicative of infection occurring later than six weeks after 
surgery 85. Nevertheless, some technical considerations should be regarded. 
If some kind of bloody or traumatic arthrocentesis is performed, serum white blood cells (WBC) 
and neutrophils are introduced into the joint which can then create false-positive readings. In 
order to minimize such phenomenon, it is recommended that observed synovial fluid WBC 
count results be transformed using the synovial red blood cell (RBC), serum RBC and serum 
WBC concentrations to adjust for traumatic aspirations according to a previously validated 
formula291: expected WBC = (WBCblood=RBCblood) x RBCfluid. The difference between the 
observed number of fluid leukocytes and the expected number of WBC introduced into the 
knee joint with the blood yields the real number of WBC present in the joint fluid before 
arthrocentesis: adjusted WBC = observed WBC - expected WBC.
Another limitation of this test relates to metal-on-metal (MoM) bearing surfaces or metal 
corrosion. It is well established that a hypersensitivity adverse reaction to metal debris (ARMD) 
with either aseptic lymphocytic vasculitis-associated lesions (ALVAL) or metallosis can occur 
even in the new generation metal-on-metal bearings and its clinical presentation may mimic 
infection243. Wyles et al.296 have shown that the synovial fluid in failed MoM THA, may not 
only be macroscopically indistinguishable from bacterial induced purulence but may also offer 
extremely high WBC readings.
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More recently, Yi et al.259 published their results of revision THA with metal-on-metal bearings
or metal corrosion. They found that excluding synovial fluid samples found to be inaccurate
(if the laboratory technician noted the presence of metal debris, amorphous material, 
fragmented or degenerating cells or the presence of clots; or if the sample had some defect, 
for instance excessive viscosity, that prevented an automated cell count from being performed) 
the synovial fluid leukocyte count diagnostic accuracy was improved, setting an optimal cutoff 
at 4,350cells/μL with 100% sensitivity and 95% specificity. Both these papers, recommend 
that manual synovial fluid WBC count should be requested when evaluating these samples. 
Although a manual count will not necessarily lead more accuracy259, it can alert the physician 
to an unreliable count.
Table III Leukocyte count and differential results.
PJI Definition Cell counttechnique Joint
Proposed 
cutoff(s)
Sensitivity 
(95% CI)
Specificity 
(95% CI)
Trampuz 
et al. 2004 294
At least one of the following: 1) growth of 
the same micro-organism in at least two 
cultures of synovial fluid or periprosthetic
tissue; 2) purulence at the time of arthro-
centesis or surgery; 3) acute inflamma-
tion on histopathologic examination.
Microscopic
examination TKA
1,700 cells/μL
PMN >65%
94%
(80-99)
97%
(85-100)
88%
(80-93)
98%
(93-100)
Della Valle 
et al. 2007 297
Same organism ≥2 cultures OR ≥2 of 
the following:  1) one positive culture; 2)
consistent histopathology >10PMN in the
5 most cellular field; 3) gross purulence.
Not specified TKA
3,000 cells/μL
PMN >65%
100%
97.6%
98.1%
84.9%
Schinsky 
et al. 2008 293
Two of the following: 1) positive intra-
operative culture; 2) gross purulence, 
3)consistent histopathological result.
Not specified THA
4,200 cells/μL
PMN >80%
84%
(74- 94)
84%
(74-93)
93%
(88-98)
82 %
(76-89)
Ghanem 
et al. 2008 292
At least one of the following:
1) the presence of an abscess or sinus 
tract communicating with the joint; 2)
positive preoperative culture of aspirate 
on solid medium; 3) ≥2 intraoperative 
cultures of the same organism, or one 
positive culture on solid medium + gross 
purulence or abnormal histology.
Manually with
use of the
Wright-Giemsa 
stain
TKA
1,100 cells/μL
PMN >64%
90.7%
(85.1–94.7)
95.0%
(90.4–97.8)
88.1%
(83.6–91.7)
94.7%
(91.3–97.1)
Cipriano 
et al. 2012 265
Same organism ≥2 cultures OR ≥2 of 
the following: 1) sinus tract or gross 
purulence; 2) one positive deep culture; 
3) consistent histopathology >10PMN in
the 5 most cellular field.
Not specified
THA 
& 
TKA
3,450 cells/μL
PMN >78%
91.0%
(81-94)
95.5%
(94–97)
93.0%
(91-95)
87.3%
(85-90)
Zmistowski 
et al. 2012 295
Three of the following: 1) positive culture 
from aspirate; 2) positive culture from 
intraoperative tissue; 3) purulence; 4) 
serum ESR>30 mm/h; 5) serum CRP> 
10 mg/L.
Automated 
analysis TKA
3,000 cells/μL
PMN >75%
93%
93%
94%
83%
Dineem 
et al. 2013 290
At least one of the following:
1) histological examination of tissue 
yielding >5PMN per HPF; 2) ≥3 culture 
samples growing identical organisms; 
3) frank pus >50,000 leukocyte/μL + 
growth of pathogenic organism.
Manually in
a Neubauer
 cell counting
chamber
THA 
& 
TKA
1,590 cells/μL
PMN >65%
89.5%
(78.3–99.7)
89.7%
(79.5–99.9)
91.3%
(82.7–99.9
86.6%
(76.1–97.1)
*TKA Total knee arthroplasty; THA total hip arthroplasty; PMN polymorphonuclear neutrophil; HPF high power field.
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LEUKOCYTE ESTERASE
Leucocyte esterase (LE) is an enzyme secreted by neutrophils that have been recruited to 
the site of an infection. A rapid colorimetric strip test for this enzyme has long been used to 
diagnose urinary tract infections, especially as a rule out test298. 
Parvizi et al.299 were the first to recognize the potential of this simple test and ascertain its 
role in the diagnosis of PJI. Since them, others have found similar results300-303 (see table IV). 
Given its simplicity and wide availability it may be easily used as a fast test in the office when 
performing diagnostic aspirations or it can even be used as an adjunct to intraoperative 
decision making. 
There are however some important practical limitations. Firstly, sometimes it is not possible 
to gather enough synovial fluid to perform an LE test in addition to all other examinations (i.e. 
leukocyte count, culture, etc.). Secondly, often there is some blood or debris in the aspirate 
that preclude a decent test reading. In this regard, it has been proposed that a centrifugation 
protocol with the use of the supernatant for colorimetric strip testing is simple and does not 
affect the accuracy of the test304. Finally, it is also important to emphasize that most studies
do not specifically mention certain sub-group of patients such as those with inflammatory 
arthropathy, metallosis or those with previous antibiotic therapy. As such, its role in the 
presence of these confounding variables is yet to be established.
Table IV Leukocyte esterase test results.
Joint Definition	of	infection Positivity criteria
Sensitivity 
(95% CI)
Specificity	
(95% CI) Observations
Parvizi et al.299 
2011 TKA
Criteria for PJI: 1) sinus tract or 
open wound communicating with 
the joint; 2) purulence at the time of 
arthrocentesis or surgery; 3) pos-
itive cultures; 4) elevated serum 
markers as well as elevated leuko-
cyte count and/or PMN proportion.
++
+ or ++
81%   
(62–92)
94%    
(77–99)
94%   
(77–99)
87%
(77–93)
26% inadequate samples 
(i.e. too much blood or 
insufficient amount)
Wetters et al.303
 2012
THA 
& 
TKA
WBC count >3,000 cells/μL
2 positive cultures
or sinus tract
+ or ++
93%
93%
89%
77%
29% unable to be read     
(i.e. blood, debris or a 
result that could not be 
differentiated between 
positive and negative)
Tischler et al.302 
2014
THA 
& 
TKA
MSIS Criteria: 1) sinus tract com-
municating with the joint; 2) same 
pathogen ≥2 cultures; 3) at least 
three of the following: a) ESR>30 
and CRP>10; b) synovial leuko-
cyte >2,000 cells/μL; c) PMN pro-
portion>65%; d) purulence; e) one 
positive culture.
++
+ or ++
66%
79%
97%
81%
12% incomplete synovial 
fluid data (i.e. inadequate 
fluid sample to perform all 
tests or a dry tap)
Shafafy et al.301 
2015
THA 
& 
TKA
IDSA Criteria: 1) sinus tract com-
municating with the prosthesis; 2) 
acute inflammation on histopathol-
ogy; 3) purulence in the absence of 
other etiology; 4) same pathogen 
≥2 cultures.
125 WBC
70 WBC
81%
86%
93%
87%
significant agreement      
between 
LE semi-quantitative 
automated readings and 
leukocyte count
* TKA total knee arthroplasty; THA  total hip arthroplasty; PMN polymorphonuclear neutrophil; HPF high power field; MSIS Musculoskeletal Infection 
Society; ESR erythrocyte sedimentation rate; CRP C-reactive protein; IDSA Infectious Diseases Society of America; LE leukocyte esterase.
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OTHER BIOMARKERS
Much as the synovial fluid leukocyte count and leukocyte esterase, other biomarkers (i.e. molecules
that are involved in the host response to infection) are being actively researched 305-308. 
Gollwitzer et al.307 further demonstrated that, for the vast majority of them, analysis in the 
synovial fluid is more accurate than analysis of serum levels. They can broadly be divided into 
two categories: proinflammatory cytokines and antimicrobial peptides. 
Although an exhaustive report on every molecule ever tested is perhaps not warranted, countless
cytokines (e.g. IL-1b, IL-6, IL-8, IL-17, TNF-α, IFN-∂, etc.) have already been shown to be 
substantially more elevated in the synovial fluid of patients with periprosthetic infection when 
compared to those patients with aseptic failures 305-308. Of these, IL-6 is perhaps the most widely
studied in clinical practice. Lenski et al.309, studying 69 TJA (mostly hip and knee) found an 
optimal threshold at 30,750 pg/ml which is much higher but also more accurate (91% sensitivity;
95% specificity) than previously described. In 2010, Deirmengian et al.306 found the optimal 
cutoff to be 13,350 pg/ml (100% sensitivity; 100% specificity); Jacovides et al.308 a year later 
proposed 4,270 pg/ml as the best threshold (87% sensitivity; 100% specificity) and Gollwitzer 
et al.307 located the ideal limit at 1,896 pg/ml (60% sensitivity; 95% specificity).
Randau et al.310 presented their results on 120 patients (both TKA and THA) and found that 
adding synovial fluid IL-6 measurement might increase diagnostic accuracy as opposed to 
measuring it in the serum only. Nevertheless, synovial fluid IL-6 levels at >2,100 pg/ml, offered 
reasonable specificity (85.7%) but limited sensitivity (62.5%). Increasing the cutoff to >9,000 
pg/ml naturally raised specificity to 97.6% but also significantly reduced sensitivity to 46.9%. 
Recently, Frangiamore et al.311 focusing specifically in total shoulder arthroplasties showed the 
ideal cutoff for IL-6 was 446 pg/mL (86% sensitivity; 95% specificity).
In addition to the large discrepancy between proposed cutoffs (around 2,000-4,000 pg/mL 
to over 30,000 pg/mL even if we consider THA/TKA findings only) and suboptimal diagnostic 
accuracy with limited sensitivity in most studies, there is also the topic of laboratory 
processing. Cytokines measurement is not easy and it requires immunoassays that are not 
widely available thus limiting its role in clinical practice. 
 
Antimicrobial peptides are a large group of peptides that constitute crucial components of the 
innate immune system and have the capacity to directly kill or inhibit the growth of microbes 312. 
Examples of such molecules that have proven its value in distinguishing infected from aseptic
total joints are alpha- and ß-defensins, skin-derived antileukoproteinase and cathelicidin 
LL-37305,307. By far the most widely known and studied molecule thus far has been alpha-defensin.
In their groundbreaking initial study, Deirmengian et al.313 analyzed synovial fluid samples 
from 149 THA/TKA cases. Of those, 37 had PJI according to the MSIS criteria. Immunoassay 
measurement of the synovial fluid alpha-defensin protein was optimized to operate at a cutoff 
value of 5.2 mg/L, providing results as a semiquantitative signal-to-cutoff ratio of 1. It was able 
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to correctly classify 143 of the 149 patients, corresponding to a specificity of 95.5% (95%CI, 
89.9 - 98.5%) and a sensitivity of 97.3% (95%CI, 85.8 - 99.6%). 
Since then, the same research group has demonstrated the value of the alpha-defensin assay 
in different scenarios. Based on their synovial fluid sample’s bank, they were able to select 244 
positive culture out of 498 alpha-defensin positive samples and showed the alpha-defensin
test provides consistent results regardless of the organism type, Gram type, species or 
virulence of the organism314. Studying the records of 106 patients (77 TKA and 29 THA) meeting
 the MSIS criteria for PJI and with a positive alpha-defensin test, they found 30 of them had 
received antibiotics within 2 weeks before the diagnostic workup. Although synovial fluid 
leukocyte counts and proportion of PMN (as well as serum CRP) were significantly lower in this 
sub-group of patients, alpha-defensin level was not significantly decreased, thus showing the 
alpha-defensin test is not affected by prior antibiotic treatment315. Comparing alpha-defensin 
test to leukocyte esterase colorimetric strips they also found it to be much more accurate316. 
A closer look into these findings shows that LE tests were performed at the time of sample 
collection without processing of the synovial fluid thus showing all the known limitations: eight 
out of 46 joint fluids were unreadable as a result of blood interference and defining 2+ result to 
be positive yielded a sensitivity of 68.8% and a specificity of 100%. Samples for alpha-defensin 
testing were subjected to centrifugation to separate all particulate and cellular material and the 
resulting supernatant was then used for the immunoassay. This specific methodology correctly 
diagnosed 100% of patients in this study316.
Independent researchers have also been able to replicate these results hence underlining 
the great promise of this test. Bingham et al.317 found the alpha-defensin assay to correctly 
diagnosed all 19 infections in their 61 hip and knee arthroplasties samples, with an overall
sensitivity of 100%and specificity of 95%. Frangiamore et al.318 showed similar results in 
their cohort of first- and single-stage revision THA or TKA procedures performed for aseptic 
loosening or suspected PJI (100% sensitivity; 98% specificity). Interestingly, they also looked 
at second stage revisions and in this setting it performed less well (67% sensitivity; 97% 
specificity). With regards to total shoulder arthroplasty, Frangiamore et al.319 also found 
results to be less favorable than for THA or TKA (63% sensitivity; 95% specificity). Just recently,
Bonanzinga et al.320 published their experience with the alpha-defensin assay. The major 
particularity of this study is that alpha-defensin measurement was performed by an indepen-
dent blinded laboratory, unlike all the previously mentioned papers, which is useful in proving 
the reproducibility of the test. Using the ICM definition of PJI, they found the sensitivity of the 
alpha-defensin immunoassay to be 97% (95% CI, 92%-99%) and the specificity 97%(95% CI, 
92%-99%).
There seems to be sufficient evidence that the alpha-defensin immunoassay performed in a 
laboratory by trained staff is a very promising diagnostic tool for PJI diagnosis. However, such 
laboratories are not widely available and in order to overcome that lack of practicality a quick 
lateral flow assay (Synovasure®, Zimmer, Warsaw, IN) has been developed. Nevertheless,
there is still a paucity of information regarding this test specifically. It is possible that 
publication bias may exist. This is an important issue in diagnostic accuracy studies, as results 
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of new tests with poor sensitivity and specificity may remain unpublished. In the only published 
paper focusing specifically in the use of this specific lateral flow assay as a point-of-care test 
without laboratory sample processing, results lack behind those previously reported. Kasparek 
et al.321 used this test intra-operatively at the time of revision surgery in 29 TKA and 11 THA. 
Twelve patients had confirmed PJI based on MSIS criteria. The test offered a sensitivity of only 
67% (95%CI, 35%-89%) and a specificity of 93% (95%CI, 75%-99%). Just recently,  Sigmund
et al.322 focusing on 50 revision arthroplasty surgeries, showed 69% sensitivity and 94% 
specificity. As such, care must be taken before extrapolating the alpha-defensin quantitative 
test results obtained in the laboratory after due processing of the synovial fluid to the lateral 
flow test device that is commercially available and is intended to be used as a point-of-care test.
In addition to the aforementioned cytokines and antimicrobial peptides that require complex 
laboratory methodologies that are not widely available in routine daily practice and/or expensive
tests (in Portugal the Synovasure® test costs around 400€), other simpler and inexpensive 
biomarkers can be tested. 
In their initial study, Jacovides et al.308 screened 46 inflammatory proteins and cytokines and 
found synovial CRP and α2-macroglobulin to be among the five most accurate biomarkers. In 
recent years, numerous papers (see table V) have demonstrated the potential use of synovial
CRP to differentiate between infected and non-infected total joint arthroplasties despite some 
variability in proposed cutoffs323-329. Moreover, in their seminal paper on alpha-defensin, 
Deirmengian et al.313 found that a 3.0 mg/L threshold for synovial CRP offered a 97.3% 
sensitivity and 78.6% specificity. They further demonstrated that applying this test to every 
alpha-defensin positive test correctly reversed all five false-positive alpha-defensin results to 
true-negatives but did not erroneously reverse any true-positive alpha-defensin results.
Synovial CRP may be measured using different methodologies including complex ELISA 
assays but also the more common high sensitivity nephelometry test. This test is already 
routinely performed in many laboratories as it is commonly used to stratify cardiovascular 
risk330. An exploration of table V shows this nephelometry method failed to measure samples 
with very high viscosity as is often the case in synovial fluids324,328,329. As will be discussed 
further ahead we were able to overcome this limitation by diluting samples in solution of 
hyaluronidase.
Our research aimed to focus on a specific list of biomarkers that could perhaps make a 
difference in routine daily clinical decision making. As such, alongside leukocyte count we 
chose to focus on C-reactive protein, adenosine deaminase, alpha-2-macroglobulin and 
procalcitonin. These tests are not only inexpensive (they cost around 8€, 9€, 6€ and 14€ 
respectively) but were already being routinely performed in our own institution laboratory (and 
widely available in most other laboratories).
Prophylaxis, Diagnosis and Treatment of Prosthetic Joint Infections  Diagnosis
58
Table V Synovial C-reactive protein results.
Definition	of	
infection Laboratory technique
Proposed 
cutoffs
Sensitivity 
(95% CI)
Specificity	
(95% CI) Observations
Parvizi et al.325 
2012
similar to 
MSIS criteria
Individual ELISA
(10 infected, 5 aseptic) 0.06 mg/L
70%      
(62-92)
100%    
(77-99)
66 revision TKA for septic or 
aseptic reasons; accuracy and 
diagnostic threshold highly 
dependent on the CRP mea-
surement technique used.
Multiplex ELISA
(25 infected, 34 aseptic) 3.7 mg/L
84%     
(77-99)
97%     
(77-93)
automated turbidimetric 
method
(25 infected,30 aseptic)
16.5 mg/L 76%     (77-99)
93.3%   
(77-93)
Parvizi et al.326 
2012
AAOS 
guidelines
automated turbidimetric 
method 9.5 mg/L 85% 95.2%
35 aseptic and 20 infected 
revision THA/TKA but also 8 
primary TKA.
Vanderstap-
pen et al.329 
2013
MSIS criteria
automated 
immunoturbidimetric 
assay (detection limit 
0.3 mg/L)
1.8 mg/L 100%    (72-100)
84.9%   
(68-95)
44 TKA requiring revision 
surgery; 51 cases CRP as-
say not performed because 
fluid was too viscous (43) or 
insufficient (8)2.8 mg/L
90.9%  
(59-100)
93.9%   
(80-99)
Ronde-Ostau
et al.327 2014 MSIS criteria immuno-nephelometry
2.8 mg/L 100%  (69-100)
82%   
(48–98) 10 aseptic and 10 infected re-
vision TKA but also 10 aseptic 
effusions in native knees.
5.4 mg/L 90%   (56–100)
91%   
(59–100)
Treteault et 
al.328 2014 MSIS criteria
automated turbidimetric 
method
6.6 mg/L 
(overall)
88%    
(82–93)
85%   
(79–91)
119 THA/TKA requiring revi-
sion surgery; 22 cases CRP 
assay not performed because 
fluid was too viscous.
8.5 mg/L 
(hip)
87%   
(78–95)
86%   
(78–95)
14.1 mg/L 
(knee)
82%   
(73–92)
93%   
(87–99)
Buttaro et 
al.323 2015 MSIS criteria
high-sensitivity 
turbidimetry (detection 
limit 0.2 mg/L)
9.5 mg/L 90%      (71–99)
94%    
(84–99)
71 THA reoperation including
debridement, first or second-
stage; No difference to frozen 
section in ability to diagnose 
infection.
Omar et al.324 
2015
AAOS 
guidelines immuno-nephelometry 2.5 mg/L
95.5%
(87–100)
93.3%
(84–100)
89 chronic painful THA (i.e. 
acute infections excluded); 9 
cases excluded cause of dry 
tap or fluid was too viscous.
*MSIS Musculoskeletal Infection Society; AAOS American Academy of Orthopedic Surgeons; ICM International Consensus   Meeting; TKA total 
knee arthroplasty; THA total hip arthroplasty.
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Diagnosing the Acute Infection 
As it was previously mentioned the diagnosis of infection in the acute postoperative period 
is not always straightforward. Inflammatory signs and even wound leakage are a common 
finding after surgery and distinguishing aseptic from potentially infected cases is often difficult. 
On one hand, timely recognition and intervention may lead to successful infection eradication 
with preservation of the original prosthesis. On the other hand, unwarranted surgery with all its 
costs and potential complications must be avoided.
SEROLOGY
Diagnostic accuracy of ESR and CRP are extensively studied in the context of chronic 
infections to try and distinguish them from aseptic failures. In the acute postoperative 
infections, their role is not as clear. In the recent consensus definition85, CRP >100mg/L in the 
first six weeks after surgery was considered indicative of infection but no threshold for ESR 
could be determined.
Two major papers specifically address the issue of laboratory diagnoses of PJI in first six 
weeks after surgery. Bedair et al.331 focuses on TKA and Yi et al.332 studies hip replacements. 
While they both found that synovial fluid white cell count was the most informative test, they 
reached different conclusions regarding serum inflammatory markers. ESR was significantly
different between infected and non-infected cases in the hip study332 but not in the knee 
setting331. CRP was found to be significantly higher in infected cases in both studies and 
suggested cutoffs are similar at around 93 and 95mg/L for hip and knee respectively. 
Notwithstanding, sensitivity/specificity of these proposed thresholds was much better for THA 
(88%/100%) than for TKA (68%/66%)331,332.
To understand the importance of these markers in the postoperative period it is essential to 
know their normal kinetic patterns after uncomplicated arthroplasty. As one would expect both 
these markers rise after surgery. The peak seems to be higher after TKA in comparison to 
THA333,334, maybe because the bone and soft tissue trauma is higher in TKA, helping to explain 
the different diagnostic accuracy demonstrated by the proposed cutoff. Nonetheless, after 
the initial peak, these values should steadily decrease after uncomplicated arthroplasty. ESR 
levels usually peak around the fifth postoperative day and drop close to preoperative levels 
by the end of the third month after THA or even as late as the ninth to twelfth month after 
TKA333,335,336. As one would expect, CRP respond much quicker usually peaking at the second
or third day and falls swiftly by the fifth to seventh day. Return to basal levels also occur 
much faster than ESR, at around the sixth week although again it occurs faster in hips than in 
knees 273,333,335,336. Despite this mean trend, there are wide inter-individual variations and many 
cases do not follow the typical patterns. In this regard C-reactive protein has less frequent atypical
temporal patterns than ESR and is therefore more useful shortly after surgery336. All the 
same, many patients especially after total knee replacement do have CRP values >100mg/L 
during the first postoperative days thus recommending caution in interpreting an isolated CRP 
measurement.
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IL-6 seems to be an even superior marker for the acute inflammatory phase after TJA as it 
shows an analogous but faster pattern273,334. It peaks at around the 6th postoperative hour and 
rapidly falls with a half-life of 15h. Return to base levels also occur faster than CRP. A slightly 
prolonged inflammatory course is also seen in TKR patients but the peak falls well within the 
first 24 hours 334.
Understanding this normal pattern after uncomplicated arthroplasty is the key to better using
these inflammatory parameters to our advantage in the diagnosis of early acute PJI. A 
sustained persistent elevation of these parameters or rebound after the initial fall (especially
CRP or IL-6) should raise the suspicion of an infectious complication. Maathuis et al.337 
proposed  a protocol using ESR and CRP as an adjunct to clinical judgement to help dictate
the need and timing for debridement in patients with persistent drainage after total joint 
replacement. Serial measurements of these inflammatory parameters were taken in suspicious 
circumstances and only decrease in ESR and CRP or a decrease in drainage could postpone 
or alter the decision to perform open debridement. Persistent wound leakage by the tenth day 
would command surgery for debridement. We have been using a similar protocol in the past 
few years in our institution. It allowed us to accurately detect early infection in 96% (28/29) of 
patients that underwent early debridement after primary hip or knee arthroplasty. 
SYNOVIAL FLUID TESTING
Much as serum inflammatory markers, synovial fluid leukocyte count and differential are 
much more exhaustively studied in the context of chronic infection. Christensen et al.338 have 
assessed the natural progression of synovial fluid leukocyte counts and the percentage of 
PMN after primary total knee arthroplasty. They found that total leukocyte count decreases
rapidly during the first three months whilst proportion of PMN continued to decrease 
significantly throughout the first two postoperative years. Most importantly they showed that 
the use of the thresholds defined for chronic infection during the first ninety postoperative days 
may result in a significant proportion of false-positive results.
As such, proposed thresholds for acute infections occurring in the first six weeks after surgery 
are much higher than for chronic infections: Leukocyte count >10,000 cells/μL and proportion 
of PMN > 90%85. These cutoffs are based mostly on only two papers focusing on this specific
clinical scenario and a closer look at their results may help to further comprehend them. 
Bedair et al.331 studied 224 knees (1.9%) out of 11,964 primary TKAs that had arthrocentesis 
performed within the first 6 weeks after primary surgery. After excluding 78 aspirations for 
several different reasons they were left with146 knees (19 infected and 127 aseptic) for 
analysis. Two potential cutoff values for the synovial fluid leukocyte count were found. With the 
threshold set at 10,700 cells/μL, acute infection could be diagnosed with a sensitivity, specificity,
positive predictive value (PPV) and negative predictive value (NPV) of 95%, 91%, 62%, and 
99%, respectively. With the threshold set at 27,800 cells/μL the sensitivity, specificity, PPV, 
and NPV were 84%, 99%, 94%, and 98%, respectively. The lower leukocyte count cutoff 
around 10,000 cells/μL is helpful in excluding infection and only around 30,000 cells/μL is the 
leukocyte count a useful positive predictor of infection. Proportion of PMN >89% was found 
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to have sensitivity, specificity, PPV, and NPV of 84%, 69%, 29%, and 97%, respectively (i.e. 
good for excluding infection). Yi et al.332 performed a similar study focusing on THA. On a 
consecutive series of 6033 primary THA, 122 (2%) were found to have undergone a 
reoperation within the first 6 weeks postoperatively. Seventy-three hips (36 infected and 37 
aseptic) were available for analysis after exclusion of 49 patients. Setting the optimal cutoff at 
12,800 cells/μL they found the sensitivity, specificity, PPV, and NPV to be 89%,100%, 100% 
and 88% respectively. Proportion of PMN >89% was found to have sensitivity, specificity, PPV, 
and NPV of 81%, 90%, 91%, and 79% respectively. This study found a highly specific cutoff at 
around the lower threshold previously determined for knees.
To the best of our knowledge there is no study comparing leukocyte counts and percentage 
of PMN natural progression after uneventful THA and TKA. As such, one can only speculate if 
the higher postoperative inflammatory response after TKA previously demonstrated in serum 
markers is also true for synovial fluid. If that is the case perhaps using the same cutoff for both 
TKA and THA is not the most adequate and more studies are needed to clarify this. Meanwhile, 
one should be aware of this seeming difference. 
Other synovial fluid biomarkers that are being studied in the chronic setting (e.g. CRP, IL-6, 
etc.) lack research in the acute postoperative setting and certainly no recommendation can be 
made at this point. 
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Nuclear Medicine and other Imaging Techniques
Despite substantial evidence regarding the effectiveness of nuclear imaging in the diagnosis of 
PJI, currently there seems to be no role for its routine use85. Several methodologies have been 
proposed but they are expensive and time-consuming thus limiting their role in the work-up
for PJI.  
Notwithstanding, there are a few selected cases where it might be indicated. In cases where 
repeated attempts at joint aspiration failed to provide fluid for analysis, especially if other 
co-morbidities ill advise against more invasive testing or surgery, nuclear imaging may prove to 
be a valuable asset. In addition, such tests are often solicited in trying to identify other causes
of joint pain/failure and physicians must be aware of its real value in affirming or excluding 
infection.
Bone scintigraphy with technetium-99m labeled diphosphonates, which is often requested to 
ascertain the presence of loosening, is undoubtedly the most extensively investigated nuclear 
medicine test for imaging total joint arthroplasties. Several different (and often contradicting) 
uptake patterns have been proposed to serve as better indicators of infection but regardless 
of how images are interpreted, its overall accuracy for diagnosing infection of lower extremity 
joint prostheses, at around 50-70%, is low339-341. At the present time this test is used primarily 
for screening purposes, especially after the postoperative period where periprosthetic activity 
may persist for up to 12-24 months340. A normal study makes it very unlikely that the patient’s 
symptoms are related to an infection.
Over the years, various techniques designed to overcome the limitations inherent to bone 
scintigraphy have been proposed. Gallium-67 citrate imaging is a classic and several studies 
were performed mostly in painful total hip prostheses with a wide range of diagnostic accuracy 
variability, but overall low sensitivity340. Over the years the use of gallium for joint replacement 
infection has declined, and it has been replaced in most circumstances by labeled leukocyte 
imaging. In vitro labeled leukocytes will accumulate at a site of infection but also accumulate
in bone marrow, the normal distribution of which can be variable after TJA surgery thus 
decreasing the specificity of the test340. Using any periprosthetic activity regardless of intensity, 
as the criterion for infection greatly increases sensitivity (while naturally decreasing specificity) 
for PJI diagnosis. Following this test with bone marrow imaging greatly increases specificity 
by mapping reticuloendothelial cells of the bone marrow where labeled leukocytes will also 
accumulate. Several papers report diagnostic accuracy of this combined approach around or 
above 90%340,342-344. 
Positron Emission Tomography (PET) bone imaging also shows great promise in the 
evaluation of suspected PJI. The rationale being that activated leukocytes demonstrate 
increased uptake of 18F-fluorodeoxyglucose (FDG). There are numerous and conflicting results 
on the real accuracy of this test in diagnosing infection but a recent meta-analysis found the 
pooled sensitivity and specificity of FDG-PET for the detection of prosthetic hip or knee joint 
infection to be 82.1% and 86.6% respectively. Direct comparison with combined leukocyte/
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marrow imaging344 or even simple three-phase bone scintigraphy341 however, does not yet 
seem favorable. Adding advanced imaging that provides detailed anatomical information 
such as Single Photon Emission Computed Tomography (SPECT-CT) seems to have great 
potential. There seems to be gains in both sensitivity and specificity over plain scintigraphy in 
a number of fore mentioned radiopharmaceuticals345,346. The advantages may extend beyond
diagnosing infection. In patients with negative studies, the CT component could provide 
information about other causes of prosthetic failure. 
Although research is underway in these more advanced nuclear imaging modalities as 
well as “infection-specific” molecules such as antibiotics or antimicrobial peptides currently, 
combined labeled leukocytes/bone marrow imaging seems to be the most accurate340. There 
are, unfortunately, disadvantages. The leukocyte labeling procedure is technically demanding
and not routinely available. As such radiolabeled antigranulocyte antibodies and antibody 
fragments have been explored as alternatives with reported suboptimal sensitivity and 
specificity at around 80%347. Surprisingly, even though in-vivo labeled leukocytes accumulate 
in the marrow, in much the same way that in-vitro labeled leukocytes do, scant attention has 
been paid to combining these studies with bone marrow imaging. In trying to validate such 
an approach, that could be integrated into our own clinical practice we performed our own 
research348. We confirmed the lack of specificity of isolated leukocyte scans using sulesomab 
(antigranulocyte antibody). We did however confirm that a subsequent bone marrow scan and 
combined imaging interpretation greatly increases specificity348. Results will be presented in 
more detail ahead.
CT AND MRI
There is a paucity of data regarding the diagnostic value of other advanced imaging modalities 
such as CT or MRI. One paper specifically focusing on this topic found, found that CT scan soft 
tissues findings such as joint distention, fluid-filled bursae and fluid collection in muscles and 
perimuscular fat were accurate in diagnosing infection around THA349. However, these findings
cannot be extrapolated to other joints and confirmation in similar studies is missing. Despite 
known technical difficulties in performing MRI around prosthesis, metal artifact reduction
sequences have been developed and some reports state it may be helpful in distinguishing 
qualitative differences in the appearance of the synovium in TKA between particle-induced 
synovitis, infection and nonspecific synovitis350. Nonetheless, it is not presently recommended 
to use CT or MRI to evaluate for a potential PJI85.
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Microbiological Investigation
Obtaining precise microbiological information is obviously a crucial part of prosthetic joint 
infection management. It is widely considered a definite evidence of infection if the same 
undistinguishable organism grows in two separate samples and, if only a single sample shows 
growth, it is viewed as a minor criterion that must be framed together with other laboratory 
findings244,302,340. 
Aside sustaining diagnosis, it is also a vital piece of information that allows for adequate 
antibiotic treatment thus surrendering the best chance for success. That being said, it is 
natural to conclude that considerable efforts must be undertaken to avoid cases where no 
isolation of microorganisms can be achieved, the so-called culture-negative PJI. Furthermore, 
if a standardized sample gathering protocol is implemented in every TJA revision case, there 
is a consistent proportion of cases that will ultimately reveal themselves to have an infection 
that was previously unrecognized255,351,352.
PREOPERATIVE SAMPLING
In the face of a possible PJI, most patients will have had some kind of specimen sent to culture 
before surgery. Limitations inherent to culture of the synovial fluid obtained by arthrocentesis
have already been discussed elsewhere. These concern mainly limited sensitivity either 
in being able to isolate a microorganism or even being able to identify the full spectrum of 
microorganisms involved in a particular infection279,286,288. Performing a biopsy of either the 
synovium or the bone-implant interface membrane seems to be helpful in increasing diagnostic
accuracy280,353.
Oftentimes, cultures are obtained from a draining wound in the early postoperative period or 
later from a sinus tract. In chronic osteomyelitis, sinus tract swabs are admittedly unreliable in 
predicting bone cultures isolates354,355. The same seems to be true in periprosthetic infections. 
Treteault et al.356 studied the results of superficial cultures taken from 34 draining wounds in 
the acute postoperative period and 21 patients with chronic draining sinuses and compared
them to intraoperative tissue samples. They found that superficial cultures matched the deep 
intra-articular cultures in less than half of patients356. One other study offers scarce evidence
that superficial samples may have different intrinsic value in these two different clinical 
scenarios. Cuñe et al.357 evaluated the relationship between superficial swab and deep 
intraoperative cultures in 56 patients (30 hip and 26 knee) exclusively among patients with 
acute postoperative PJI. They found the overall concordance between superficial and deep 
samples was 80.3%. Superficial swabs were especially accurate when Gram negative bacilli 
or S. aureus were isolated but performed poorly for other Gram positive microorganisms357. 
Notwithstanding, intraoperative samples should always be considered mandatory and 
withholding administration of antibiotics until deep samples are obtained is recommended 
whenever possible.
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INTRAOPERATIVE TISSUE SAMPLING
Adequate deep tissue sampling obtained during revision surgery is still the gold standard for 
the microbiological diagnosis of PJI. There are however a few simple principles that must be 
met in order to achieve satisfactory results.
There is a worldwide agreement that numerous perioperative samples are needed to diagnose 
PJI. In 1998, Atkins et al.358 recommended that five or six specimens should be sent in order 
to increase diagnostic accuracy. Multiple samples increase the chance of growing a pathogen
(i.e. sensitivity) and it also allows more correct interpretation in cases where a skin flora 
organism such as coagulase negative staphylococci is grown. Specificity is increased by 
interpreting the number of samples in which such species is grown. If more than one sample 
grows the same indistinguishable organism it is likely that it is indeed a pathogen and not 
dismissed as a contaminant. Otherwise, it would be very difficult to interpret such findings if 
such commensal bacteria grew in an isolated sample.
Recent guidelines recommend at least three but no more than six distinct intraoperative tissue 
samples should be sent for aerobic and anaerobic culture85,359. Obtaining intraoperative culture 
specimens by using swab cultures should be discouraged. It has been repeatedly shown that 
they perform significantly worse than tissue cultures360-362. Tissue sampling should be obtained 
from different sites within the joint and it has been recommended that in order to reduce the 
risk of cross contamination, they must be taken with different set of instruments and sent to the 
laboratory separately358,363. It has also been shown that they should be immediately transferred
directly to a sterile container or bottle after being taken from the joint. The samples should 
not be placed on the OR table for the duration of the surgical procedure as a significant 
proportion of false positives may arise364.The exact location of each biopsy is naturally 
determined by the treating surgeon but generally, any suspicious looking material should be 
biopsied. A special consideration should be paid to obtaining samples from the bone-implant 
membrane interface248,249,365. Although some authors do recommend obtaining more samples 
in cases of suspected less virulent organisms or in patients with recent antibiotic therapy, 
there is a consensus that culture specificity should not be compromised by taking more than 
five samples85. In such cases, other techniques (e.g. increased incubation time, molecular 
techniques or sonication) may be more helpful. The adoption of this kind of standardized 
procedures carries a definite positive impact on clinical care363.
Another typical concern regards to timing of prophylactic antibiotics administration in revision
arthroplasty. Previous antibiotic therapy is a well-established risk factor for negative 
cultures281,366. With this fact in mind, many over the years have advocated withholding 
perioperative prophylactic antibiotics until deep samples are collected as there is concern that 
occult infection may be present. In recent years, there has been sufficient evidence that such 
a distress is not called for367-369. In a multicenter randomized trial including 37 TKA and 28 
THA with known PJI, Treteault et al.369 were able to show there was no effect on the results of 
cultures obtained intraoperatively when prophylactic antibiotics were administered before skin 
incision or after intraoperative cultures were obtained. Intraoperative cultures yielded the same 
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organisms as preoperative cultures in around 80% of cases in both groups369. More recently, 
Bedencic et al.367 prospectively collected three paired tissue samples before and after the 
administration of prophylactic antibiotics in 29 THA and 11 TKA. Measured tissue concen-
trations of cefazolin in the second set of samples were greater than the minimum inhibitory 
concentration in all samples. Still, no difference was found in cultures results taken before and 
after administration of antimicrobial prophylaxis367. In cases of high suspicion of PJI especially
if a low virulence pathogen is thought to be involved but has yet to be identified, the use 
of prophylactic antibiotics is dependent upon clinical judgment85. Also, if antibiotic therapy is 
prematurely started, a minimum of two weeks’ interval after cessation should be respected 
before surgery if the patient’s clinical condition will allow it359.
SAMPLE PROCESSING
Laboratory processing of tissue samples gathered during surgery is naturally, a vital part of 
accurate diagnosis. Due to the wide spectrum of possible pathogens potentially involved 
in PJI, samples should be investigated for both aerobic and anaerobic bacteria. Although 
fungal370,371 and even mycobacterial372,373 prosthetic joint infections have been described often, 
there is a generalized consensus that acid-fast bacillus (AFB) and fungal testing should not be 
routine but rather reserved for patients at high risk for such infections or when other traditional 
pathogens have not been identified and clinical suspicion persists374,375.
The orthopedic surgeon is obviously not the more qualified physician to appreciate all the 
variables involved in processing microbiology specimens but he should nevertheless be able 
to accurately convey his needs to the laboratory personnel. 
There a number of techniques increase the diagnostic ability of microbiological detection. 
Extending incubation time is one of them. Traditional cultures are maintained for about 
seven days and indeed, most common infecting organisms can be isolated within a few days. 
However, there is evidence that extending cultures for up to 14 days significantly increases 
sensitivity (especially increased detection of fastidious organisms such as Propionibacterium 
acnes) while not increasing the risk of contaminants376,377. In cases of suspected PJI with low 
virulence organisms or if preoperative cultures have failed to show bacterial growth and the 
clinical picture is consistent with PJI, extending periprosthetic cultures, significantly increases 
sensitivity while not increasing the risk of contaminants378. 
Different culture media naturally yield  different diagnostic sensitivity379. There is increasing 
amount of evidence that blood culture bottles may be advantageous not only for joint aspirate
but also for periprosthetic tissues360,361,380,381. Extrapolating from previous studies on native 
septic arthritis, Font-Vizcarra et al.360 compared the frequency of positive synovial fluid cultures 
inoculated into aerobic and anaerobic blood culture flasks with the results of periprosthetic 
tissue and swab samples cultured in standard media. They found synovial fluid inoculated 
in blood culture flasks had greater sensitivity, specificity and positive and negative predictive 
values than swabs or even standard tissue samples360. Others have replicated these findings 
suggesting that blood culture bottles should become standard methodology for synovial fluid 
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culturing361. More recently, Peel et al.380 extended this concept into tissue specimens. They 
compared inoculation of periprosthetic tissue samples into blood culture bottles with standard 
agar and thioglycolate broth culture. Not only did they find increased sensitivity but also faster
time to microorganism detection using the automated blood culture bottles system (both 
aerobic and anaerobic) than with standard media380.
All these demands dramatically increase the number of samples to be processed by bacteriology
laboratories, with a major impact on both the staff work load as well as increased costs. A 
recent French prospective multicenter study tried to determine a cost-effective protocol for the 
microbiological diagnosis of PJI taking into account these novel developents382. Their study 
included 264 suspected cases with 215 confirmed PJI out of seven different centers. They were 
able to show that taking four samples instead of five had no impact on diagnosis effectiveness. 
Although they did not confirm the superiority of interface membranes over other samples, they 
argue that it seems preferable to privilege tissue in contact with the material and the joint fluid. 
Joint fluid should be seeded directly into a blood culture bottle by the surgeon in the operating 
room. As to the amount of culture media necessary, they determined that a combination of a 
blood culture bottle, a chocolate agar plate and Schaedler broth offered similar results as those 
obtained with four or five culture media382.
SONICATION AND OTHER BIOFILM-DISRUPTION TECHNIQUES
Even before the advent of sonication, there were attempts on removing the bacterial biofilm 
of the explanted prosthesis by simply scraping it with a scalpel. Although there are anecdotal
evidence that this simple technique may be superior than traditional tissue cultures383 it 
soon became apparent that scraping is not an efficient technique for dislodgement of biofilm 
bacteria384.
In 2007, Trampuz et al.385 published a landmark paper on sonication. They studied the 
effectiveness of a sonication protocol of 331 explanted total knee or hip prosthesis for aseptic 
failure or presumed infection and compared it to conventional fluid and tissue sampling. They 
found that sonicate fluid culture was significantly more sensitive (78.5%) than tissue cultures 
(60.8%) in general. However, further analysis on their results show the sensitivity of tissue 
culture increased from 50.0% to 54.1% to 66.7% to 72.7% as the number of specimens 
collected increased from two or three to four or five or more respectively. Furthermore, the 
authors acknowledge this a time-consuming laboratory process and the equipment to perform 
sonication is not widely available. Nevertheless, many have since then showed that sonication 
increases the likelihood of isolating pathogens without increasing the rate of contaminants in 
revision arthroplasty of the hip, knee, shoulder and elbow249,381,386-391. Sensitivity of sonicate 
fluid cultures can be even higher if molecular detection methods237,238 are used or simply by 
inoculating it into blood culture bottles381,392 which is much more simple and widely available.
In 2010 we were able to publish a retrospective analysis of 75 hip or knee prosthetic joint 
infections and described our microbiological results. We found an upsetting 18% proportion 
of culture-negative cases96. Several common mistakes were identified such as insufficient 
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intraoperative sampling (many cases with a single fluid sample), antibiotics were often and 
unjustifiably started before surgery, etc. Working alongside the microbiology department to 
change and improve methodologies (including sonication) and also by educating surgeons we 
were able to change the scenario. A recent analysis of our experience, confirmed the benefits 
of this collective effort. In a total of 93 patients with PJI treated between 2009 and 2013, there 
were only three cases (3.2%) in which we failed to isolate any microorganism. Sonication was 
used in 52 cases. Interestingly, although sonication enabled us to find the infecting pathogen in 
four cases in which tissue cultures were negative (all of them chronic infections with previous
attempts at debridement and implant retention and antibiotic therapy), it did not grow an 
organism in 22 cases with positive tissue cultures (mostly acute postoperative and 
hematogenous infections). In the remaining 25 patients (27 microorganisms) there was 
complete correspondence between the findings of sonication and traditional tissue culture. As 
such, we currently view sonication not as a surrogate for traditional tissue sampling but rather 
as supplemental tool that increases overall sensitivity (especially in cases of chronic infections 
with previous antibiotic therapy) and can perhaps reduce the ideal number of tissue samples 
to be collected. Recent results from the Oxford Bone Infection Unit in the United Kingdom, 
presented at the 35th Annual Meeting of the European Bone and Joint Infection Society allow 
a similar conclusion. Analyzing over 200 joint prostheses (aside from many other orthopedic
hardware), they found tissue culture (4-5 independent periprosthetic tissue samples) was more 
sensitive than sonication alone. The combination of tissue culture and sonication provided 
optimum sensitivity especially in chronic infections where the biofilm burden is presumably 
higher.
Being a time- and resource-intensive procedure, routine sonication is not routinely warranted
in cases where preoperative identification of pathogen is already available. It has been 
demonstrated that in early or acute infections, sonication is not clearly superior to periprosthetic
tissue cultures393. Its greatest advantage over standard tissue culture is appreciated when 
antibiotics were provided within the two weeks previous to surgery385. As such, the recent 
ICM on PJI recommends its use be limited to cases of suspected or proven PJI in which 
preoperative aspiration does not yield positive culture and antibiotics have been administered 
within the previous 2 weeks85.
Their role in routine revision surgery for presumably aseptic failure is much more controversial 
since there are conflicting results. On one hand, Puig-Verdie et al.393 examining 54 THA and 98 
TKA,  found sonication to be significantly more sensitive than conventional tissue cultures in 
unsuspected septic failure (100% vs. 48.5% respectively) and in delayed implant failure (88% 
vs. 58% respectively). On the other, Kempthorne et al.351 prospectively examining the role of 
sonication of the implants in cases of presumed aseptic loosening of 77 THA and 29 TKA, 
found that conventional sampling techniques provided more positive cultures than sonication.
There are other alternatives to dislodging bacteria from biofilm of implants after its removal. An 
Italian research group has been working with Dithiothreitol (DTT) which is a strong reducing
agent commonly used in chemical laboratories. Initial in vitro analysis suggested that 
sonication and DTT treatment seem to provide reproducible results in removing bacteria from 
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biofilm in polyethylene and titanium discs suggesting that treatment of prostheses with DTT 
may be a reasonable alternative to sonication394.  Clinical data from 80 patients undergoing 
removal of the prosthetic joint or cement spacer showed encouraging results with treatment 
with DTT displaying the same specificity of sonication but a higher sensitivity especially a 
higher recovery of S. epidermidis than sonication395. The same research group has developed 
this principle into a ready-to-use technology specifically designed to collect, transport and 
process explanted prosthesis that may be more practical than sonication396. These findings and 
hypothetical advantages are still lacking confirmation from larger and independent research.
MOLECULAR TECHNIQUES
The high cost and limited availability of molecular techniques such as polymerase chain reaction
will probably prevent its broad application in the near foreseeable future. Nevertheless, they 
are worth mentioning as their findings may ultimately have an impact on how we define aseptic 
failure of a total joint arthroplasty.
Molecular techniques have repeatedly been shown to be more sensitive than conventional
methods especially when sonicate fluid and not periprosthetic tissue is the analyzed 
specimen237,238,397. But such an advantage is however, not universally found. In 2012, Gomez
et al.398 focused on 366 prostheses from unique subjects. Defining PJI as (i) synovial fluid
or periprosthetic purulence, (ii) sinus tract communicating with the prosthesis and (iii) 
periprosthetic tissue histopathology showing acute inflammation, 135 were classified as PJI 
and 231 as aseptic failures. These authors found broad-range PCR and culture of sonicate 
fluid have equivalent performance for PJI diagnosis398.
A main concern of such PCR techniques is their specificity.  Bacterial DNA is often found in 
cases where current standards for defining infection are absent (i.e. aseptic failures)397-399. 
More information is needed to understand the real pathogenic value of this finding. A very 
recent paper clearly illustrates a major interpretation dilemma associated with research being
performed on these ultra-sensitive diagnostic molecular techniques. Do these techniques 
lack specificity or are current definitions of infection in need of amendment? Rak et al.397 
prospectively studied 87 patients who underwent revision operation of total knee or total hip 
arthroplasty. Using MSIS criteria for defining infection, aseptic failure was diagnosed in 58 
cases and PJI in 29 cases. Molecular methods detected the presence of bacteria in 13 out 
of 58 aseptic failures. In seven of those, one additional minor criterion was fulfilled: positive 
culture from periprosthetic tissue in one sample (4), positive histology (2), and positive synovial
fluid leukocyte count (1). Even by dismissing some cases that did not fulfill their previously 
determined cutoff for significance of PCR results400, the authors believe some cases were 
ultimately misclassified as having aseptic failure and should have been classified as having 
PJI. As such, molecular techniques are not currently a recommended routine diagnostic test 
for PJI85.
Another customary limitation of this technology compared to traditional cultures is knowing 
complete antibiotic susceptibility of isolated microorganisms. Early detection of resistant genes 
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using PCR (e.g. mecA gene which is the coding gene for the most important mechanism of 
resistance to beta-lactams in methicillin-resistant S. aureus) is currently available but few 
clinical studies have been performed using test kits specifically designed for the diagnosis of 
PJI. Prieto-Borja et al.401 recently published data from 88 prostheses of 68 patients using a new 
commercial molecular biology technique designed to detect 27 species or groups of organisms 
and simultaneously detect 19 resistance genes frequently involved in PJI. Interestingly, they 
found a very high specificity and positive predictive value with good performance in detecting
antibiotic resistance when compared to traditional tissue cultures and sonication. Nine 
resistance mechanisms genes were detected and all of them were confirmed by standard 
phenotypic antimicrobial susceptibility testing. One Staphylococcus simulans resistance 
to erythromycin and clindamycin, was not detected by the system401. Despite promising 
research being made, there are still important limitations. Low overall sensitivity is at least 
partially explained by the fact that some relevant microorganisms as well as some resistance 
mechanisms are not yet included in this technique401. 
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Histological Analysis 
Positive histological analysis is considered to be a minor criterion for the diagnosis of PJI85,241. 
Positivity is determined by the amount of polymorphonuclear neutrophils existing in a given 
periprosthetic tissue sample collected during revision surgery. Tissue sampling follows much 
of the same rules as microbiological investigation. Multiple samples should be collected as the 
expression of infection may vary according to the anatomical location and the bone-implant 
interface membrane should be privileged248. 
Histopathological exploration can be performed in conventional formalin-fixed, paraffin-
embedded permanent sections as part of a complete diagnostic protocol to distinguish 
between aseptic and septic loosening402,403. However, most of the times it is especially useful 
in cases of equivocal preoperative investigation. In this context, intra-operative frozen sections
will offer a swift answer that may help decide on the more adequate treatment. There seems 
to be enough evidence that there is good concordance between frozen and permanent 
sections404,405.
Performance of intraoperative frozen sections in the diagnostic of PJI has been extensively
studied over the past decades. Table VI depicts some of the most recent studies and illustrates 
the wide range of proposed cutoffs for interpretation that have already been proposed293,297,405-413. 
A meta-analysis performed in 2012414, found that regardless of the criteria defined by the 
histopathologist, frozen section analysis of periprosthetic tissue was very good at predict-
ing culture-positive joint infection and it was moderately accurate in ruling out this diagnosis. 
This overall suboptimal sensitivity seems to be related to the false-negative results when the 
infection is due to low-virulence microorganisms. Bori et al.415 analyzing the results of 38 
resection arthroplasty of infected hips found the percentage of positive histology in documented
infections due to coagulase-negative staphylococci was significantly lower than in infections 
due to other microorganisms. They further reviewed available data on the relationship between 
histology and microbiology from previous papers and found the same significant difference. 
Positive histology was significantly less prevalent among coagulase-negative staphylococci
infections (71%-39/55) when compared to all other microorganisms (89%-66/74)415. The 
vast majority of publications deal with either revision THA or TKA but the same principles 
seem to hold true into other joints. Ahmadi et al.416 reviewed 296 consecutive revision elbow 
procedures. With a positive histology when any single high-power field contained at least five 
neutrophils they found frozen sections to display high specificity (93%) and low sensitivity 
(51%). 
A very recent paper by Kwiecien et al.410 accurately condenses current knowledge. They 
assessed the value of intraoperative histology in a study that included 100 TKA and 100 THA 
with complete information to diagnose or exclude PJI as defined by the MSIS criteria. Both 
frozen sections and permanent histology demonstrated excellent approximation of modified 
MSIS criteria, and there were no significant between them. A very high specificity of the test 
was confirmed (when at least one of the samples presented at least 5 neutrophils in at least 
3 high power fields) at around 99% but only a moderate sensitivity (74% overall). The authors
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conclude that in the availability of experienced pathologists, frozen sections analysis is a 
valuable tool that can reliably guide surgeons in intraoperative planning of treatment410.
Table VI Summary of recent frozen section results.
Joint(s) Standard	for	PJI	definition Sensitivity Specificity PPV NPV
Positivity	criteria:	≥5	PMN	in	>1	HPF	(400x)
Ko et al.409 
2005 34 THA + 6 TKA intraoperative culture results 67% 97% 86% 91%
Nilsdotter et 
al.412 2007 THA (n=85)
preoperative clinical and laboratory 
results or significant intraoperative 
culture results
81% 100% 100% 87%
Nuñez et al.413 
2007 THA (n=136) intraoperative culture results 85% 87% 79% 91%
Positivity	criteria:	≥5	PMN	in	≥3	HPF	(400x)
Kwiecien et 
al.410 2016
Overall (n=200)
MSIS criteria
74% 99% 93% 94%
TKA (n=100) 68% 99% 93% 93%
THA (n=100) 79% 99% 94% 94%
Positivity	criteria:	≥10	PMN	in	≥1	HPF	(400x)
Banit et al.406 
2002
Overall (n=121)
intraoperative culture results
67% 93% 67% 93%
TKA (n=55) 100% 96% 82% 100%
THA (n=63) 45% 92% 55% 88%
Positivity	criteria:	≥2	PMN	in	>10	HPF	(400x)
Tohz et al.405 
2010 THA (n=64)
Same organism ≥2 cultures; sinus 
tract; gross purulence; consistent 
histopathology
87% 100% 100% 95%
Positivity	criteria:	≥5	PMN	in	>5	HPF	(400x)
Muswso et 
al.411 2003 26 THA + 19 TKA intraoperative culture results 50% 95% 60% 92%
Bori et al.407 
2006 THA (n=61)
clinical, laboratory, nuclear medicine 
and culture results 50% 81% 40% 86%
Kanner
et al.408 2008
137 THA +107 
TKA
intraoperative culture results and 
other pertinent clinical data 29% 95% 40% 92%
Positivity	criteria:	≥10	PMN	in	>5	HPF	(400x)
Della Valle 
et al.297 2007 TKA (n=105)
Same organism ≥2 cultures OR ≥2 
of the following: 1) one positive cul-
ture; 2) consistent histopathology; 3) 
gross purulence.
88% 96% 91% 93%
Schinsky 
et al.293 2008 THA (n=201)
Two of the following: 1) positive 
intraoperative culture; 2) gross 
purulence, 3) consistent histopatho-
logical result.
73% 94% 82% 90%
PMN polymorphonuclear neutrophil; HPF high power field; TKA Total knee arthroplasty; THA Total hip arthroplasty; MSIS Musculoskeletal Infection 
Society.
The timely availability of an experienced pathologist is perhaps the major limitation of 
performing histological frozen section analysis intraoperatively. Not every institution will be 
able to accommodate this requirement. Plus, there is increasing evidence that other diagnostic
tools may perform just as well with the added advantage of ease-of-use. We have already 
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discussed the value of leukocyte esterase test strips or alpha-defensin and these tests can be 
performed promptly intraoperatively 301,321. Even laboratory synovial fluid leukocyte count is a 
relatively quick procedure and can be very informative in cases where it was not performed 
preoperatively. Buttaro et al.323 directly compared the utility of synovial C-reactive protein and 
frozen section in 76 patients who underwent hip revision. Using MSIS criteria for PJI, and at a 
threshold of synovial CRP of 9.5 mg/L, sensitivity was 90% and specificity was 94% which was 
comparable to intraoperative frozen section. 
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Diagnostic Approach 
Infection is known to be a major cause for revision. We have already established that it may 
be present without obvious signs and symptoms and is frequently found in cases thought to 
be aseptic, especially in the early years after surgery255,351,352. As such, all patients who present 
with a painful or failed arthroplasty should undergo investigation to rule out infection.
Figure 4 portraits an algorithm for the diagnosis of PJI proposed in the 2013 ICM85. Naturally, 
the use of this (or any other) algorithm should not outweigh clinical judgment. Nor should any 
one individual test as we have already discussed that all of them have limitations and there is 
no perfect gold standard. Moreover, preoperative aseptic diagnosis using this algorithm should 
not completely eliminate suspicion for PJI85. There are also practical limitations and experiences
in each institution that in some point may influence the diagnostic flow chart. 
There is a wide consensus that serum inflammatory markers, with all its known limitations, 
should be a universal first preoperative screening test. Most of the times, arthrocentesis will 
follow if laboratory or clinical suspicion persists. Sometimes, in patients who have a hard time 
getting to our hospital for instances, we will do them simultaneously. If enough synovial fluid is 
gathered a number of tests should be performed: leucocyte esterase immediately in the office
or after centrifugation, leukocyte count and differential, C-reactive protein, ADA and other 
more sophisticated markers if available such as IL-6 or alpha-defensin and of course culture 
(preferably in a blood culture bottle). In cases of a dry tap or equivocal results a second joint 
aspiration may be attempted in a later stage. We find that nuclear medicine testing (combined 
sulesomab/nanocolloids scan) may be a very helpful tool in these circumstances, especially if 
revision surgery is not being considered. 
Finally, intraoperative testing with adequate microbiological sampling and eventually histological
analysis offer the best chance for a definitive diagnosis and should be performed routinely
in every revision arthroplasty. In dubious cases, some tests such as leukocyte esterase, 
alpha-defensin lateral flow test or even frozen section histology may be performed during 
surgery and help decide on the more adequate course of action.
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Major Criteria:
· Sinus tract communicating with the joint
Minor Criteria:
· Culture
· Leukocyte Esterase
· Synovial White Blood Cell Count
· Synovial Neutrophil Percentage
Normal ESR and CRP and 
Low Probability of Infection
(based on history/PE/X-ray)
History 
Physical Examination (PE)
X-Ray (Joint Specific) 
Serology
Presence 
of Major Criteria
Abnormal ESR and/or CPR 
or Higher Probability of 
Infection 
(based on history/PE/X-ray) 
without major criteria
Joint Aspiration
Culture Positive and One
Positive Minor Criteria or
Minor Criteria ≥ 3 Positive
All minor criteria
negative
No Fluid or Culture Positive
Without Other Positive
Minor Criteria or One or
Two Positive Minor Criteria 
or Clinical Suspicion 
Persists without Positive
 Minor Criteria
All minor criteria negative
Repeat Aspitarion with 
Addition of AFB/Fungal 
Cultures
Culture positive or
Minor criteria ≥ 2 Positive
No fluid or Culture negative 
and only one minor criteria 
positive
Infection
Unlikely
Infection
Likely
Biopsy (Micro
and Histology)Negative
Positive
►
►
►
►
►
►
►
►
►
Fig. 4 International Consensus meeting algorithm for the diagnosis of prosthetic joint infection.
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Treatment
Once a diagnosis of prosthetic joint infection has been reached, little treatment alternatives 
exist. The overwhelming majority of patients will require some form of surgical treatment, ranging
from debridement with implant retention to revision arthroplasty (be it a one or two-stage 
exchange), followed by adequate antibiotic therapy with curative intent. In selected cases, the 
host medical condition is so dismal that it precludes these often very demanding treatments. 
In such cases, salvage procedures or even chronic suppressive antibiotic therapy may be the 
best palliative care options. 
Classification	of	Infection
Ideally, the first step in ascertaining the best treatment alternative would be to accurately 
classify each case using some kind of helpful classification system. Infections can be broadly 
classified according to the route of acquisition as perioperative or hematogenous depending 
on whether the bacteria gained direct access to the joint during surgery or via the blood stream 
at a later stage. Infections reaching the joint through contiguity by progression of an adjacent 
infectious focus are also possible. This classical criterion offers no therapeutic guidance.
In 1996, Tsukayama et al.417 defined four different clinical settings for THA infection and made 
treatment recommendations for each one. Early postoperative infections were defined as 
wound infection that developed less than one month after the operation. Acute hematogenous 
infections were those associated with a documented or suspected antecedent bacteremia 
and were characterized by an acute onset of symptoms in the affected prosthetic joint. Both 
of these settings would undergo debridement with implant retention. Late chronic infections 
developed a month or more after the index operation and had an insidious clinical course. 
These should be dealt with revision surgery. A final type was Positive intraoperative cultures 
and it was assumed when at least two specimens taken during revision surgery for supposedly 
aseptic loosening with no obvious clinical infection were positive on culture and they should be 
treated with antibiotics. The same model was also later on adopted for infection after TKA418.
In 2004, Zimmerli et al.247 proposed a different system in which infections were classified as 
Early (those that develop less than 3 months after surgery), Delayed (3 to 24 months after
surgery) or Late (more than 24 months after surgery). According to these authors, early and 
delayed infections are usually acquired during implantation of the prosthesis, whereas late 
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infections are predominantly acquired by hematogenous seeding. Still, there seems to be 
a gap between their classification system and treatment recommendations. It is clear that 
acute hematogenous infection can occur several years after surgery (in which case they would 
be classified as late infections) and early infections (up to three months after surgery) may 
exceed the three weeks’ duration of symptoms they recommend as the threshold for choosing 
debridement with retention over exchange arthroplasty. More recently,  Senneville et al.419 
sought to refine this classification. They defined time to infection or “joint age” using the 
same criteria but added a new criterion based on the duration of symptoms which was critical 
in selecting treatment modality. Acute or chronic PJI was defined as time from initiation of 
symptoms of infection to diagnosis lasting for less or more than one month respectively. 
Although they can serve as rough guides to selecting appropriate treatment (debridement with 
implant retention vs. revision surgery), none of these classification systems takes into account 
other variables that greatly influence the outcome such as host and microorganism factors. 
The concept of stratifying bone and joint infections according to the host’s condition has been 
in place for many years in the context of adult osteomielytis420 and its extrapolation into PJI 
seems to hold prognostic value421. McPherson et al.251,252 also acknowledge the importance 
of systemic compromising factors but further introduce local wound compromising factors 
such as multiple incisions, soft tissue loss or sinus tract, or even previous radiation therapy or 
vascular insufficiency into their three-parts staging system for PJI that includes infection type, 
systemic host grade and local extremity grade.
Romano et al.422 tried to devise a comprehensive classification proposal for bone and joint 
infections in adults that also includes PJI. Their so-called Seven-Item Comprehensive 
Classification System includes clinical presentation, etiopathogenesis, host systemic and local
(both bone and soft tissue) features. Interestingly, they are the first to take into consideration
microorganisms characteristics. This is however a very complex system which is hardly 
applicable to clinical practice and according to the authors’ own admission this proposal is 
intended for didactic and scientific purposes422. 
As such, although numerous classification systems exist for PJI, a flawless classification 
system is still lacking. In our Institution, we follow the simple classification system originally 
proposed by Tsukayama et al. as we believe in its intrinsic therapeutic guidance. 
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Debridement and Irrigation with Implant Retention
Debridement and Irrigation with Implant Retention (DAIR) is an appealing treatment alternative.
It is less demanding than revision surgery both for the surgeon and the patient. It is less time 
consuming and technically easier to perform than revision surgery and it represents a reduced 
physiologic insult making it easier to recover from. It has been shown that successful DAIR 
procedures lead to equivalent outcomes to uninfected controls with regards to function and 
quality of life423. There is however extensive controversy in the literature regarding its real 
worth with success rates ranging from 0% to over 90%, and averaging at around 50% both for 
knees and hips424-426. 
INDICATIONS AND RISK FACTORS FOR FAILURE
Despite the wide variability of recommendations present in the literature, it is indisputable that 
such an attempt should only be made when facing a well-fixed, well positioned and stable 
prosthesis (i.e. one worth saving) and when there is a good soft tissue envelope to cover the 
prosthesis. Also, DAIR should not be viewed as an emergent procedure except in patients 
with overt generalized sepsis. Whenever possible, all efforts should be made to optimize the 
patient’s comorbidities to reduce the risk of medical complications, which can ultimately prove 
to be fatal.
Several variables have been implicated in likelihood of success of this procedure. Some of 
them such as the actual technique of the procedure and the antibiotic regimen are under the 
direct control of the medical team, others such as time since presentation, host medical status 
or even the causative pathogen are not, but may serve as selection criteria to find the best 
indication for treatment with implant retention.
DURATION OF SYMPTOMS
Duration of symptoms is a major factor implicated in the prognosis of DAIR. In interpreting 
the literature, it is important to emphasize the difference between duration of symptoms (i.e. 
time since infection manifests itself and treatment) and the “joint age” (or time from implant/
index surgery to presentation). The recent consensus meeting suggests that DAIR may 
be performed in early postoperative infections that occur within 3 months of index primary 
arthroplasty or in late hematogenous infection that occur within 3 weeks of an inciting event 
with less than 3 weeks of symptoms in either case85. There seems to be no difference in 
outcome between acute postoperative and hematogenous infections427,428. In other words, it 
would seem duration of infection and not “joint age” is the decisive factor. 
The problem in clinical practice is how to be sure that a hematogenous infection is really an 
acute infection and not an exacerbation of a chronic infection. In fact, not all patients report
long lasting symptoms prior to their presentation with a chronic infection. Despite the 
large amount of evidence describing the importance of symptom duration, there are many 
discrepancies concerning the best threshold for optimal outcomes (see table VII). Nevertheless,
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the three weeks limit that was proposed by Zimmerli et al.247 in their original treatment 
algorithm was adopted by the consensus group and finds support in the current literature 
although many authors extend the ideal time frame up to four weeks429-435.
Table VII Summary of selected findings that increase risk of failure after DAIR.
Joint(s) Countryof Origin
Success 
Rate
Duration of 
Symptoms Microorganism(s) Host Status
Byren et al.430 
2009
52 THA + 
51 TKA + 9 
other joints
UK 81% >14 days from presen-tation to debridement
S. aureus PJI Presence of co-morbidity
Azzam et 
al.427 2010
53 THA + 53 
TKA USA 44%
Duration of    
symptoms failed to 
predict outcome
Staphylococci PJI; 
frank purulence ASA score III/IV
Peel et al.436 
2012
118 THA + 
29 TKA Australia 71%
Only included PJI 
within 90 days of 
implantation
Gram negative PJI
Previous septic             
exchange; hypotension 
at presentation;
Buller et al.429 
2012
62 THA + 
247 TKA USA 52%
>21 days duration of 
symptoms
Staphylococci PJI; 
VR Enterococci
Previous joint infection; 
higher ESR at 
presentation;
Kuiper et al.433 
2013
62 THA + 29 
TKA Netherlands 66%
> 7 days before the 
start of treatment
CoN Staphylococci 
PJI
Rheumatoid Arthritis; 
ESR>60mm/h at              
presentation
Fehring et 
al.432 2013
40 THA + 46 
TKA USA 47%
31-90 days worse than 
<30 days (joint age)
Type of 
microorganism failed 
to predict outcome
Charlson Comorbidity 
Index failed to predict 
outcome
Tornero et 
al.434 2015
85 THA + 
137 TKA Spain 77%
Only included PJI with 
duration of symptoms 
<21 days
All cultures positive 
during debridement
Chronic renal failure; 
liver cirrhosis; revision 
surgery or cemented
prosthesis; CRP 
>11.5mg/dL;
DAIR Debridement and Irrigation with Implant Retention; TKA Total knee arthroplasty; THA Total hip arthroplasty; UK United    Kingdom; USA United 
States of America; PJI Prosthetic Joint Infection; VR Vancomycin-resistant; CoN coagulase negative; ASA American Society of Anesthesiologists; 
ESR Erythrocyte sedimentation rate; CRP C-reactive protein.
Host Status
Overall health status and medical comorbidities of the patient afflicted by any kind of infection 
and of course also PJI is of chief importance251,252,427,430,433,434. It plays a major role in the patient’s 
ability to overcome infection but also has a significant impact on the patient’s vital prognosis 
as we have discussed earlier. Other patient-related factors such as elevated BMI, past history 
of joint infection or revision arthroplasty have been implicated in worse outcomes429,430,436,437.
Interestingly, clinical presentation features such as hypotension at presentation436, higher blood 
inflammatory markers (ESR or CRP)429,433,434 or even intraoperative findings such as frank 
purulence around the prosthesis427 or positivity of all cultures obtained during surgery434,438 may 
also have inherent prognostic value. Presumably, these represent more severe infection with 
higher bacterial load and consequent greater risk of treatment failure.
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Type of Microorganism
It is only natural to expect that the specific pathogen involved in each PJI case to be of 
importance on the final outcome. 
Indeed, staphylococci infections have frequently been implicated in unfavorable results after
DAIR427,429,430,439,440. Methicillin-resistant S. aureus (MRSA) specifically, are traditionally 
considered to be a major risk for failure of debridement with component retention even in 
acute infections441-443. Bradbury et al.443 have even proposed that if MRSA is encountered, 
subsequent treatment with exchange arthroplasty should be considered. Joulie et al.444 
analyzed which variables were associated with treatment failure in 93 PJI caused by S. 
aureus. Although they found that exchange arthroplasty offered a better probability of success
than debridement alone, they did not find the healing rate to be influenced by methicillin 
resistance444. In a more recent large retrospective, multicenter, observational study of cases of 
S. aureus PJI that were managed with DAIR, the authors found no difference in failure rates 
in MRSA compared to methicillin sensitive cases445. Nevertheless, both these papers showed 
DAIR was able to save only about 55-57% of S. aureus infections444,445.
Gram negative microorganisms are also a classic concern as they have traditionally been 
implicated in worse outcomes with implant retention surgery436,446. Nevertheless, it seems that 
if fundamental principles such as short duration of symptoms and anti-biofilm antibiotic therapy
are upheld, success of DAIR procedure can be just as good in this group of patients447-450. 
The key problem in managing Gram negative PJI is the growing antibiotic resistance pattern, 
especially in the European Mediterranean region451. It has been shown that the prognosis after 
DAIR is dramatically decreased when fluoroquinolone resistance is found448. Nevertheless, 
even more serious problems such as combined resistance to third-generation cephalosporin,
fluoroquinolones and aminoglycosides are often encountered greatly reducing antibiotic 
treatment alternatives451. Carbapenemase-producing Enterobacteriaceae are also on the 
horizon and have already been implicated in PJI with dire consequences452.
Enterococcus sp. infections although uncommon, are also of special concern as they are 
implicated in poor outcomes with overall success rates of around 50%453-455. This is particularly
true when enterococci infection occurs in a polymicrobial setting or exhibits vancomycin 
resistance429,453. A major European multicenter study including data from 18 hospitals of six 
different countries focused exclusively in PJI due to Enterococcus sp.455. They found an overall
success rate of 56% (100/178) among patients with at least one year follow-up after surgery.
Implant removal showed a higher remission rate than DAIR but this reached statistical 
significance only in those patients with more than two years from arthroplasty to infection455. 
A recent American multicenter study confirms these findings as their overall success rate 
was also low at 52% (45/87)453. In this study, success rate after DAIR was only 39% (13/33) 
which was significantly lower than results after two-stage exchange. Notwithstanding, it has 
been shown that a standardized DAIR protocol for treatment of early infections can lead to 
slightly superior results. Duijf et al.456 reported on 44 patients with early Enterococci infections
(35 polymicrobial). Debridement was performed at an average of 15 days after the index 
implantation and patients were treated with teicoplanin, rifampicin, vancomycin or amoxicillin
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or a combination of these antibiotics for 3 months postoperatively. The prosthesis could 
successfully be retained in 29 patients (66%) which is nevertheless worse than with other 
microorganisms456. 
Streptococcal infections on the other hand seem to have a more favorable prognosis439,457. 
Depending on the specific microorganisms involved, polymicrobial infections potentially 
accumulate many of the limitations aforementioned and it is natural that they are often 
implicated in limited success rates after DAIR458,459. 
Technical Aspects of the Procedure (including Mobile Parts Exchange)
The main goal of surgical debridement is to lower as much as possible the bacterial load within
the joint. In that regard debridement, must be thorough and meticulous and all devitalized 
tissues must be excised. This is a major variable that is not possible to accurately assess when 
reviewing the results in the literature. 
Nevertheless and despite the wide range of suggestions regarding on how to best perform
a DAIR procedure, common ground has been reached as to what constitutes a favorable 
debridement85. After preoperative optimization of the patient has been achieved, good 
visualization and thorough debridement should be performed, multiple culture samples should 
be obtained before copious irrigation (6 to 9 L) of the joint is made. Even when choosing to 
perform a DAIR, patients should be advised that the prosthesis may still need to be explanted 
if indicated (e.g. if it is found to be loose). 
In our hands, we always start by excising the previous incision. If the fascial layer is still closed, 
we collect superficial samples for microbiology before undergoing superficial debridement. 
After this first step and before opening the fascial layer, we do a joint puncture to collect 
synovial fluid for testing. After the arthrotomy is completed, all devitalized tissues as well as 
a thorough synovectomy are performed both for debridement and exposure purposes while 
collecting representative culture samples as discussed earlier in the diagnosis chapter. All 
modular parts are removed. Once all suspicious tissue is excised (as well as suture remnants) 
a copious lavage with chlorhexidine gluconate scrub initially and normal saline subsequently 
is made. After all members of the surgical team change their scrubs and the extremity has 
been repreped and redraped, a final lavage is made and using fresh instruments new mobile 
parts are inserted whenever possible. Usually, one deep drain is used (no irrigation-aspiration 
system) and all tissues are closed in layers much the same as a primary procedure.  
Mobile parts exchange seems to be an important factor for success. It allows access to 
parts of the joint that otherwise be inaccessible plus it allows for removal of slime from the 
undersurface of such components, leading to better reduction of bacterial load85. Polyethylene 
exchange is widely recommended and there seems to be enough evidence of its beneficial 
impact on outcome85,247,428,429,431,433,435,437,448,460-470. In a massive retrospective study including 
over 16,600 PJI, the authors tried to determine risk factors for reinfection after treatment of 
infected TKA in the United States461. They found that patients who underwent DAIR as a 
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first-line treatment had the highest risk of reinfection, compared to one- and two-stage revision 
surgery or amputation461. More interestingly, they found that DAIR with liner exchange had 
significantly reduced risk of reinfection even after adjusting for all other available variables461. 
Considering all of the above premises, it is natural to expect that arthroscopic debridement will 
not suffice. Indeed, even when a posterior portal is routinely used to enable debridement of 
the posterior compartment this approach is not as effective as an open debridement430,471,472.   
One big uncertainty concerns the reoperation decision for a draining wound and/or hematoma 
formation in the immediate postoperative period. Hematoma formation is a common event 
after TJA and they are often hard to differentiate between superficial and deep seated. The 
consequences of missing a possibly infected deep hematoma may be deleterious. Thus, the 
recent consensus states that if debridement is considered, the deep fascia should always be 
opened in TKA cases but only in patients with a clear fascial defect or hematoma/fluid deep 
to the fascia confirmed by aspiration in THA patients85. Still, it is acknowledged that little or no 
guidance to this decision exists in the literature. There is scarce evidence suggesting that even 
in TKA, superficial complications can be safely managed conservatively473. 
Based on our experience, we believe every reoperation in the immediate post-operative 
period should be regarded as a formal DAIR. Following the criteria for re-intervention 
previously discussed in the diagnosis section, infection was confirmed in 28 out of 29 patients
that underwent early debridement after primary hip or knee arthroplasty. This assertive 
approach lead to an 86% success rate in eradicating infection without any medical complications
related to the additional procedure or negative impact on the functional outcome of these 
patients when compared to a matched control population of uneventful primary arthroplasties. 
Adjuvant(s) of Debridement
Although they should not be considered surrogates for adequate surgical debridement, some 
adjuvant therapies have been advocated as useful during the procedure. By far the most 
commonly used is to irrigate the joint with copious amounts of normal saline. Although there 
is the concern that high-pressure pulsatile lavage systems may cause iatrogenic bacterial 
seeding into deeper tissue layers474, both low-pressure or high-pressure lavage can be used 
and no significant difference as been shown to exist in clinical practice475. Some authors argue 
that adding some kind of chemical to the irrigation liquid could help in reducing bacterial load. 
In that regard detergents, antiseptics or even antibiotics have been proposed but there is very 
limited evidence of its real efficacy in clinical practice and most findings originate from in vitro 
studies. Simply adding antibiotics to the lavage fluid, as appealing as it may be, has been 
shown to be no better than normal saline alone476,477. In light of our current knowledge about the 
pathogenesis of PJI, it is natural to expect that some kind of “anti-biofilm” agent would perform 
better. In fact, there is evidence that detergents such as castile soap or benzalkonium chloride 
are more effective is disrupting biofilm from metal surfaces than normal saline alone476,478. More 
recently, chlorhexidine gluconate scrub (antiseptic and detergent) was shown to be the most 
effective option at decreasing bacterial colony counts when compared to normal saline, povi-
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done iodine scrub or castile soap479,480. An interesting alternative may be acetic acid, commonly 
known as vinegar. It has been shown in vitro to be highly effective against both Gram positive 
and Gram negative biofilms481. There is also limited clinical evidence of the efficacy and safety 
profile of a 20 minutes’ soak of 3% acetic acid solution in the debridement of infected TKA482.
A different approach is to try and complement surgical debridement by delivering local 
antibiotics in extremely high concentrations that are able to help eradicate biofilm remnants. 
Two different ways of achieving this goal have been pursued although there is insufficient 
evidence to definitively support the use of either until now. Direct continuous intra-articular 
delivery of antibiotics into the joint was initially promoted by Whiteside as an additional 
treatment in exchange revision surgery483,484. Fukugawa et al.467 were the first to apply this 
concept after DAIR. They reported on a small series of six infected primary TKA, one revision 
TKA and five tumor mega-prosthesis.  There were four recurrences, all of them occurring in the 
mega-prosthesis group467. There are some potential concerns associated with this practice,
including drug reactions or possible re-infection through the catheters used to infuse the 
antibiotic and the need for an additional surgery (to remove the Hickman catheter necessary for 
the intra-articular infusion) and the available evidence is not enough to state that intra-articular
delivery of antibiotics into the joint is an independent success factor.
Another way to deliver local antibiotics that has been explored, is to use some kind of antibiotic-
impregnated conduit (PMMA beads, calcium sulphate pellets, collagen fleece, etc.). Antibiotic 
impregnated PMMA beads have a long tradition in bone septic surgery and there are some 
papers exploring its use after DAIR in total joint infections431,433,468,485. They do however force 
a second surgery for its removal and this has moved the focus on to resorbable material 
such as collagen fleece or calcium sulphate pellets433,468,485. Although small series have shown 
encouraging results, there are no randomized, controlled studies to clearly demonstrate that the 
use of these materials enhances the outcome of a properly performed procedure. Furthermore,
resorbable antibiotic carriers are not without problems such as increased cost, local reactions 
and increased/persistent wound drainage.
Repeated Debridement
There is a lot of controversy and conflicting results surrounding the decision whether or not 
to perform repeat debridements. The ICM on PJI recommends the surgeon should give 
consideration to implant removal following the failure of a single DAIR85. There is some 
evidence to support this recommendation. Vilchez et al.486 found the need for a second 
debridement was associated with failure in their series of 53 early post-operative PJI due to 
Staphylococcus aureus. These results were confirmed in a large, retrospective multicenter 
study of S. aureus PJI (n=345) where the need of a second debridement was an independent 
variable associated with failure445. 
A potential alternative strategy is to standardize a debridement every 48-72h in order to 
reduce the bacterial load. There is a lot of controversy and conflicting results surrounding this 
protocol. Peel et al.469 performed multiple debridements, in keeping with established protocols, 
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and found the optimal number to be two or three as there was significantly higher risk of failure 
in patients with either a single or at least four surgical debridements. More recently, Moojen 
et al.487 compared two different strategies in the treatment of acute THA infection. In the first 
group consisting of 33 patients, each one received a single surgical debridement and only 
additional surgery if infectious symptoms persisted. In the second group (35 cases), patients 
always received multiple surgical debridements. Although it was not statistically significant, 
they did find an increased failure rate in the second group (10/35) as compared to the first 
group (4/33)487. Additionally, in the second group new and more resistant microorganisms were 
found in subsequent debridements suggesting every time the wound is opened there is a risk 
for further contamination487.
Notwithstanding, there are a number of papers that did not find the need for more than one 
unplanned debridement to be associated with worse outcomes430,433,468. Even so, the maximum 
number of reasonable attempts seems to be three as more than that is unlikely to improve the 
odds of successful treatment468,469,488. 
ANTIBIOTIC TREATMENT
Following adequate debridement, correct antibiotic therapy is critical in achieving infection 
eradication. Most of the times, DAIR procedures will take place without previous knowledge 
of the responsible pathogen and effective empiric antibiotic therapy must be initiated while 
waiting for intraoperative culture results. 
Initial therapy
In the early phase of acute PJI, planktonic bacteria predominate and so treatment usually starts 
with intravenous (IV) therapy. After the initial debulking of bacterial load caused by surgery and 
IV antibiotics the switch to regimens with high oral bioavailability and anti-biofilm activity can be 
made thus avoiding prolonged hospital stay and related complications. Traditionally, 2-6 weeks 
of intravenous antimicrobial therapy has been recommended359 but there is growing evidence 
that shortening IV therapy before switching to oral therapy is probably not detrimental489.
Analyzing our own findings back in 2010, we recommended initiating therapy with vancomycin 
in combination with carbapenem immediately after surgery96. Given the worldwide concern of 
emerging carbapenem-resistance we have since adapted our protocol based on a retrospective
analysis of 93 consecutive PJI cases treated in our institution between 2009-2014. We found 
a persistent high prevalence of methicillin-resistant staphylococci but also an increasing trend 
in the proportion of Gram negative infections that were now present in almost 30% of all PJI 
isolates. Among Gram negatives, resistance to piperacillin/tazobactam (7%) was the lowest
even when compared to meropenem (11%), aminoglycosides (14%) or third-generation 
cephalosporin’s (18%). As such our current protocol is to initiate IV vancomycin in combination
with piperacillin/tazobactam even if there is a known pathogen before surgery. It has been 
shown that only about half of the preoperative isolates fully match both microorganism 
and antimicrobial sensitivity when compared to final intraoperative samples289. As soon as 
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definitive microbiology results are available, antibiotic therapy is scaled down according to 
isolated pathogen(s) and antibiotic susceptibility pattern.  
Continuation Therapy
The heterogeneous nature of PJI concerning both the microorganisms and the host, results in 
a huge diversity of clinical scenarios that make it impossible to offer universal solutions. Every 
case must be considered on an individual basis and multidisciplinary cooperation is critical. 
There are however some helpful guidelines available for consultation247,359. 
Notwithstanding, antibiotic therapy after DAIR procedures holds some peculiarities that must 
be observed. Unlike revision surgery where the implant is removed, it is natural to expect 
the presence of biofilm remnants in the prosthesis even after surgical debridement. As such, 
selected antibiotics should ideally have anti-biofilm activity. In this regard, ever since the 
pioneer work by Zimmerli490 et al., rifampicin has gained an indisputable role in biofilm-related 
staphylococci infections247,428,437,469,470,486,489,491,492. Interestingly, it has also been suggested that 
rifampin in combination with other antibiotics may also lead to lower rate of failure in early 
Enterococcus sp. infections treated with DAIR455. It is important to stress that, because 
bacteria rapidly develop antimicrobial resistance, rifampicin should never be administered 
alone but rather always in combination therapy247. Plus, it should only be used after the bulk of 
bacterial load has been eliminated and never in persistently draining wounds493. Acherman et 
al.493 have found that rifampicin therapy with inadequate surgical debridement or less than two 
weeks of intravenous treatment was independently associated with emergence of rifampicin 
resistance. 
An analogous declaration of importance can be made regarding the use of quinolones in Gram 
negative infections. There is good evidence to recommend the use of quinolones when facing
adequately sensitive Gram negative microorganisms447,448,489,494. In a recent large multicenter 
study including 242 Gram negative PJI, ciprofloxacin therapy exhibited an independent 
protective effect448. In patients with ciprofloxacin-susceptible GN-PJI treated with ciprofloxacin, 
success was 79% (98/124). In ciprofloxacin-resistant cases, the efficacy of DAIR management 
was at 41% (14/34). In those with susceptible isolates not treated with ciprofloxacin success 
rate was similar at 40% (6/15) suggesting lack of ciprofloxacin use and not resistance pattern 
is responsible for the negative impact. 
The effectiveness of ciprofloxacin in these patients is probably attributable to its acceptable 
oral bioavailability, optimal diffusion into synovial fluid and bone, and activity against biofilm496.
Although choosing the correct antibiotic regimen may prove to be a hassle for the orthopedic
surgeon, this is a critical part of therapy. 
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Table VIII Summary of selected recent findings regarding antibiotic regimen after DAIR .
Joint(s) Countryof Origin
Overall
Success Rate Major	finding(s)
Aboltins et 
al.447 2011
15 THA 
+ 2 TKA Australia
94% at the 
2-years 
follow-up
· Exclusively GN PJI - oral ciprofloxacin in 14 cases and amoxicillin/clavu-
lanic acid in three cases.
· Median duration of oral antibiotic treatment was 12 months.
Vilchez et 
al.486 2011
18 THA 
+ 35 TKA Spain
75% minimum 
two-year 
follow-up
· Exclusively S. aureus PJI - rifampin combination therapy in 91% of the 
patients. Only 4 MRSA.
· Duration of antibiotic therapy >90days did not improve outcome.
Puhto et al.470 
2012
55 THA 
+ 77 TKA Finland
65% at the 
2-years 
follow-up
· Rifampin combination(s) preferred for staphylococci and quinolones 
preferred for GN.
· Reducing duration of treatment to 3 months (vs. 6) for TKA and 2 months 
(vs. 3) for THA did not influence outcome.
Peel et al.469 
2013
28 THA 
+ 15 TKA Australia
77% at the 
2-years 
follow-up
· Exclusively MR staphylococci PJI – rifampin combination therapy in 93% 
of the patients.
· MRSA infections and <90 days antibiotic therapy were more likely to fail.
Rodríguez- 
Pardo et al.448 
2014
115 THA 
+ 57 TKA 
+ 2 other 
joints
Spain
68% median 
25-months 
follow-up
· Exclusively GN PJI – 79% (98/124) success rate in ciprofloxacin-suscep-
tible treated with it.
· 41% (14/34) success rate in ciprofloxacin-resistant and 40% (6/15) 
success rate in ciprofloxacin-susceptible not treated with it.
· 79% (33/42) success rate in Pseudomonas PJI increased to 88% (29/33) 
when treated with ciprofloxacin.
· 53% (8/15) success rate in ESBL-producing Enterobacteriaceae PJI.
· Median antibiotic treatment duration was 70 days.
Holmberg et 
al.428 2015 145 TKA Sweden
75%
minimum 
one-year 
follow-up
· Risk of failure was 4 times higher if no rifampin used in staphylococci 
infections (59% vs 19%).
· Failure rate was higher in polymicrobial (9/30) and Gram negative cases 
(2/5) - albeit not statistically significant.
· Large variation in duration of antibiotic treatment.
Lora-Tamayo 
et al.495 2016
29 THA 
+ 24 TKA Spain
93% minimum 
one-year 
follow-up
· Randomized and open trial. Exclusively staphylococci acute PJI receiving 
rifampin-levofloxacin combination.
· Cure rate in the patients who completed antibiotic treatment was 22/24 
(92%) in the short (8 weeks) protocol vs. 19/20 (95%) in the long (3 and 6 
months for THA and TKA respectively).
Grossi et al.494 
2016
35 THA 
+ 18 TKA + 
23 Hemi hips
France
79% minimum 
one-year 
follow-up
· Exclusively GN PJI: 35 DAIR procedures -8 (22%) failed.
· Failure rate was similar whether fluoroquinolones or three month IV 
ß-lactams were used.
· Median antibiotic treatment duration was 90 days.
DAIR Debridement and Irrigation with Implant Retention; TKA Total knee arthroplasty; THA Total hip arthroplasty; MRSA methicillin-resistant S. 
aureus; GN Gram negative.
A very recent paper by Tornero et al.489 confirms that correct antibiotic selection is the 
most important predictor of late failure after DAIR.  In their study of 143 patients, an-
tibiotic treatment was categorized as optimal if it included a combination of rifam-
picin plus rifampicin-independent antibiotic (levofloxacin, ciprofloxacin or amoxicil-
lin) or monotherapy without rifampicin for Gram positives and when it included a 
fluoroquinolone for Gram negatives. It was found to be suboptimal if it included a combination 
of rifampicin plus rifampicin-dependent antibiotic (linezolid, co-trimoxazole or clindamycin) for 
Gram positives or a regimen without fluoroquinolone for Gram negatives. Receiving suboptimal
antibiotic treatment proved to be the only independent predictor of failure in this study489.
The duration of antibiotic treatment after DAIR is also matter of intense controversy.  Traditionally,
guidelines have recommended 3 months for infections in total hip and 6 months for total knee 
prosthesis359. There are however several papers questioning this axiom.
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Byren et al.430 have found that the risk of relapse increases after stopping antibiotics (6 weeks 
mean duration of intravenous and 1.5 years mean duration of oral antibiotic treatment) but 
increased length of treatment (>180 days) did not affect the outcome suggesting that most 
patients cured of PJI by DAIR are either cured early on or not and prolonging antibiotic therapy 
does not prevent failures but merely postpones them. Tornero et al.489 also found no relationship
between failure and duration of treatment after a median duration of intravenous and oral 
antibiotic treatment of 8 days and 69 days respectively. A similar finding was reported by 
Lora-Tamayo495 et al. in a randomized clinical trial including over 60 patients with acute 
staphylococcal PJI managed with DAIR. Patients were randomized to receive 8 weeks of 
treatment (short schedule) versus a long schedule (3 months or 6 months for hip or knee 
prostheses, respectively) of levofloxacin plus rifampicin. They suggest that the short schedule
could be just as effective as a longer standard treatment for THA but some doubt persisted 
over its value for TKA495.  Despite some conflicting evidence, extending therapy for 3 months 
seems to be sufficient for the majority of cases469,470,486,489,494. Although many physicians rely 
on C-reactive protein serial measurements to guide antibiotic discontinuation, this practice
has been found to be unreliable and not predictive of failure and should therefore be 
discouraged495,497,498.
CONTRA-INDICATIONS 
Only a loose prosthesis and the inability to close the wound are considered absolute 
contra-indications for implant retention85. A loose prosthesis is obviously an absolute indication
for revision surgery and is therefore not amendable for DAIR. Likewise, an open wound allows
for contamination and colonization of the prosthesis and will result in a chronic infection. 
Although it has been suggested that the presence of a sinus tract is also an absolute contra-
indication85 a detailed analysis of the literature shows apparently successful outcomes are 
possible after DAIR even with a sinus tract that is inherently associated with chronic 
infections427.  Of course, this should be viewed as extreme cases with very low probability of 
success499. Additionally, all of the other risk factors for failure that were previously discussed 
such as PJI due to highly virulent organisms or patients with extensive comorbidities may be 
regarded as relative contra-indications.
In some extreme clinical conditions, simple debridement and antibiotic therapy may be 
indicated as a means to temporarily alleviate symptoms caused by planktonic bacteria leaving 
the biofilm during acute exacerbations of a chronically infected implant. It will not be able to 
eradicate biofilm and ensuing chronic suppressive antibiotic therapy is required but sometimes 
this may be the lesser of two evils in situations where the patient is not fit to undergo revision 
surgery.
In conclusion, some variables such as adequate patient selection, rigorous surgical procedure 
and correct “anti-biofilm” antibiotic therapy seem to be essential cornerstones for success and 
can to some degree be influenced by the treating physician. Others, such as the host medical 
comorbidities or past history, drug allergies or adverse reactions precluding optimal antibiotic
regimens escape our control. Although it is of great consequence, specific information
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about the infecting microorganism(s) and its antibiotic susceptibility is frequently not fully 
known when deciding whether or not to perform DAIR. Adopting specific surgical strategies 
to treat “difficult” microorganisms has already been proposed regarding revision surgery. Still, 
preoperative recommendations for selecting DAIR as treatment are yet fairly pathogen 
independent. 
It is our belief that if appropriate minimal conditions are met (short duration of symptoms in a 
stable and well-fixed prosthesis with sound soft tissues and no sinus tract), debridement and 
irrigation with implant retention should be regarded as first-line treatment choice in the vast 
majority of cases. The results of this approach in our institution have been encouraging.
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Revision Surgery
Exchange revision surgery is widely considered to be the gold standard treatment for PJI. It 
is viewed as the only meaningful alternative in chronic infections and even in some cases of 
acute infections where DAIR procedures are not recommended. 
Presently, removing the infected implant is the only reliable way to eradicate a long-lasting 
mature biofilm. Still, biofilm can reside in other sites other than the implant itself. Inert foreign 
material such as bone cement and screws for instances, as well as dead bone (i.e. sequesters)
can also constitute a nidus for biofilm formation. The goal of surgery in this setting is to 
completely remove all the possibly contaminated sites thus aiming to prevent infection 
recurrence after the new prosthesis is put in place. 
Accordingly, regardless of whether a one- or two-stage approach is encouraged, the initial 
treatment for the overwhelming majority of cases should be complete implant removal and 
exhaustive debridement12,85,247,500-527. Despite this broad worldwide consensus, it has been 
recently suggested that partial revisions may have a role especially in treating complex THA 
with ingrown femoral stems or complex acetabular components that are well fixed in patients 
with poor bone stock in whom extracting the implant would create significant bone loss and 
compromise future fixation528,529. Nevertheless, until or unless larger groups of patients with 
longer term data have been studied, this option must be considered as exceptional in extremely
selected cases that do not exceed 6-7%, even in the proposing authors’ experience528,529.
ONE OR TWO-STAGE 
In the absence of randomized controlled trials addressing this important issue, concrete 
indications or contra-indications for one- or two-stage revision surgery cannot be firmly 
established. Currently, two-stage exchange is still the most popular strategy for the surgical
management of PJI particularly in North America461 but also in Europe and elsewhere530. 
However, as more centers are becoming more experienced in dealing with infected 
arthroplasties, the one stage exchange is gaining momentum. A survey performed in the 2015 
European Bone and Joint Infection Society Meeting (EBJIS) showed that single stage revision
is being performed regularly according to specific selection criteria in around 40% of 
participants’ institutions530.
Despite the fact that two-stage exchange is frequently considered to be the gold standard, 
there are no conclusive evidences of its superiority over the one-stage approach to date. A 
number of review and meta-analysis of the published data have been performed but they 
offer conflicting conclusions531-537. Some, concerning the knee specifically clearly favor the 
two-stage approach stating that it offers higher rate of infection eradication531,532 while others 
reach comparable re-infection rates at around 8-10% for both hips and knees533,536,537. Focusing
not only at the infection eradication endpoint but also on the functional outcome535 or the 
overall risk-benefit balance534 some have favored the single stage exchange in infected total 
hips. 
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However, these reviews are based on publications that share certain limitations such as small 
numbers of patients, limited follow-up and strict exclusion criteria for the one-stage approach 
such as unknown or difficult to treat microorganisms, compromised soft tissues (e.g. sinus 
tract), significant bone loss or even relevant comorbidities. Accordingly, interpretation of the 
literature becomes complex and direct comparison of success rates with the two-stage approach
cannot be easily (or fairly) drawn as the latter does not exclude these difficult to treat cases.  
Given that a lot has changed in recent years regarding surgical and medical practice and 
older papers may not accurately reflect contemporary standards, tables IX and X summarize 
one-stage exchange latest and relevant findings. We focused on each paper’s selection 
criteria as it greatly influences outcome. Tables XI and XII summarize recent pertinent findings 
regarding two-stage exchange.
Table IX Summary of selected recent findings regarding one-stage exchange for chronically infected THA.
Study Number of cases Selection criteria
Success 
rate
Follow-up
Mean/
Minimum
Local 
Antibiotics 
delivery
Observations
Engesaeter et 
al.500 2011
86*
Retrospective registry study 
with indications for two-stage, 
one-stage or partial exchange 
at surgeon discretion
91% NS /2 years Not specified
two-stage revision success 
rate was 95% (155/164)* in 
the same study period; fail-
ures not undergoing revision 
surgery are not reported
De Man et 
al.501 2011 22
1) no compromised soft-tissue; 
2) no difficult to treat microor-
ganism
86% 5/2 years Uncemented implants
two-stage revision success 
rate was 92% (46/50) in the 
same study period
Klouche et 
al.502 2012 38
1) known germ before surgery; 
2) minor bone loss preoper-
atively and after components 
removal
100% NS /2 years
No ALBC even 
when cement-
ed implants 
were used
two-stage revision success 
rate was 91% (42/46) in the 
same study period (not statis-
tically significant)
Bori et al.538 
2014 24
1) no fistula
2) no major soft tissue defect 
3) no bone defect affecting 
implant stability
96% 3 years/ 2 years
Cementless 
stems. 7 out 
of 9 cemented 
cups with 
antibiotics
the only one failure was suc-
cessfully treated with DAIR
Zeller et al.503 
2014 157
1) identified organism with 
available culture and sensi-
tivities (fungus and difficult to 
treat organisms excluded); 2) 
no bone grafting required; 3) 
<2 prior PJI treatment
94% 3.5/2 years
No ALBC even 
when cement-
ed implants 
were used
10 patients required further 
revision (only one confirmed 
infection), there were 3 other 
septic episodes managed 
without revision
Wolf et al.504 
2014 37
Retrospective study with no 
specific indications
(Early postoperative and 
hematogenous infections as 
well as lower local extremity 
grade were significantly more 
prevalent in one-stage)
57% NS /2 years Not specified
two-stage revision success 
rate was 94% (49/52) in the 
same study period; if only 
chronic infections are con-
sidered (25% success rate of 
one-stage)
Jenny et al.505 
2014 65
Consecutive patients including 
failures of previous infection 
treatments and cases requiring 
bone graft
80% 3/3 years
Gentamicin 
loaded bone 
cement
2 early deaths and 11 cases 
of re-infection, no analysis 
of failure risk factors was 
performed
THA total hip arthroplasty; NS not specified; ALBC antibiotic-loaded bone cement; * considering only the more recent 2002-2009 period.
Despite slight variability between different reports, there is nonetheless some agreement on 
some conditions that might be considered relative contra-indications to one-stage surgery 
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or in other words, specific circumstances where a two-stage exchange may be preferred85. 
They include: 1) patients with systemic manifestations of infection (i.e. sepsis); 2) a scenario 
where infection appears obvious but no organism has been identified; 3) preoperative cultures 
identifying difficult to treat and antibiotic-resistant organisms; 4) presence of a sinus tract; and 
5) inadequate and non-viable soft tissue coverage85. Still, other criteria such as failure of two 
or more previous one-stage attempts and infection involving the neurovascular bundles are 
also acknowledged509. 
Table X Summary of selected recent findings regarding one-stage exchange for chronically infected TKA.
Study Number of cases Selection criteria
Success 
rate
Follow-up
Mean/ 
Minimum
Local 
Antibiotics 
delivery
Observations
Singer et al.507 
2012 57
1) known microorganism with 
an antibiotic susceptibility 
profile (MRSA and MRSE    
excluded); 2) wounds that 
could be closed during surgery
95% NS /2 years
ALBC 
according to 
specific sus-
ceptibility
9 patients with contra-  
indications underwent 
two-stage surgery
Jenny et al.511 
2013 47
All patients except: 1) fungal 
infections; 2) repeat failures of 
previous infection treatments
87% NS /3 years
Gentamicin 
loaded bone 
cement
-
Tibrewal et 
al.512 2014 50
1)identified organism with 
available culture and sensitivi-
ties; 2) intact soft-tissue cover 
of the knee
92% 10/ 2 years
ALBC 
according to 
specific sus-
ceptibility
10 patients required 
further revision (one infect-
ed); three septic episodes 
managed without revision
Haddad et 
al.513 2015 28
1) insignificant bone loss; 2) 
soft tissue defect allowing for 
primary closure; 3) non-im-
munosuppressed (includes 
diabetes, RA, etc.); 4) isolation 
of a single low virulence micro-
organism preoperatively
100% NS /3 years
ALBC 
according to 
specific sus-
ceptibility
two-stage revision if any 
contra-indication with 
93% (69/74) success rate 
(difference was not statisti-
cally significant)
Jenny et al.506 
2016
114
1) patient’s good general 
condition; 2) non-acute infec-
tion; 3) responsible pathogen 
sensitive to standard antibiotic 
treatment; 4) good bone stock 
without the need for bone 
grafting *
78% 3/2 years
Gentamicin 
loaded bone 
cement in 84 
cases
* in one center (54 cases) 
one-stage was performed 
routinely and did not follow 
these criteria; there was 
no significant difference 
between both strategies
Zahar et al.510 
2016 59
1) PJI with known causative 
organism 90% 10/9 years
ALBC 
according to 
specific sus-
ceptibility
11 procedures other than 
one-stage were performed 
during the same period
TKA total knee arthroplasty; ALBC antibiotic-loaded bone cement.
When these selection criteria are applied, infection eradication rates after one-stage exchange 
seem to be comparable to traditional two-stage. However, it is noteworthy that routinely 
performing one-stage without clear selection criteria, seems to be associated with substandard 
results504-506.
In addition to comparable infection eradication rates, better functional outcomes after 
completion of treatment is also often invoked as an advantage of the one-stage approach508. 
Although some studies do find this alleged advantage507,513, a number of other papers dispute
this conclusion501,505,511. Radical debridement required in one-stage revision surgery often 
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leads to extensive soft tissues including ligamentous debridement and subsequent potential 
instability or flexion and extension gap mismatch in the knee. As such, there is often the need 
for constrained implants such as rotating hinges in the knee that are associated with higher 
overall failure rates539,540.
Table XI Summary of selected recent findings regarding two-stage exchange for chronically infected THA.
Study Number of cases
Success 
rate after
reimplantation
Follow-up
Mean/Minimum Observations 
Romano et 
al.514 2012 183
94%
 (173/183) 5/2 years three patients required spacer exchange before 2
nd stage
Neumann et 
al.515 2012 44
98%
(41/42) 6/3 years two patients died before 2
nd stage (unrelated deaths)
Macheras et 
al.516 2012 35
94%
(33/35) 12/7 years
one patient had reimplantation postponed at 2nd stage 
due to persistent infection
Berend et al.12 
2013 202
84%
 (157/186) 4 years/NS 
14 patients died before 2nd stage 
(no information regarding possibly related causes of death)
Johnson et 
al.517 2013
66 91%
(60/66) 4/2 years 
positive intra-operative frozen sections at 2nd stage 
precluded reimplantation
Schwarzkopf 
et al.518 2014 60
94%
 (45/48)
3 years/6 
months 
five patients lost to follow-up before 2nd stage; 
six resection arthroplasties and one persistent spacer
Gomez et 
al.520 2015 178
82%
 (89/137) 5/1 years
five permanent resection arthroplasties; 
34 retained spacers
Lange et al.521 
2016 130
85% 
 (70/82) 5 years/NS
35 permanent resection arthroplasties; 
13 other interventions
In fact, some of the longer-term follow-up studies after one-stage revision knee PJI show 
significant rates of aseptic loosening and this must also be considered510,512. In addition, as we 
have already discussed, most one-stage series include selected patients with less extensive
bone and soft tissue damage, less previous revision surgeries, etc. that are important 
predictors of final functional status.
Our personal experience is that a well performed two-stage revision surgery with the use of mobile
spacers leads to good functional results. Although we were not able to directly compare the 
functional outcome of two-stage versus one-stage revision surgery, we did compare infected
TKA patients treated with a two-stage protocol with single-stage revision cases for aseptic
reasons and a control group of primary complex TKA. We applied a validated patient 
reported outcome measure, the Knee injury and Osteoarthritis Outcome Score (KOOS) and a 
satisfaction scale to a total of 11 two-stage revision, five aseptic revision and four primary 
complex TKA cases all of them with the use of the same semi-constrained implant and a 
12 months’ minimum follow-up. Infected patients presented at least similar (if not sometimes 
superior) outcomes in every scale when compared to either control group.
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Table XII Summary of selected recent findings regarding two-stage exchange for chronically infected TKA.
Study Number of cases
Success 
rate after
reimplantation
Follow-up
Mean/Minimum Observations
Mahmud et 
al.522 2012 253
94%
(237/253) 4/1 years 7% additional failure rate for aseptic reasons after reimplantation
Kubista et 
al.523 2012 368
84%
(310/368) 8 years/NS median time to reinfection was 3.6 years
Schwarzkopf 
et al.519 2013 84
91%
(48/53) 2/1 years
six patients died and three patients lost to follow-up before 2nd stage; 
three amputations; 19 arthrodesis
Castelli et 
al.524 2014 50
92%
(46/50) 7/2 years -
Sabry et al.526 
2014 314
72%
(209/291) 3 years /2 months Numerous risk factors for failure are identified
Gooding et 
al.527 2015 115
88%
(101/115) NS /5 years 10 patients required revision surgery for aseptic reasons
Gomez et 
al.520 2015 326
81%
(179/280) 5/1 years six amputations; four arthrodesis; 38 retained spacers
Sakellariou et 
al.525 2015 110
86%
(95/110) NS /2 years Numerous risk factors for failure are identified
In conclusion, one-stage revision surgery is demonstrably successful and may offer obvious 
advantages in appropriately selected cases.  We do however believe that two-stage revision 
surgery is perhaps a technique with greater tolerance to error and is therefore easier to adopt 
in less experienced centers. A massive retrospective Medicare population-based American 
study focusing on 3069 infected TKA treated with one-stage exchange and 5364 treated with 
two-stage revision surgery, found that one-stage revision patients had 34% greater adjusted 
risk of reinfection than two-stage patients461. Our experience in dealing with prosthetic joint 
infections requiring revision surgery has been with a two-stage approach. The results of such 
a protocol have been encouraging.
SPACERS  
When a two-stage strategy is preferred, most surgeons agree on the use of antibiotic loaded
cement spacers85. Spacers accommodate two main goals that are perceived as major 
advantages. They allow for local antibiotic delivery that is believed to contribute to infection 
eradication. Garvin and Hanssen in a classic literature review found the success rate for 
two-stage procedures was lower without the use of antibiotic-loaded spacer, 82% (130/158) 
compared to 91% (385/423) with them541. In addition, they help maintain some joint stability and 
function between stages thus offering some comfort to the patient and preventing soft-tissue
contractures. Ultimately, they contribute to an easier and faster second stage reimplantation 
surgery85,542.
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Mobile or Static? 
Spacers can be divided into two main groups: non-articulating or static and articulating or 
mobile. The choice between both types of spacer is not influenced by their influence on the 
success of infection control but rather on the risk-benefit analysis of added mobility.
A massive literature review performed by spacers’ study group of the recent ICM on PJI85 
found no difference with regards to rates of infection eradication comparing non-articulating or 
articulating spacers or even different types of articulating spacers. Although it has been 
previously reported that articulating knee spacers might provide better infection eradication 
rate than revision with static spacers532, this finding has not been confirmed by others543,544. A 
similar conclusion was reached for the hip, suggesting static and articulating spacers can be 
equally considered in the treatment of PJI. 
The real difference between them lies in the functional outcome, both between stages and 
following second-stage reimplantation. Articulating or mobile spacers offer improved patient 
comfort and better functional outcome after initial removal of the implant and before definitive 
surgery85,514,527,545. In our experience, pain relief after removal of the infected prosthesis is so 
notorious that some patients do so well and are so happy with their new level of function 
that they are willing to adopt the spacer as a definitive solution. While this is uncommon 
in knees, it is more frequent in low-demand elderly hip patients and even more frequent in 
shoulders520,521,546. The majority of studies comparing outcomes after second-stage exchange 
surgery also favor articulating compared to static spacers suggesting there is a relevant yet 
small trend to better functional and range-of-motion outcomes especially in TKA85,543,547. 
Prefabricated or Hand-made? 
Regarding its manufacture, spacers may be either prefabricated or surgeon made. Surgeon 
made spacers have the extra advantage of allowing for easy manipulation of antibiotic(s) 
that are added to the cement and may be manufactured purely by hand or with the use of 
molds518,545. There is some scarce evidence suggesting the addition of high dosages increases
the amount of antibiotics actually released within the joint as compared to prefabricated 
spacers548. Nevertheless, there are no perceptible differences in the rate of infection eradication
or even functional outcomes between them85. Still, other issues such as cost and availability,
ease of use and specific antibiotic delivery should be considered. Commercially available 
spacers are naturally more expensive and accessibility may also limit its use in unanticipated
settings. Traditionally they have been gentamicin loaded although more recently, spacers 
containing both vancomycin and gentamicin have become widely available and some 
manufacturers even produce custom-made spacers with a variety of different antibiotics. 
The type and the dose of antibiotic(s) needs to be individualized for each case based on the 
pathogen antibiotic susceptibility profile as well as the patient’s renal function and allergy profile. 
Choosing the correct drug(s) is of paramount importance. They must possess certain charac-
teristics in order to be effective after cement mixing. Thermal stability is one of them, as the 
polymerization of PMMA is an exothermic reaction and may otherwise hamper its efficacy177. 
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Other important characteristic is water-solubility, to permit elution into surrounding tissues, 
while allowing a gradual release over time for a sustained bactericidal effect177. A last but 
relevant practical issue is that it must be available in powder form since adding a liquid antibiotic
to the cement mixture significantly decreases its mechanical strength177. 
Table XIII displays a list of antimicrobials frequently used in bone and joint infections that have 
been shown effective after being added into bone cement85,177.
Table XIII Antimicrobials frequently used in bone and joint infections that may be added into bone cement.
Amphotericin B Ceftaroline Levofloxacin
Amikacin Ciprofloxacin Linezolid
Ampicillin Clindamycin Meropenem
Aztreonam Colistin Piperacillin/Tazobactam
Cefazolin Daptomycin Teicoplanin
Cefotaxime Erythromycin Tobramycin
Cefuroxime Fluconazol Vancomycin
Ceftazidime Gentamicin Voricanazole
Another issue is the ideal dosage of antibiotic loading. Although there is insufficient data to 
make a definitive recommendation, most authors and expert opinions agree it should range 
somewhere between 10 to 15% of total weight (4-6g per 40g of cement)177. This much 
has been shown to be necessary in order to keep antibiotic concentrations in the spacer 
membrane above minimum inhibitory concentration for several isolates after six weeks549. 
Increasing the dosage not only reduces the mechanical strength of the spacer but also increases
the risk of adverse reactions when using common nephrotoxic drugs such as vancomycin and 
aminoglycosides. Although the overall safety profile of high-dose antibiotic spacers has been 
well documented, there are some reported cases of spacer induced renal failure85,177,550.  The 
final amount of antibiotic(s) eluted from the spacer is influenced by numerous factors other 
than dose and type of antibiotics included. The shape and surface area of the spacer as well 
as the porosity and type of cement used are also relevant550. The cement and antibiotic mixing
technique is also of great influence. Traditionally, we have been combining both powders 
(antibiotic and PMMA) first and then add the liquid monomer. We then proceed with hand 
mixing in a bowl without vacuum to increase porosity of the final cement. Increased porosity, 
while reducing the mechanical resistance, has been shown to increase antibiotic elution550. 
Recently, it has been suggested that the best way to optimize antibiotic elution may be to 
gradually add the powder antibiotic after first mixing the PMMA powder with standard amounts 
of liquid monomer551,552. Another strategy to increase antibiotic elution might be to add some 
kind inert additives such as sucrose, xylitol or glycine85.
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Complications and Contra-indications
Presently, there are no clear indications for the use of any specific type of spacer other than 
technical considerations and feasibility. While mobile spacers seem to be beneficial regarding
functional results, their use is not without increased risks. In the aforementioned massive 
literature review, overall complication rate was found to be 11.6% using articulating and 6.9% 
using non-articulating spacers85.
Some precautions are therefore essential in reducing the risk of complications. Dislocation 
and fracture are the most frequent mechanical complications when using an articulated hip 
spacer514,520. While some risk factors such as history of hip dislocation, multiple prior surgeries, 
abductor muscle insufficiency and patient compliance to the required partial weight bearing 
protocol are not under direct control by the surgeon, others such as spacer’s geometry or 
resistance, size mismatch between spacer’s head and acetabulum, technique of femoral 
fixation and addressing acetabular and/or femoral bone defects can and should be addressed 
during spacer choice and implantation. In the past few years, we have been using spacers
reinforced with a central metallic core in order to prevent fractures (Fig. 5A)553. We also 
acknowledge a few technical tips and tricks to prevent dislocation such as: 1) choosing a 
slightly larger head spacer and if necessary, ream the acetabulum to enlarge it and find 
adequate head coverage; 2) improve femoral fixation of the spacer stem by avoiding a simple 
press fit method and using the glove cementing technique; 3) address proximal femur bone 
defects by using a long-stemmed spacer and; 4) address bone loss in the superior-lateral 
and posterior-superior part of the socket by creating a temporary cement “tectoplasty” with 
additional antibiotic-loaded cement553.
When a mobile spacer is chosen for the knee the most frequent complications are tibiofemoral 
and patellofemoral instability but also wound problems and fractures520,550. 
To minimize pain and mechanical complications both the femoral and tibial parts must be 
cemented in with additional antibiotic-loaded cement554,555. While the spacer must adhere 
strongly to the bone surface, excessive penetration of the cement mantle must be avoided, 
because it might further damage residual bone stock at the time of removal.
Despite this theoretical concern, the use of articulated spacers and a crude cementing technique
has been shown to reduce the amount of bone loss between stages524,547,556. Tibial components 
should be implanted with some type of cement keel for improved stability and attention must 
be paid to the final implant slope554,555. In our experience limited femoral component sizes are 
an additional source of potential problems when using preformed spacers, especially due to 
patellofemoral overstuffing. In the past couple of years, we have moved from using articulating
knee spacers made using silicone molds to purely hand-made mobile spacers in order to 
overcome this limitation and reduce costs (Fig. 5B). 
Mobile spacers may simply be contra-indicated if a mechanically sound construct cannot 
be achieved. Major acetabular bone loss may lead to hip spacer dislocation or even pelvic 
protrusion and in such difficult cases not using spacers at all should be considered as it has 
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been shown that favorable results are also possible without them516,542. In the knee, major bone 
loss and/or lack of soft tissue and ligamentous integrity should also advise against the use of 
articulating spacers 555. It has been shown that static spacers (Fig. 5C), while not exempt of 
potential complications, are also able to offer favorable outcomes557-559.  A recent study on 133 
static knee spacers revealed 14 (10.5%) mechanical complications, most commonly tibia but 
also femur fractures558. Second stage surgery is technically more demanding with their use and 
a high rate of partial avulsions of the patellar tendon has also been described559.
A CB
ANTIBIOTIC THERAPY 
Antibiotics are usually administered systemically but they can also be delivered locally. 
Systemic antibiotic therapy is naturally the cornerstone of adjuvant medical treatment. Although 
a detailed discussion of all the available and appropriate antibiotic(s) is perhaps beyond the 
scope of this thesis, it is important to once again stress the importance of interdisciplinary 
cooperation for the appropriate management of PJI. Traditionally, therapy is initially started 
with IV antibiotics in order to obtain minimum inhibitory concentrations in the shortest time 
possible and allow for empirical broad-spectrum therapy. When definitive culture results are 
available the switch to pathogen-specific, highly bioavailable oral therapy can them be safely 
made85,359. In contrast to the implant retention scenario, there is no evidence to support a chief 
role for the use of rifampicin in the setting of prosthesis removal85.
Ideal duration of systemic antibiotic therapy is also a matter of open debate. Most literature 
recommends a six weeks’ duration after the removal of the infected implant with no clear 
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evidence to support it against alternative intervals12,85,247,359,511-527. Regarding one-stage 
revision surgery, 2-6 weeks IV therapy is recommended85,359 followed by longer term oral 
therapy. Most papers report on total duration of antibiotic therapy that extends form six 
weeks507,513 to three months503,506,511,512. In this setting, an analogy can perhaps be made to 
specific antibiotic therapy after DAIR. Rifampicin associations when dealing with staphylococci 
and fluoroquinolones when facing Gram negative bacteria are recommended247,359. There is 
also a lack of solid evidence concerning the usefulness and merits of using serial inflammatory 
parameters to determine the length of antibiotic therapy495,497,498.
Local antibiotic therapy is a major issue in revision surgery of infected joints as it allows for very 
high local concentrations that would be impossible to obtain without significant toxicity using 
systemic antibiotic therapy only. In the two-stage approach, antibiotics are delivered via the 
spacer as previously discussed. The worth of this tactic is further strengthened by the findings
of Stockley et al.560 that were able to show infection eradication in 100 out of 114 patients
(88% success rate) with the use of high-dose antibiotic loaded spacers and no additional 
oral or intravenous systemic antibiotics. Regarding the one-stage exchange, the possibility
of adding effective antibiotics into bone cement seems to be the cornerstone for success of 
this approach507-509,512,513. Although some have presented favorable results with the use of 
uncemented implants501,503, it seems that results are not as consistent when antibiotic-loaded
according to specific susceptibility bone cement is not routinely used504-506. In trying to 
overcome this limitation other methods of local antibiotic delivery have been proposed. In 
2008, Winkler et al.561 presented favorable results, on their cohort of infected THA treated with 
one-stage uncemented revision using allograft bone impregnated with high levels of antibiotics 
as a carrier. At their last evaluation562, 91 hips had been treated using this methodology with 
a total of eight recurrences (88% success rate). Another method that has been proposed by 
Whiteside et al.483 is direct intraarticular infusion of antibiotics via Hickman catheter. In their 
original series of 18 MRSA infected TKA, they had one single recurrent infection (94% success 
rate). The same authors showed similar favorable results of the same protocol in a different 
and difficult population of 18 patients with reinfection after revision TKA (89% success rate)484. 
Recently, an independent group showed similar infection eradication infection rates in a study 
comprising 53 PJI treated with a single stage exchange and direct intra-articular infusion of 
antibiotics563. Notwithstanding, evidence available regarding alternative antibiotic delivery 
methods is not enough to acknowledge them as independent factors of improved outcome 
plus there are potential concerns associated with this practice as we have discussed earlier. 
THE SECOND STAGE
Safely reimplanting a new prosthesis after infection eradication is the main goal of the two-stage
approach. Failure to perform the second stage may occur for a variety of reasons such 
as medical comorbidity or mortality, patients lost to follow-up or even patient’s satisfaction 
with their current level of function in the setting of a retained spacer as we have previously 
discussed520,521,546. Other frequently underreported problems are the complications that arise 
between stages that are often responsible for not completing the intended treatment. Additional
surgeries such as new debridements and spacer exchange with all its inherent risks are not 
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uncommon520,564. Uncontrolled infection may even ultimately result in definitive treatment with 
alternative salvage procedures.
Optimal Timing
One of the most difficult decisions when choosing the two-stage approach is to when to go 
ahead with reimplantation. Preferably, the new prosthesis would be implanted in a sterile and 
advantageous background. As such, theoretically, there should be enough time complete 
antibiotic therapy and eradicate infection. 
Traditionally, surgeons have been relying on serial measurements of blood inflammatory 
parameters (most often ESR and CRP) to determine infection status and postponing surgery 
accordingly. However, there is absolutely no evidence to support this practice that naturally 
leads to longer intervals between stages and subsequent increased morbidity to the patient. 
In fact, there is evidence clearly refuting its worth. In 2009, Ghanem et al.565 examined a cohort 
of 109 consecutive infected TKA patients undergoing a two-stage exchange. Infection was 
eradicated in infection in 86 patients (79%) and 23 patients (21%) were revised for recurrent 
PJI. They were not able to determine a level for ESR or even CRP that could discriminate 
between patients in whom infection had successfully been eradicated. A year later, Kusuma 
et al.566 retrospectively reviewed the measurements of 76 infected TKA patients treated with a 
two-stage exchange protocol and reached the exact same conclusion. Although inflammatory 
parameters decreased in cases of infection control, they frequently remained elevated not 
allowing them to identify any patterns indicative of persistent infection566. At the same time, 
Shukla et al.567 reported on 87 infected THA undergoing a similar two-stage protocol in which 
persistent infection was identified in nine hips. Naturally, mean ESR and CRP significantly 
decreased between stages but it is noteworthy that ESR remained elevated (>30 mm/h) in 50 
patients (62.5%) and CRP remained elevated (>10 mg/L) in 22 patients (27.5%) in whom the 
infection had been eradicated567. Bejon et al.498 looked at serial CRP measurements of 260 
PJI patients, including 1406 separate measurements from 151 patients undergoing two-stage 
revision (comprising 71 THA, 76 TKA and 4 elbows). They found that the CRP profile was not 
significantly different in patients experiencing treatment failure. CRP did not predict additional 
debridement between stages nor did it predict treatment failure at the time of re-implantation498. 
It did however predict delayed re-implantation suggesting definitive surgery was deferred 
simply due to apprehension caused by elevated CRP498. Kubista et al.523 retrospectively 
examined data of 368 patients, looking for risk factors for failure after two-stage reimplantation 
for periprosthetic knee infection. They found no statistically significant differences in mean 
values for CRP or ESR prior to resection or reimplantation when comparing the treatment 
failure group (n=58) to the control group523.
Acknowledging these limitations, some authors further examined the role of joint aspiration 
before the second stage. Earlier studies focused on cultures results with conflicting results. 
Mont et al.568 compared a control group of 35 patients with a study group of 34 patients in which 
preoperative fluid cultures were taken four weeks after antibiotic discontinuation. In the control 
group, there were five infection relapses (86% success rate). In the study group, three patients 
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(9%) had a positive culture. The protocol was repeated for all three and they subsequently had 
a successful second revision. There was one case (3%) of infection relapse that occurred in 
patient with negative cultures. Lonner et al.569 looking at 34 TKA found two preoperative false 
positive cultures and negative cultures in 32 knees. They had 8 cases of persistent infection, 
none of which were identified on preoperative cultures. In the series by Ghanem et al.565, 34 
out 109 infected TKA patients had arthrocentesis before reimplantation as a result of a high 
clinical suspicion of unrelenting infection. Thirty-three had negative aspirates, but five of them 
(15%) had positive intraoperative cultures at the time of reimplantation565. Just recently, Janz et 
al.570 confirm that the low sensitivity of cultures is also so true in hips. These findings suggest 
negative synovial fluid culture results are not accurate in ruling out persistent infection. Much 
as for the first diagnosis of infection, attempts to refine synovial fluid testing have been made 
in order to overcome the low sensitivity of cultures and offer additional value to preoperative 
joint aspiration. Kusuma et al.566 did show that total leukocyte count was somewhat more 
accurate than ESR or CRP but still did not have sufficient sensitivity or positive predictive value
to reliably diagnose persistent TKA infection. Shukla et al.567 performed a similar analysis 
regarding THA and found that synovial fluid total leukocyte count was the best test for identifying 
persistent infection, with an optimum cutoff of 3.528 cells/μL (sensitivity, 78%; specificity, 96%). 
In contrast, Newman et al.571 analyzed data from 98 hips (80 patients) with antibiotic-eluting 
cement spacers to determine diagnostic accuracy of traditional cutoffs and optimal thresholds 
total leukocyte count and PMN proportion to diagnose infection in this setting. They found the 
optimal threshold for synovial total leukocyte count was 1,166 cells/μL which corresponded to 
overall diagnostic accuracy of 78%571. Hoell et al.572 studied 59 infected TKA and 56 infected 
THA treated with a two-stage protocol, and confirmed that aspiration of synovial fluid with a 
PMMA spacer in place is not an appropriate method for excluding persistent infection. Results 
so far are overall discouraging and there is no evidence to support joint aspiration before the 
second stage85. In addition, it seems that most failures after the second stage are probably the 
consequence of re-infection and not persistent infection. Indeed, the microorganism isolated in 
failure after the second stage is often different than the one found in the first stage573.
Given the low accuracy of current laboratory testing to determine infection eradication before
second stage surgery, clinical signs of improvement (adequate wound healing, no local 
inflammatory signs) and blood inflammatory parameters are frequently used together as a 
surrogate for infection control and effective antibiotic therapy in daily clinical practice. However, 
this improvement may persist only whilst antibiotic therapy is in place281. As such, a holiday 
period before surgery has been traditionally recommended85. Although there is no conclusive 
evidence to support or refute this practice, the rationale is that continuing observation after 
discontinuing antibiotics may be informative. Stability or continuing improvement (and not 
necessarily complete normalization of all parameters) could indicate eradication of the 
infection while deterioration might indicate recurrence. It is also important to correct the 
underlying cause for prosthetic joint infection if it is perceivable. Naturally, attention should 
likewise be paid to the patient’s general health status and all efforts should be made to optimize
medical comorbidities before revision surgery. Favorable soft tissue status with nice wound 
healing is equally important to increase chances of success and there should be enough 
time for adequate soft tissue preparation with muscle flaps if required, especially in cases of 
previously compromised soft tissues. 
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Although most authors acknowledge these requirements, the optimal time interval 
between stages cannot be firmly established85. Reports vary from two weeks to several 
months247,514,515,518,523,559,560,574. Nevertheless, evidence suggests greater time intervals offer 
no advantage in infection eradication and are associated with worse functional outcomes 
(besides greatly increasing morbidity between stages)85,523,526,564. Our own experience confirms 
this assumption. We analyzed every PJI case treated with a two-stage revision surgery in our 
institution between 2011-2014. We found that among those who did not strictly comply to the 
suggested protocol, time interval between stages was significantly longer (around 30 vs.11 
weeks) with no added benefit as the reinfection rate was also significantly higher (20% vs. 0%).
Surgical and Medical Management
Persistent infection is an ominous concern that cannot be accurately ruled out before the 
second stage as we have discussed previously. Delay reimplantation of the new prosthesis 
and rather perform a second debridement has been advocated if the diagnosis can be made 
intraoperatively. On the other hand, decision regarding subsequent antibiotic therapy can also 
be accommodated if a diagnosis is reached postoperatively.
Although preoperative fluid cultures lack adequate sensitivity565,569,570, multiple intraoperative 
tissue cultures are naturally more accurate and most authors agree that they must be taken
during revision surgery. Cabo et al.575 reviewed second-stage culture results in 41 cases, showing
the surgical site is frequently non-sterile at reimplantation as 18 patients (44%) showed at least 
one positive culture. They also found 14 (34%) positive antibiotic-loaded spacers cultures575. 
Sorli et al.576 reporting on 55 patients (37 knee, 17 hip and one shoulder replacement) showed 
11 (20%) cases with subclinical infection in which there was positive culture from sonicated 
spacer fluid; and two or more tissue specimens positive for the same microorganism. This 
subgroup of patients exhibited a significantly higher risk of failure 63% (7/11) compared with 
25% (11/44) of those without subclinical infection even if most of them (7) received antibiotic
treatment according to definitive culture results. A couple of recent papers seems to confirm this 
increased risk of re-infection among positive sonicate results and a direct correlation seems to 
exist between higher bacterial load as measured by higher high colony counts and subsequent 
risk of failure26,577. Nelson et al.26 prospectively followed 36 consecutive patients undergoing 
two-stage revision for hip or knee PJI. Eighteen cases (50%) had positive sonication results. 
At a two-year follow up, recurrent infection rate was as high as 30% (11/36) and it correlated 
significantly with bacterial growth. Reinfection occurred in 78% (7/9) of cases with intermediate 
or significant bacterial growth (>20 CFU),  22% (2/9) in patients with subtle growth (<20 CFU) 
and only 11% (2/18) in patients with negative sonication results26. Besides confirming this 
seeming correlation, Esteban et al.577 also found isolating organisms other than those isolated 
in the first surgery is also clinically relevant. Of course, culture results are not at all useful for 
intraoperative decision but should be taken nonetheless as it has been shown that 
second-stage positive cultures are an independent risk factor for treatment failure573.
Intraoperative frozen sections, have been suggested as a means to identify persistent infection 
intraoperatively and support the decision whether or not to proceed with reimplantation564,574. 
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However, while this method offers high specificity it has low sensitivity for the diagnosis
of infection at the time of reimplantation578-580. Synovial fluid analysis is also a potentially 
informative test. Traditional leukocyte counts thresholds though, despite their great value in 
diagnosing infected implants have been shown to be poorly predictive at the time of the second 
stage566,567,571,572. These limitations have fueled the search for alternative biomarkers also in this 
scenario. Frangiamore et al.581 have studied the role of synovial fluid biomarkers such as CRP, 
IL-6, IL-1ß and alpha-defensin not only in differentiating septic from aseptic failed TKA and 
THA but also in 35 patients before second-stage surgery. They found that IL-1ß and IL-6 had 
the greatest decrease between stages. However, cytokines and MSIS criteria lacked adequate 
sensitivity to rule out infection before reimplantation. Our own ongoing study also shows some 
synovial fluid biomarkers significantly decrease between stages. Mean values at prosthesis 
removal were 31.7 mg/L, 126.1 U/L for synovial CRP, and adenosine deaminase respectively
(published results). Values at reimplantation surgery are available for 15 cases so far. Mean 
CRP concentration decreased to 3.6mg/L and ADA decreased to 41.8 U/L (unpublished 
data). As none of these cases proved to have positive intraoperative cultures or reinfection at 
follow-up, no assumption regarding their predictive value can be made yet.
In summary, current criteria used to define PJI are able to rule in persistent infection but offer 
limited screening ability to rule it out at the time of reimplantation571,580,581. As such, we believe 
the second stage should be regarded as a second chance to deal with the infection with the 
same vigor as the first stage. Meticulous debridement and thorough diagnostic workup should 
be performed and adjuvant antibiotic therapy should be instituted if needed. In fact, there a 
growing body of evidence suggesting prolonged antibiotic therapy after the second stage may 
improve outcomes. Johnson et al.517 were among the first to suggest a possible advantage 
of such a strategy. Decision to give longer-duration oral antibiotics after reimplantation was 
made by the consulting infectious disease physician and it was not based on a predetermined 
algorithm nor were there preselected assignment of patients based on any specific factors. 
They reported no reinfections on a group of 23 THA compared to six (13.6%) relapses in 44 
patients not receiving postoperative oral antibiotics although this difference was not statistically
significant. Siqueira et al.582 also showed chronic suppression with oral antibiotics significantly 
increased the infection-free survival rate following surgical treatment for PJI. However, their 
results also included patients treated with DAIR. No significant difference in between the 
suppression and non-suppression groups was found considering two-stage revision cases 
only582. Just recently, a multicenter study randomized patients to receive 3 months of oral 
antibiotics or no further antibiotic treatment after intraoperative cultures obtained during the 
second-stage reimplantation were negative583. So far, at interim analysis, 59 patients were 
successfully randomized to the antibiotic group and 48 patients to the control group (57 TKA 
and 50 THA). Results suggest that, at least at short-term follow-up, the addition of 3 months 
of oral antibiotics appears to be improving outcome as reinfection rate is significantly lower in 
the antibiotic group: 5% (3/59) vs.  19% (9/48) thus far583. Available evidence is not yet enough 
to make a definitive recommendation on the optimal medical treatment after the second stage.
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Treatment Failure and Salvage Procedures
Treatment failure after septic surgery is a real problem. While it is not the only mode of failure,
infection recurrence is probably the most problematic. Recurrent PJI may occur as a 
result of persistent infection (i.e. caused by the same microorganisms) or reinfection with new 
microorganism(s) suggesting treatment was effective at controlling the original infection. 
Recurrent PJI after DAIR procedures is most often due to identical microorganisms suggesting 
treatment failed to eradicate infection effectively427,429,430,433,434. A recent paper looked at 153 hip 
or knee PJI treated with implant retention with 52% (80/153) overall success rate440. Focusing 
exclusively on 43 cases with positive cultures at both initial and recurrent failure, they found 
84%(36/43) of them failed with the same organism(s)440. Organism persistence was especially 
prevalent in knee and Staphylococcus aureus infections440. Reinfection after revision surgery 
seems different though. Zmistowski et al.573 pooled data of three different institutions regarding
92 patients who failed two-stage exchange and had positive cultures at both initial an 
recurrent PJI. Only 29 (31.5%) of them had identical microorganisms at treatment failure573. 
Triantafyllopoulos et al.584 made a similar analysis and also found that only 19 cases (40%) 
were persistent infections and most failures were due to new microorganisms. These findings 
suggest that treatment failure after two-stage revision surgery is more commonly secondary 
to a new infection rather than an inability to eradicate the original microorganism. It is also 
possible that these “new” organisms might have been present from the start but were simply 
not captured by cultures. 
Naturally, failure is likely attributable to a combination of several factors. Some, such as 
the specific infecting microorganism or treatment with implant retention are more likely to 
contribute to PJI persistence and others are more likely to originate new infections probably by 
influencing host susceptibility status573,584.
RISK FACTORS FOR FAILURE
Risk factors for failure of a DAIR procedure have been extensively discussed elsewhere. Much 
like failure after DAIR, the specific infecting pathogen is one of the main factors influencing 
outcome after exchange surgery. Indeed, staphylococci, as the original infecting organism 
seems to be associated with worse outcomes and a higher rate of infection persistence12,573. 
Notwithstanding, this effect seems to be much more prominent after DAIR than after exchange 
arthroplasty (either one- or two-stage)444. Infections due to methicillin-resistant staphylococci
are especially at risk for revision surgery treatment failure226,293,585. Enterococci are also of 
special concern. A major multicenter European study included data of Enterococcus sp. 
PJI from 18 hospitals of six different countries455. Although implant removal was associated 
with a higher remission rate than DAIR, overall success rate of combined one- or two-stage 
exchange was only 64% (47/74)455. A recent paper focusing on 87 enterococci PJI reached 
similar conclusions453. Treatment success was 63% (27/43) for a two-stage exchange, 
46% (5/11 patients) for a one-stage exchange and only 39% (13/33) for irrigation and 
debridement453. Gram negative microorganisms on the other hand, constitute a somewhat 
different problem in revision surgery compared to implant retention. Hsieh et al.446 looked at 53 
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out 346 PJI due to Gram negative bacteria. They found treating Gram negative PJI with DAIR 
was associated with a significantly lower probability of success than treating Gram positive 
(27% vs. 47% success rate).  However, no difference was found when treatment consisted of a 
two-stage exchange or resection arthroplasty448. On the other hand, Zmistowski et al.450 found 
conflicting results in their study of 31 Gram negative infections in 282 culture-positive PJI. 
Debridement and implant retention was successful in 70% (7/10) of Gram negative cases450. 
Of those patients undergoing a planned two-stage exchange, successful reimplantation was 
performed in 52% (12/23) of Gram negative, 51% (52/103) of methicillin-resistant Gram 
positive, 69% (65/94) of methicillin-sensitive Gram positive and 0% (0/8) of polymicrobial PJI 
cases450. A recent multicenter French study involving 76 patients with Gram negative PJI, found 
a much better failure rate of only 9% (2/22) after one-stage exchange, and 27% (4/15) after 
two-stage exchange494. Polymicrobial infections, naturally accumulate all sorts of difficulties 
and are often linked to worse treatment outcomes450,458.
Such findings are not unanimous, Sakellariou et al.525 found the type of isolated pathogen and 
its virulence were not directly associated with increased incidence of recurrence but placed 
much more emphasis on patient-related factors such as an history of inflammatory arthritis or 
being chronic Staphylococcus aureus carrier. A number of other patient-related variables have 
been found to increase the risk of infection recurrence after two-stage treatment. Obesity is 
a known risk factor for PJI in the first place and it has also been shown to be a major risk for 
failure after two-stage exchange of both TKA and THA586,587. Diabetes, chronic lymphedema, 
heart disease or even psychiatric disorders have also already been implied523,525,584,588. It seems 
logic to expect that all risk factors for first-time infection will also increase the risk of treatment 
failure.
SALVAGE PROCEDURES 
Deciding what the best course of treatment is after recurrence of infection is not straightforward.
Although the real impact of previous failed DAIR on the likelihood of success after exchange 
surgery is not yet fully understood, most surgeons would agree that exchange surgery is the 
natural choice in this scenario589-591. 
Failure after revision surgery is much more difficult to address. There is no evidence to support 
how many septic exchanges are reasonable to attempt85. One of the major factors to consider
is the causative microorganism and whether it represents persistent infection or a “new” 
infection. We believe new infections should be managed according to all previously mentioned 
recommendations although lower success rates are naturally to be expected. Azzam et al.592 
showed it was possible to manage reinfection after failed two-stage TKA exchange in 10 (44%) 
out of 18 patients treated with debridement and implant retention. More recently, Kheir et al.593 
successfully treated 16 (43%) out of 37 patients with failed prior two-stage exchange in which 
debridement and implant  retention was attempted. 
A new exchange procedure (most often two-staged) may also be recommended depending on 
duration and extent of infection as well as patient willingness and medical fitness to undergo
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further surgeries. The risk of recurrent infection must be discussed with the patient. New 
infections probably reflect an increased host susceptibility rather than previous treatment 
failure and if such risk factors cannot be mitigated, other alternatives must be seriously 
considered. Technical aspects such as adequate bone stock for stable fixation of the new 
prosthesis, viable soft tissues conditions that allow for good wound healing (or possibility of 
muscle flap coverage) and extensor mechanism status in the knee must also be considered. 
Reimplantation is feasible if all these conditions are met and infection seems to be adequately 
controlled after repeat resection. Several authors have reported successful outcomes after re-
peated two-stage exchanges but unsurprisingly, failure rates are as high as 40-50%484,592,594-597. 
Patients with persistent infections on the other hand, especially those involving high risk 
bacteria such as methicillin-resistant staphylococci or enterococci should merit further 
consideration. We believe that a new attempt is reasonable when treating an otherwise healthy 
and fit patient, especially if a previous treatment error has been identified. On the other hand, 
when dealing with a patient at high risk for further treatment failure, salvage procedures are 
perhaps more sensible593,598,599. Most common salvage procedures are resection arthroplasty 
(Girdlestone procedure) for the hip and arthrodesis or even amputation for the knee. Chronic 
suppressive oral antibiotic therapy is also worth considering.
Resection Arthroplasty
Resection arthroplasty was first described by Girdlestone almost a century ago as a salvage 
procedure for complex hip infections such as tuberculosis. Nowadays, failed periprosthetic hip 
infections are the most common indication. It is important to acknowledge that simply removing 
the hip implant is not enough to guarantee infection control. Debridement must be performed 
meticulously and efforts should be made to extract all residual bone cement, foreign material 
and infected tissues including bone. If that is not the case, infection may persist despite the 
absence of an implant600 (Fig. 6). When properly performed, it may provide satisfactory pain 
relief and control of infection601,602. Of course, a significant impact on the functional outcome is 
to be expected, especially in elderly patients603.
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B: infection resolved after removal of the infected bone segment and broken drill bit.
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Resection arthroplasty in total knee replacement is not a common strategy and it has been 
largely abandoned because of the poor and unpredictable functional outcomes604,605. Our own 
though limited and retrospective observations, show that resection arthroplasty may be a 
viable alternative to knee fusion in selected patients23. A significant impact in the patient quality 
of life and functional outcome is to be expected in either case. Resection arthroplasty patients 
have more difficulty walking and often require an external brace but on the other hand are 
more comfortable sitting and using the toilet23.
Arthrodesis
Joint fusion is considered to be a main limb salvage procedures for failed periprosthetic joint 
infection. In contrast to resection arthroplasty, it is rarely considered in the hip but it is of 
proven value in the knee offering better functional outcomes and patient satisfaction. A recent 
systematic review599, suggests that arthrodesis is the procedure of choice when compared 
to suppressive antibiotics, amputation or even two-stage reimplantation for management of 
persistent infection after a failed two-stage TKA exchange.
Several different methods have been proposed to achieve fusion, including external fixation, 
plating and intramedullary nailing606-610. More recently a method of intramedullary stabilization 
without bone-on-bone fusion has been presented as a means to achieve a stable and painless 
knee, while preserving the limb length. It has the advantage of overcoming bone defects that 
often preclude successful fusion and allows for early weight bearing and deambulation611. No 
method has yet proved to be clearly superior to the others. Each has its own set of limitations 
and possible complications such as failure of fusion (i.e. nonunion), limb length discrepancy, 
residual pain, periprosthetic or implant fractures, pin site infections, etc. The most feared and 
shared complication is recurrence of infection and this seems to be especially prevalent after 
intramedullary nailing612. Some authors advocate that performing an arthrodesis in two-stages
reduces the risk of persistent infection although there is no real evidence of its advantage 
over single stage85. Final decision on which method and tactic to use depends on individual 
circumstances, surgeon experience, host factors (both medical and local) and even specific 
pathogen. 
Amputation
Control of the infection is not guaranteed after implant removal. Amouyel et al.613 have recently 
reported on 72 consecutive patients who underwent TKA removal for infection. Prosthesis 
removal was followed by knee fusion in 29 cases or implantation of a permanent cement spacer
in 43 cases. The two-year infection free rate was 69% for patients who underwent knee fusion 
and 62% for those who had a spacer implanted. After treatment of 32 recurrent infections, 23 
cases were labelled as permanent failures (32% overall)613.
In desperate cases, above-knee-amputation may be indicated85. Especially if infection persists 
after repeated failed attempts at staged exchange and aggressive debridement, severe bone 
loss precludes knee fusion, there is inadequate soft tissue coverage or significant peripheral 
vascular disease or infection recurs after arthrodesis. Many of these patients go through a lot 
of surgeries and suffering before this option is considered and this might explain why, despite 
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the obvious suboptimal functional outcomes, patient satisfaction is surprisingly good614. Khana et 
al.598 specifically assessed patient satisfaction following above-knee-amputation for chronically
infected TKA in seven patients. All seven patients reported that they were satisfied with their 
amputation (six were fitted with a prosthesis limb). Six of seven patients reported that given 
the choice, they would have chosen amputation sooner598. These findings might explain the 
increasing trend toward amputation when compared to arthrodesis for the treatment of a failed 
infected TKA in the United States615.
Chronic Suppressive Antibiotic Therapy
Prolonged suppressive antibiotic therapy is seldom indicated in the management of PJI. In a 
surgically fit patient, it is considered when all operative treatment options have been exhausted.
It may also be considered in an elderly or otherwise poor health status patient where surgical
intervention is contra-indicated or in patients unwilling to undergo further surgery. A loose 
implant is generally considered to be a contra-indication for suppressive antibiotic therapy. A 
number of other prerequisites such as causative pathogen sensitive to a well-tolerated oral 
antibiotic that can be safely administered for prolonged suppression and adequate baseline 
renal and liver function are also important616. Regular monitoring of the patient is essential 
to ensure safe treatment with suppressive antibiotics. This includes routine examination and 
tests to rule out predictable side effects such as renal, liver or gastrointestinal dysfunction. 
Methicillin-sensitive staphylococci that can controlled using penicillins, ciprofloxacin-sensitive 
Gram negative bacteria and streptococci seem to be more mendable pathogens616.
Chronic suppression with oral antibiotics has been proved to result in superior infection-free 
survival rates after surgical treatment for periprosthetic joint infection compared with those 
observed without suppression582. It is however an unproven method with high failure rates at 
the long term616-618.  It should be considered only in selected cases in which prosthesis removal 
would potentially cause an extremely poor limb or even life threatening situation. 
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Summary 
In this large study of around 2,500 total joint arthroplasty candidates we found a 12.1% 
prevalence of preoperative asymptomatic bacteriuria. It was associated with higher risk of PJI 
and appropriate preoperative antibiotics were not effective in reducing the risk.
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Abstract
Background: Infection is a major complication after total joint arthroplasty. The urinary tract is 
a possible source of surgical site contamination but the role of asymptomatic bacteriuria before 
elective surgery and subsequent risk of infection is poorly understood.
Methods: Total hip (THA) or total knee arthroplasty (TKA) candidates were reviewed in a mul-
ticenter cohort study. In all cases, a urine sample was cultured and patients with asymptomatic 
bacteriuria (ASB) were identified. Preoperative antibiotic treatment was decided on an individual
basis and it was not mandatory or randomized. The primary outcome was prosthetic joint 
infection (PJI) in the first postoperative year.
Results: 2,497 patients were enrolled. ASB prevalence was 12.1% (303/2497), 16.3% in women
and 5.0% in men (OR=3.67, 95% CI=2.65-5.09, P <0.001). Overall PJI rate was 1.7%. 
Infection rate was significantly higher in the ASB group (4.3%) than in the non ASB group 
(1.4%) (OR=3.23, 95% CI=1.67-6.27, P=0.001). In ASB group, there was no significant 
difference on PJI rate in the treated (3.9%) compared to the untreated (4.7%) patients. A 
significantly higher proportion of PJI due to Gram negative microorganisms was observed in 
ASB group compared to the non ASB group but these did not correlate to urine isolates.
Conclusions: ASB was an independent risk factor for PJI particularly due to Gram negative
microorganisms. Preoperative antibiotic treatment did not show benefit and cannot be 
recommended.
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Introduction
Periprosthetic joint infection (PJI) is one of the most challenging and frequent complications 
after joint arthroplasty [1, 2]. As the demand for total hip and knee joint arthroplasty is expected
to increase substantially over the coming decades, so too will the economic burden of 
prosthetic infections [3, 4]. Since the incidence of this complication seems to be on the rise 
worldwide despite antiseptic skin preparation and antibiotic prophylaxis, identifying those 
potentially modifiable preoperative risk factors is of great interest [5, 6].
The concern with the genitourinary tract as a possible source of hematogeneous seeding has 
been present as far back as the 1970’s when a few case reports [7-10] and a retrospective 
study [11] found a relation between patients with deep joint infection and perioperative urinary 
tract infection (UTI). 
Although there seems to be enough evidence supporting a relation between postoperative UTI 
and PJI [11-15], literature studying the correlation between asymptomatic bacteriuria (ASB) 
and surgical site infection after joint arthroplasty is scarce [15-19] .  As such, this finding is not 
currently considered to be a criterion for delaying total joint replacement surgery [13]. 
The aims of the present study were: 1) to describe the prevalence of ASB among elective total 
hip and knee arthroplasty candidates; 2) to determine if ASB is associated with an increased 
risk of PJI and finally 3) to know whether an appropriate course of preoperative antibiotics is 
effective in reducing the risk of PJI.
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Material and Methods
From January 2010 to December 2011, in three institutions from United Kingdom, Portugal and 
Spain, a urine culture before surgery was collected from all patients before undergoing a total 
hip (THA) or knee arthroplasty (TKA). Relevant information about demographics, body mass 
index (BMI), diabetes mellitus, American Society of Anaesthesiologists (ASA) physical status 
classification system and duration of surgery were collected retrospectively but unfortunately 
information regarding duration of surgery and diabetes mellitus was not possible to gather in 
the British participating institution. Duration of surgery was categorized as under or over the 
75th percentile in order to account for different average surgical times between centers [20]. 
In all cases a urine sample was obtained (regardless of dipstick test results), placed in a sterile 
container and cultured using conventional methods in the microbiology laboratory. All isolated 
microorganisms were identified with standard biochemical procedures. ASB was defined as 
the isolation of ≥ 105 CFU/mL in the absence of symptoms or signs of urinary tract infection.
Preoperative treatment of asymptomatic bacteriuria was decided by the treating physician and 
was not mandatory or randomized. For treatment an eight-day course of oral antibiotics (according
to in vitro susceptibility test) was given the week before hospital admission. Control urine 
cultures after treatment were not mandatory and only 26 of the 154 treated ASB patients had 
repeat urine cultures  (all of them negative) before surgery.  In the untreated ASB candidates
no further antibiotics were given pre- or per operatively nor were any other additional 
prophylaxis measures taken other than normal prophylaxis regimen for each institution (single 
dose 2g cefazolin in the Portuguese institution, 1.5g cefuroxime in the Spanish institution or 600 
mg teicoplanin plus 120mg gentamicin in the UK institution during the induction of anesthesia).
Postoperative UTI occurring in the early postoperative period was diagnosed when urinary 
symptoms of infection were present and urine culture showed bacterial growth ≥ 105 CFU/mL. 
After hospital discharge the patients were followed for a minimum of twelve months. The main 
outcome of the study was the diagnosis of prosthetic joint infection occurring in the first year 
after surgery accordingly to the CDC definition of implant related surgical site infection [21].
STATISTICAL ANALYSIS
Categorical variables were presented as number of patients and percentages. Continuous 
variables were compared using the non-parametric Mann-Whitney test as the study population 
did not meet the normality assumption. Proportions were compared using Chi-square test and 
Fischer’s exact test when necessary with statistical significance defined as a two-tailed P value 
< 0.05. 
To test the association between study variables and outcome (PJI) logistic regression models 
were fitted accounting for spatial clustering as data came from three different Centers (center 
effect).
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A multivariable logistic regression model was developed including variables with a P value 
≤0.20 from the univariable analysis. The role of the variables as potential modifier effect was 
also studied. The assessment of the model fit was done with the Hosmer-Lemeshow test. 
Statistical analysis was done by the program SPSS (version 19.0; SPSS, Inc., Chicago, IL, 
U.S.A.).
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Results
A total of 2497 patients were included during the study period with a similar proportion of THA 
(n=1248) and TKA (n=1247). Distribution among participating institutions is shown in table 1 
and no significant differences among them were registered either for ASB or PJI. 
Table 1 Differences between the three participating institutions regarding ASB and PJI.
Overall UK Portugal Spain P value
n=2497 n=1495 n=785 n=217
Preoperative ASB 303 (12.1%) 184 (12.3%) 88 (12.1%) 31 (14.3%) 0.45
Overall PJI 43 (1.7%) 19 (1.3%) 18 (2.3%) 6 (2.8%) 0.10
Gram negative PJI 11 (0.4%) 5 (0.3%) 4 (0.5%) 2 (0.9%) 0.45
ASB Asymptomatic Bacteriuria; PJI Prosthetic Joint Infection.
Approximately two thirds were women (63.0%) and the mean age of the patients was 68.0 
years old. Asymptomatic bacteriuria (ASB) was diagnosed in 12.1% of the cohort, 16.3% 
in women and 5.0% in men (OR=3.67, 95% CI=2.65-5.09, P<0.001). Table 2 shows the 
microorganisms isolated in these patients. 
    Table 2 Microorganisms isolated in preoperative urine cultures.
Isolated Species Frequency
Gram negative 87.6%
Enterobacteriaceae
Escherichia coli 193 (64.8%)
Klebsiella 21 (7.0%)
Proteus 12 (4.0%)
Citrobacter 8 (2.7%)
Morganella 2 (0.7%)
Pseudomonas aeruginosa 1 (0.3%)
Others 24 (8.1%)
Gram positive 11.7%
Coagulase-negative staphylococci 1 (0.3%)
Staphylococcus aureus 5 (1.7%)
Other
Enterococcus spp. 22 (7.4%)
Streptococcus spp. 6 (2.0%)
Corynebacterium spp. 1 (0.3%)
Fungi 0.3%
Candida albicans 1 (0.3%)
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ASB was significantly more common in obese women over 71 years with an ASA score of ≥ 3 
(table 3). There was no significant increase of postoperative UTI prevalence in the ASB group.
Table 3 Main characteristics of the population according to the presence of asymptomatic bacteriuria.
ASB (n=303) Non ASB (n=2193) P value OR 95% CI
Mean age (range) 70.9 (23-90) 67.7 (21-96) < 0.001 - -
Female gender 257 (84.8%) 1315 (59.9%) < 0.001 3.73 (2.70 – 5.17)
Knee Location 162 (53.5%) 1087 (49.5%) 0.220 1.17 (0.91 – 1.50)
Duration	>75th percentile 1) 25 (21.4%) 192 (22.1%) 0.906 0.96 (0.57 – 1.55)
Co-morbidities
Obesity (BMI≥30)2) 127 (47.0%) 735 (36.6%) 0.001 1.54 (1.18 – 2.00)
Diabetes 3) 23 (19.5%) 145 (16.6%) 0.433 1.22 (0.75 – 1.99)
ASA	≥	3	4) 61 (25.2%) 320 (18.6%) 0.019 1.47 (1.06 – 2.03)
Postoperative UTI 5 (1.7%) 21 (1.0%) 0.234 1.74 (0.65 – 4.64)
BMI Body Mass Index, ASA American Society of Anesthesiologists, UTI Urinary Tract Infection.1) Data available for 985 patients; 2) Data available 
for 2278 patients; 3) Data available for 993 patients; 4) Data available for 1960 patients.
The overall PJI rate in the study population was 1.7% (43/2497). Infection rate in the ASB 
group was 4.3% (13/303) significantly higher than the 1.4% (30/2194) rate in non ASB group 
(OR=3.23, 95% CI=1.67-6.27, P=0.001). Variables associated with PJI in the univariable 
analysis were ASA score ≥ 3, ASB and there was a trend towards significance for postoper-
ative UTI (table 4). Multivariable analysis, performed including variables with a P value ≤0.2, 
substantiates ASB (OR=3.95, 95% CI=1.52-10.26) and postoperative UTI (OR=6.64, 95% 
CI=1.24-35.64) as independent predictors of PJI. 
Table 4 Risk factors for prosthetic joint infection.
No PJI PJI Univariable analysis Multivariable analysis
n=2454 n=43 P value OR 95%CI P value OR 95%CI
Mean age (range) 68.1 (21-96)
68.6 
(51-87) 0.721 - - - - -
Female gender 1551 (63.2%)
21 
(48.8%) 0.005 0.56 (0.37-0.84) 0.102 0.42 (0.15-.19)
Knee Location 1222 (49.8%)
27 
(62.8%) 0.199 1.70 (0.76-3.83) 0.003 1.39 (1.11-1.72)
Duration	>75th percentile1) 209 (21.7%)
8 
(33.3%) 0.022 1.80 (1.25-2.59)
2) 2) 2)
Co-morbidities
Obesity (BMI≥30)3) 847 (37.9%)
15 
(37.5%) 0.936 0.99 (0.69-1.41) - - -
Diabete4) 163 (16.8%)
5 
(20.8%) 0.606 1.30 (0.48-3.54) - - -
ASA	≥	35) 368 (19.1%)
13 
(38.2%) <0.001 2.62 (1.66-4.14) 0.083 2.12 (0.91-4.95)
ASB 290 (11.8%)
13 
(30.2%) <0.001 3.23 (2.10-4.97) 0.005 3.95 (1.52-10.26)
Postoperative UTI 24 (1.0%)
2 
(4.7%) 0.091 4.94 (0.77-31.56) 0.001 6.64 (1.24-35.64)
PJI prosthetic Joint Infection; BMI Body Mass Index; ASA American Society of Anesthesiology; UTI Urinary Tract Infection; ASB Asymptomatic 
Bacteriuria. 1) Data available for 985 patients; 2) Duration >75th percentile was excluded from the multivariable model since data is missing in a 
significant proportion of the cohort; 3) Data available for 2278 patients; 4) Data available for 993 patients; 5) Data available for 1960 patients.
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Postoperative UTI was diagnosed in 26 patients and only five of them had preoperative ASB. 
All five cases occurred in the untreated ASB group and the same organism was present in the 
urine before and after surgery. No resistant strains to the prophylaxis regimen were present in 
these cases. Despite the higher risk of PJI in the early postoperative UTI group, microorganisms
isolated in UTI were always different from those in PJI.
A total of 51 microorganisms were isolated in 43 cases of PJI (table 5). The proportion of PJI 
cases involving GN bacteria was 1.98% (6/303) in the ASB group compared to 0.23% (5/2194) 
in the non ASB group (OR=8.84, 95% CI=2.68-29.16, P=0.001). In 32 out of 43 cases (74%), 
the infection was diagnosed within the first 6 weeks after surgery. In the other 11 cases, the 
diagnosis was made after the first three months. The proportion of GN was identical in the early 
infection group (8/32) and in the late infection group (3/11). 
                 Table 5 Microorganisms isolated in 43 prosthetic joint infection cases.
Isolated microorganisms Overall (n=51) ASB (n=17) Non ASB (n=34)
Gram positives 72.5% 47.1% 85.3%
CoN Staphylococci 16 (31.4%) 6 (35.3%) 10 (29.4%)
Staphylococcus aureus 15 (29.4%) 2 (11.8%) 13 (38.2%) 
Other
Enterococcus spp. 3 (5.9%) - 3 (8.8%)
Streptococcus spp. 2 (3.9%) - 2 (5.9%)
Corynebacterium spp. 1 (2.0%) - 1 (2.9%)
Gram negative 27.5% 53.0% 14.6%
Enterobacteriaceae  
Escherichia coli 6 (11.8%) 3 (17.6%) 3 (8.8%)
Serratia spp. 2 (3.9%) 2 (11.8%) -
Proteus spp. 2 (3.9%) 1 (5.9%) 1 (2.9%)
Citrobacter spp. 1 (2.0%) 1 (5.9%) -
Pseudomonas spp. 2 (3.9%) 2 (11.8%) -
Others
Acinetobacter spp. 1 (2.0%) - 1 (2.9%)
Polymicrobial 6 (11.8%) 2 (11.8%) 4 (11.8%)
                   ASB asymptomatic bacteriuria; CoN coagulase negative.
Microorganisms isolated in PJI among patients with ASB were not the same as in their 
preoperative urine cultures in any case (table 6). Although pulsed-field gel electrophoresis was 
not performed, E. coli isolates in the urine and in the joint of patient #4 - an untreated ASB 
case - presented different antibiotic resistance profiles suggesting they were unrelated.  There 
were no other variables significantly associated with GN infections.
A sub-analysis of ASB population on the effect of preoperative treatment of ASB was 
performed. As there was no randomization to treatment, biases as to who was selected for 
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treatment can exist. In order to address possible unrecognized selection biases, a propensity
analysis was performed and the results are no different from the ones obtained from the 
logistic regression analysis. Both groups were similar for the main risk factors except the 
proportion of females that was significantly higher in treated group (table 7). Infection rates in 
the untreated ASB group were 4.7% (7/149) and 3.9% (6/154) in the treated ASB group. There 
was no significant difference between them (OR=0.82, 95% CI=0.27-2.51, P=0.78) and they 
both had a significantly higher rate of PJI than non ASB group (untreated ASB vs. no ASB: 
OR=3.56, 95% CI=1.54-8.24, P=0.007; treated ASB vs. no ASB: OR=2.85, 95% CI=1.20-6.74, 
P=0.027).
                Table 6 Microorganisms isolated in PJI among ASB patients.
ASB microorganism PJI microorganism
#1 Enterococcus faecalis Escherichia coli
#2 Klebsiella pneumoniae Staphylococcus aureus
#3 Escherichia coli Serratia marcescens, Coagulase-negative staphylococci
#4 Escherichia coli Escherichia coli, Serratia marcescens, Proteus mirabilis, Pseudomonas aeruginosa
#5 Escherichia coli Coagulase-negative staphylococci
#6 Staphylococcus aureus Pseudomonas aeruginosa
#7 Escherichia coli Staphylococcus aureus
#8 Klebsiella pneumoniae Citrobacter
#9 Escherichia coli Coagulase-negative staphylococci
#10 Escherichia coli Coagulase-negative staphylococci
#11 Escherichia coli Coagulase-negative staphylococci
#12 Escherichia coli Coagulase-negative staphylococci
#13 Enterococcus faecalis Escherichia coli
                                    ASB Preoperative Asymptomatic Bacteriuria; PJI Prosthetic Joint Infection.
  
                               Table 7 Microorganisms isolated in PJI among ASB patients.
Treated ASB 
(n=154)
Untreated ASB 
(n=149) P value
PJI 6 (3.9%) 7 (4.7%) 0.78
Mean age (range) 71.6 (23-90) 70.1 (36-90) 0.059
Female gender 139 (90.3%) 118 (79.2%) 0.010
Knee Location 82 (53.3%) 80 (53.7%) 1.000
Co-morbidities
Obesity (BMI≥30) 1) 61 (45.9%) 66 (48.2%) 0.716
Diabetes 2) 4 (18.2%) 19 (19.8%) 1.000
ASA	≥	3	3) 27 (24.3%) 34 (26.0%) 0.882
Postoperative UTI 1 (0.65%) 4 (2.7%) 0.208
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Discussion
Prosthetic joint infection is a dreadful complication of arthroplasty surgery and its prevention is 
a priority for U.S. Department of Health and Human Services [22]. Under contemporary aseptic 
conditions and the use of antibiotic prophylaxis the infection rate after joint arthroplasty has 
significantly decreased [23]. Nevertheless, there seems to be a worldwide trend to an increase 
in the incidence of this complication and a recent retrospective study performed in California 
demonstrated a surgical site infection rate of 2.3% and 2% following total hip and total knee 
arthroplasty respectively [24], which is even higher than the one reported in the present study 
(1.7%).
Although many orthopedic surgeons worry about an undiagnosed UTI as a possible source of 
bacterial contamination, the real impact of ASB as a preoperative marker or risk factor for PJI 
has not been well established and to our knowledge, our study is the largest case series that 
addresses this matter.
Prevalence of asymptomatic bacteriuria in the present cohort was 12% (16% in women and 
5% in men) which is comparable to previous descriptions in total joint replacement candidates 
ranging from 4-19% [16, 17, 19, 25]. It is also in agreement with previous descriptions of the 
prevalence of asymptomatic bacteriuria in similar age groups of the general population [26, 
27]. In addition, older age, female gender, BMI>30 and a higher ASA score were significantly 
more prevalent in ASB population which is consistent with previous studies [26-29]. 
Our data clearly shows that patients with preoperative ASB have a significantly higher risk of 
PJI when compared to the group of patients with non ASB (4.3% vs. 1.4%). Two classic papers 
are often cited to illustrate the lack of association between ASB and PJI. Ritter and Fechtman 
[16] studied 364 total joint replacements and the infection rate in ASB group was 2.8% (1 out 
of 35) and 0.6% in the non ASB group (2 out of 329). Glynn and Sheehan [17] reported data 
on 299 patients who underwent total joint replacement, and found the infection rate in patients 
with bacteriuria was 3.5% (2 out of 57) and 0% (0 out of 242) in non bacteriuria group. The 
results of this specific paper should be interpreted cautiously as not only patients with ASB but 
also patients with symptomatic UTI were included. Furthermore there were different antibiotic 
treatment regimens (before, during and even exclusively after surgery) among patients with 
bacteriuria. Although both papers found a non significant higher infection rate in the bacteriuria 
group, neither author assumed a potential relationship because the microorganisms isolated 
from surgical site infections and urine cultures were not the same.
Nevertheless, our cohort is larger, which made it possible, not only to show an increased risk 
for PJI but also a significant higher rate of GN infections. It is of great significance that, in 
accordance with previous studies, microorganisms found in PJI have no direct correspondence
with the species found in urine cultures. 
Since part of our cohort of patients with ASB was treated with a course of preoperative 
antibiotics, we analyzed the potential benefit of this strategy. No difference was observed in 
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the infection rate between both groups (4.7% vs. 3.9%). To the best of our knowledge there is 
only one study in which patients with ASB have undergone arthroplasty after randomization to 
antibiotic therapy [19]. The authors identified no case of PJI from urinary origin in patients with 
asymptomatic bacteriuria whether or not they had been treated with specific antibiotics [19].
Although it is extremely difficult to be sure of the exact pathogenesis of infection (hematogenous
or acquired during surgery), the majority of infections in our series occurred within the first six 
weeks after surgery, suggesting most of them were the consequence of wound contamination
during surgery [30]. The lack of correspondence between ASB and PJI microorganisms could 
be explained by the fact that patients with ASB are at risk for recurrence with a different 
organism. However, the short interval between preoperative antibiotic treatment and surgery 
makes recurrent ASB/UTI with a different organism and subsequent hematogenous seeding of 
the new organism unlikely to justify for most GN infections found.
An alternative potential explanation for the increased risk of infection could be a relationship 
between ASB and other known risk factors admittedly more common in ASB patients. However,
the multivariable model showed ASB to be an independent predictor of PJI after adjusting for 
the main known risk factors (gender, age, location, duration of surgery, BMI or co-morbidity) 
suggesting it may actually be a surrogate marker for some kind of other not yet known feature. 
A plausible explanation could be that skin flora of patients with ASB is different from patients 
without ASB. The study of Ollivere et al. [31] on a cohort of 558 arthroplasty patients supports 
the fact that ASB patients are at increased risk for wound contamination. Over 36% of the 39 
patients with preoperative positive urine culture showed some form of postoperative delayed 
wound healing or confirmed superficial infection versus 16% in the other subgroup.
There are limitations of our study. The first is that the definition of asymptomatic bacteriuria 
relies on a single urine sample. This is not entirely in accordance with the Infectious Diseases
Society of America guidelines for the diagnosis of asymptomatic bacteriuria in adults that 
requires two consecutive urine specimens with isolation of the same bacterial strain in women 
[32]. The second one regards to the lack of routine control urine cultures to confirm eradication 
of ASB before surgery. These are of course not ideal conditions to assess the precise value 
of urine sterilization before arthroplasty. Nonetheless, the prescribed treatment is the usual 
clinical practice and has been shown to be highly effective in treating urinary tract infection 
[33]. Data regarding other possible confounding risk factors for ASB and PJI such as urinary 
incontinence, immobility, residence in a nursing home or long-term care facility or the presence 
and duration of urinary catheter before and after surgery are not available. Also, preoperative
antibiotic prophylaxis regimen was not the same in all three institutions and respective 
rates of compliance are not available; however, this concern was addressed by performing 
statistical analysis accounting for spatial clustering. Finally, antibiotic treatment for ASB was 
not randomized which may lead to selection biases (i.e. physicians may have chosen to 
treat the patients who they thought were at higher risk). However, a propensity analysis was 
performed and comparing treated and untreated ASB populations showed no significant 
differences apart from a higher proportion of females in the treated group. Since female 
gender was not an independent risk factor for PJI, it seems not to be clinically relevant. 
Prophylaxis, Diagnosis and Treatment of Prosthetic Joint Infections  Asymptomatic Bacteriuria & Arthroplasty
119
Possible negative consequences of preoperative antibiotic treatment of ASB (e.g. C. difficile 
infection) were not registered. In contrast, the analysis of the influence of treatment helped us 
to better understand the role of ASB.
In conclusion, ASB is a common finding among total joint arthroplasty candidates and it emerges
as an independent risk factor for PJI. Our results support that there is no direct seeding of 
urine microorganisms on to surgical site but rather, that ASB is a surrogate marker for some 
kind of condition that increases risk of bacterial colonization/infection especially due to GN 
microorganisms. Preoperative antibiotic treatment did not show benefit and so, postponing 
surgery or even treating known asymptomatic bacteriuria patients before surgery cannot be 
recommended. 
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Abstract 
In order to study the prevalence of S. aureus carriage and the impact of preoperatively treating
carriers in prosthetic joint infection (PJI), a prospective randomized trial was organized. 
From January 2010 to December 2012, 1028 out of 1305 total joint arthroplasties performed 
were screened and selected carriers underwent preoperative decolonization. We observed a 
22.2%(228/1028) S. aureus colonization rate and only 0.8% MRSA. PJI rate was higher, albeit 
not significantly, in S. aureus carriers than among non carriers - 3.9%(9/228) vs. 2.0%(16/800). 
Treated and untreated carriers showed no significant differences - 3.4%(3/89) vs. 4.3%(6/139). 
Most of the 14 S. aureus PJI occurred in non carriers suggesting a lack of causal relation 
between nasal and PJI S. aureus. No clear benefit in screening/decolonizing carriers before 
total joint arthroplasty could be demonstrated. 
Keywords
Carrier State; Prospective Studies; Prosthesis-Related Infections; Risk Factors; Staphylococcus
aureus; Surgical Site Infection 
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Introduction
Periprosthetic joint infection (PJI) is one of the most challenging and frequent complications 
after total joint arthroplasty [1;2]. As the demand for total hip and knee joint arthroplasty is 
expected to increase substantially over the coming decades, so too will the economic burden 
of infection [3;4]. Despite all the recent focus, the incidence of this complication seems to 
be on the rise worldwide [5;6]. Prevention is therefore paramount and identifying potentially 
modifiable preoperative risk factors is of great interest.
Staphylococcus aureus, especially MRSA, is unanimously considered to be a major pathogen
implicated in surgical site infection (SSI) and PJI specifically [7;8].  About 20-30% of the 
general orthopedic population is S. aureus carrier and the anterior nasal cavity is the main 
site of colonization [9;10]. Nasal carriage has long been considered an established risk factor 
for infection in many situations, such as dialysis, intravascular device bearers and even those 
undergoing surgery [11]. It has even been reported that S. aureus isolated in deep infections 
match those from the nares in over 80% of cases [12].
This link has driven the interest on treating S. aureus nasal carriage status preoperatively to 
potentially reduce infection rates in many fields of surgery including orthopedics. The goals of 
the present study are: 1) to describe the prevalence of both methicillin sensitive and resistant 
S. aureus carriage among elective total hip and knee arthroplasty candidates; 2) to evaluate
the real impact of preoperatively treating carriers by decolonization of the nares and skin 
bathing in the prevention of PJI.
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Material and Methods
Study Design and Patient Population
This is a prospective randomized controlled clinical study that received institutional review 
board approval. All patients undergoing elective primary total hip (THA) or knee arthroplasty
(TKA) at a single institution between January 2010 and December 2012 were eligible for 
enrollment regardless of preoperative diagnosis. Screening of Staphylococcus aureus carriers 
was made available to surgeons as a part of preoperative patient preparation but it was not 
mandatory. Our orthopedic department includes 25 surgeons and ten of them perform total 
joint arthroplasty surgery regularly. Surgeons were informed of the potential benefits of the 
intervention and asked to cooperate by informing their patients and timely ask for screening 
before surgery. Patients were enrolled after they gave informed consent.
Three major patient groups were formed: non-carriers, treated carriers and untreated carriers. 
Information about S. aureus nasal carriage status as well as other relevant variables such 
as demographics, body mass index (BMI), diabetes mellitus, inflammatory arthritis, American 
Society of Anesthesiologists (ASA) physical status classification system and duration of 
surgery were collected prospectively.
Study Intervention: Screening/Decolonization Protocol
S. aureus nasal carriage screening was performed in the outpatient setting two to four weeks 
before surgery. Samples were taken by a dedicated nursing team by swabbing the inside 
circumference of both nares with the same swab. Each swab was cultured aerobically on the 
selective and differential mannitol salt agar medium, which was incubated for 48 hours at 37ºC. 
If suspected colonies grew at 18-24 hours, a Pastorex® Staph Plus latex agglutination test 
(Bio-Rad, Marnes-la-Coquette, France) was performed for the simultaneous detection of pro-
tein A, clumping factor and capsular polysaccharides of S. aureus. Biochemical identification
was performed on Vitek MS® (BioMérieux, Durham, NC, U.S.A.) and detection of methicillin 
resistance was performed according to the European Committee on Antimicrobial Susceptibility
Testing guidelines by use of a cefoxitin screen test.
Patients with nasal cultures positive for S. aureus that were allocated for preoperative 
treatment were reconvened at least one week before surgery, and educated about the rationale 
for the decolonization protocol, which was performed in the outpatient setting. Patients were 
instructed to apply a 2% mupirocin nasal ointment (Bactroban®; GlaxoSmithKline, Middlesex, 
United Kingdom) twice daily to both nares and to bathe with chlorhexidine soap (Cyteal®; 
Pierre Fabre, Gien, France) daily for five days immediately before the scheduled surgery. No 
information regarding patient compliancy was gathered.
All patients received prophylactic perioperative antibiotics. The standard regimen was cefazolin 
2g administered 30 to 60 minutes before surgery followed by 1g every 8 hours for 24 hours and 
all patients got it. Identified MRSA carriers in the intervention group or patients with a history of 
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MRSA infection (regardless of S. aureus carrier state) were concomitantly given vancomycin 1g, 
60 minutes before surgery followed by 1 g every 12 hours for 24 hours. As such, dual antibiotic
coverage occurred in all three groups: non-carriers, treated carriers or untreated carriers.
Follow-up, Outcomes and Definitions
All patients were followed regularly in the outpatient clinic. No patients were lost to follow-up 
at a minimum of one year after surgery. Duration of surgery was categorized as under or 
over the 75th percentile in order to account for different average surgical times between THA 
and TKA[13]. The main outcome of the study was the diagnosis of prosthetic joint infection 
occurring in the first year after surgery accordingly to the CDC definition of implant related 
surgical site infection[14]. 
Definitive diagnosis of prosthetic joint infection (PJI) was made when at least two intraoperative 
microbiological samples grew the same organism or only one positive sample in the presence 
of a sinus tract, elevated serum erythrocyte sedimentation rate(ESR)/C-reactive protein(CRP) 
or elevated synovial leukocyte count or neutrophil percentage in accordance with a recently 
proposed definition [15]. No cases of culture-negative PJI were found. The primary outcome 
measure was defined as the overall rate of surgical site infection including all pathogens and a 
secondary outcome was defined as infections involving S. aureus bacteria only.
Randomization Process
Each S. aureus carrier was given a consecutive identification number as it was identified in the 
microbiology laboratory. They were subsequently assigned to the intervention or control group 
according to an assignment sequence prepared in advance by the first author on an online 
randomization tool. Allocation ratio between the two groups was 1:1. 
Statistical Analysis
Categorical variables are described as number of patients and percentages, and compared 
using Chi-square test and Fischer’s exact test when necessary. Continuous variables are 
described as mean and range and compared using the non-parametric Mann-Whitney test as 
the study population did not meet the normality assumption. A significance level of p<0.05 was 
used for all statistical analyses. 
No intent-to-treat analysis was performed. To test the association between study variables and 
outcome (PJI) a multivariable logistic regression model was developed including variables with 
a P value ≤0.20 from the univariable analysis. The role of the variables as potential modifier effect
was also studied. The assessment of the model fit was done with the Hosmer-Lemeshow
test. Results are reported as odds ratio (OR) with 95 % confidence intervals (95% CI). 
Statistical analyses were done using the software SPSS (version 19.0; SPSS, Inc., Chicago, 
IL, U.S.A.).
Because of the low prevalence of PJI, any study designed to prove a significant decrease in 
infection rate must necessarily include a massive number of patients. In order to demonstrate 
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a significant decrease from 4 to 2% (e.g. untreated vs. treated) one would need to include 
over 1,100 patients in each group. Knowing this study would not be able to reach the figures 
necessary to be adequately powered, the authors were hoping to determine trends between 
groups. With the actual number of patients included, the power of this study to detect a 
difference between treated and untreated groups is around 40% (i.e. clearly underpowered).
Source of Funding
There was no external funding source for this study.
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Results
During the study period, 1305 primary total joint (hip and knee) arthroplasties were performed in 
our institution. Of those, 1028 patients were included in the study after informed consent, yielding
a 79% successful screening rate. Figure 1 shows a participant’s flow diagram throughout
the study. 
Of the 228 identified carriers, 113 were randomly assigned to the intervention/decolonization 
group. Unfortunately, 24 patients did not receive the intended treatment. Most cases failed to 
receive treatment because it was not possible to timely reconvene the patients after culture 
results became available. This happened in cases where nasal carriage screening was not 
performed at least two weeks before surgery. One patient withdrew its willingness to cooperate. 
All patients were available for outcome analysis as no patients were lost to follow-up in the first 
year. Outcome analysis was performed considering the 89 patients that received preoperative 
treatment in one group and the 139 S. aureus carriers that were not treated in a second group.
We observed a 22.2% (228/1028) S. aureus colonization rate. There were eight patients 
colonized with MRSA (0.8%). Comparing carrier and non-carriers it is possible to ascertain that 
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Total Hip/Knee Replacement 
Candidates (n=1305)
Excluded (n=277)
· Surgeon choice not to screen (n=185)
· Patient declined to participate (n=92)
Patients screened dor nasal 
S. aureus (n=1028)
Non carriers (n=800) S. aureus carriers randomized
for treatment (n=228)
Allocated to Intervention Group (n=113)
· Received preoperative intervention (n=89)
· Did not receive allocated intervention (n=24)
· Insufficient time before surgery or cultura 
results available after surgery (n=23)
· Withdrew willingness to participate (n=1)
Allocated to No intervention Group 
(n=115)
No patients lost to follow-up after 1 year No patients lost to follow-up after 1 year
89 treated S. aureus carriers were
included in the analysis
139 untreated S. aureus carriers
were included in the analysis
►
►
► ►
►►
► ►
►
Fig 1a  Participants flow chart.
128
the former are slightly younger and have a significant increased prevalence of inflammatory 
arthritis and hospital admission within the year before arthroplasty surgery (Table I).
Table I.B Main characteristics of the population according to S. aureus colonization status.
S. aureus carrier Non-carrier P value OR 95% CI
n=228 n=800
Mean age (range) 64.5 (23-91) 67.1 (21-92) 0.055 - -
Female gender 150 (65.8%) 564 (70.5%) 0.173 0.8 (0.58-1.12)
Knee Location 120 (52.6%) 497 (62.1%) 0.01 0.68 (0.50-0.92)
Duration	>75th percentile 62 (27.2%) 209 (26.1%) 0.747 1.06 (0.74-1.49)
Co-morbidities
Obesity (BMI≥30) 76 (33.3%) 287 (35.9%) 0.479 0.89 (0.65-1.23)
Diabetes 50 (21.9%) 164 (20.5%) 0.639 1.09 (0.75-1.57)
Inflammatory Arthritis 15 (6.6%) 20 (2.5%) 0.003 2.75 (1.28-5.74)
ASA	≥	3 65 (28.5%) 206 (25.8%) 0.404 1.15 (0.81-1.61)
Hospital Stay < 1 year 53 (23.2%) 127 (15.9%) 0.007 1.65 (1.12-2.42)
BMI Body Mass Index, ASA American Society of Anesthesiologists.
Table II summarizes the main demographic and clinical characteristics as well as infection 
rates of the cohort. There are significant differences between THA and TKA candidates. Knee 
patients are older, predominantly females and more obese. S. aureus colonization rate is 
nevertheless significantly less prevalent among TKA patients.
Twenty-five cases with prosthetic joint infections were identified with an overall infection rate 
of 2.4%. Table III shows us that there were 14 cases involving S. aureus which results in a 
1.4% S. aureus PJI rate. Although PJI among S. aureus carriers considered together is higher 
than among non carriers - 3.9% (9/228) vs. 2.0% (16/800) - the difference was not statistically 
significant. If we compare the rate of PJI between untreated carriers only and non carriers - 
4.3% (6/139) vs. 2.0% (16/800) - the difference was also not statistically significant. Comparing
treated and untreated carriers, PJI rate also did not reveal significant differences either for 
overall or S. aureus infection rate (Table IV) (power of the study to detect a Type-II error is 
40%). There was no case of PJI among MRSA carriers.
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Table II.B Main demographic and clinical characteristics of the study population.
Overall THA TKA P value
n=1028 n=411 n=617
S. aureus colonization 228 (22.2%) 108 (26.3%) 120 (19.4%) 0.010
Overall PJI rate 25 (2.4%) 8 (1.9%) 17 (2.8%) 0.410
S. aureus PJI 14 (1.4%) 4 (1.0%) 10 (1.6%) 0.380
Mean age (years) 66.5 (21-92) 64.4 (21-91) 67.9 (28-92) 0.001
Female gender 714 (69.5%) 220 (53.5%) 494 (80.0%) <0.001
Duration of surgery (minutes) 108.8 (43-280) 115.6 (43-280) 104.3 (45-235) <0.001
Co-morbidities
Obesity (BMI≥30) 363 (35.3%) 105 (25.5%) 258 (41.8%) <0.001
Diabetes 214 (20.8%) 74 (18.0%) 140 (22.7%) 0.070
Inflammatory Arthritis 35 (3.4%) 13 (3.2%) 22 (3.6%) 0.727
ASA	≥	3 271 (26.4%) 109 (26.5%) 162 (26.2%) 0.925
PJI Prosthetic Joint Infection, BMI Body Mass Index, ASA American Society of Anesthesiologists.
                 Table III.B Microorganisms isolated in 25 PJI cases.
Isolated microorganisms Overall (n=34)
Gram positives 23 (67.6%)
Staphylococcus aureus 14 (41.2%)
MRSA 6 (17.6%)
MSSA 8 (23.5%)
CoN Staphylococci 6 (17.6%)
MR CoNS 5 (14.7%)
MS CoNS 1 (2.9%)
Other Gram Positive 3 (8.8%)
Enterococcus spp. 1 (2.9%)
Streptococcus spp. 1 (2.9%)
Corynebacterium spp. 1 (2.9%)
Gram negative 11 (32.4%)
Enterobacteriaceae 6 (17.6%)
Enterobacter spp. 2 (5.9%)
Escherichia coli 1 (2.9%)
Serratia spp. 1 (2.9%)
Proteus spp. 1 (2.9%)
Providencia spp. 1 (2.9%)
Pseudomonas spp. 3 (8.8%)
Acinetobacter spp. 2 (5.9%)
Polymicrobial* 5 (20.0%)
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Table IV.B PJI rate comparison between different subgroups.
Non carriers TreatedS. aureus carriers
Untreated
S. aureus carriers P value
n=800 n=89 n=139
Overall PJI rate 16 (2.0%) 3 (3.4%) 6 (4.3%) 0.219
S. aureus PJI 9 (1.1%) 2 (2.2%) 3 (2.2%) 0.470
PJI Prosthetic Joint Infection.
Variables associated with PJI in the univariable analysis were ASA score ≥ 3, longer duration of 
surgery and the presence of inflammatory arthritis (Table V). Multivariable analysis, performed 
including variables with a P value ≤0.2, substantiates ASA≥ 3 (OR=3.42,95% CI=1.51-7.74) 
and duration of surgery above the 75th percentile (OR=2.74,95% CI=1.22-6.16) as independent
predictors of PJI. A non significant trend towards higher prevalence of S. aureus carriers among 
infected cases was observed. A similar analysis was performed considering the secondary 
outcome (infections involving S. aureus bacteria) and no relevant differences were found 
compared to the primary outcome measure. 
Out of the 14 cases where S. aureus was present in PJI, only five were S. aureus carriers pre-
operatively.  Of those five cases, one untreated MSSA carrier ultimately got an MRSA infection. 
Table V.B Risk factors for overall prosthetic joint infection.
No PJI Overall PJI Univariable analysis Multivariable analysis
P value OR 95% CI P value OR 95% CI
Mean age (range) 66.4 (21-92) 70.0 (56-85) 0.22 - - - - -
Female gender 699 (69.7%) 15 (60.0%) 0.30 0.65 (0.27-1.64) - - -
Knee Location 600 (59.8%) 17 (68.0%) 0.41 1.43 (0.58-3.86) - - -
Duration	>75th percentile 259 (25.8%) 12 (48.0%) 0.01 2.65 (1.09-6.38) 0.02 2.71 (1.20-6.10)
Co-morbidities
Obesity (BMI≥30) 351 (35.0%) 12 (48.0%) 0.18 1.71 (0.71-4.12) 0.48 1.35 (0.59-3.12)
Diabetes 206 (20.5%) 8 (32.0%) 0.16 1.82 (0.67-4.53) 0.39 1.50 (0.60-3.73)
Inflammatory Arthritis 32 (3.2%) 3 (12.0%) 0.02 4.14 (0.75-14.84) 0.08 3.25 (0.87-2.14)
ASA	≥	3 257 (25.6%) 14 (56.0%) <0.01 3.69 (1.53-9.10) 0.01 3.04 (1.32-7.05)
Hospital Stay < 1 year 219 (21.8%) 9 (36.0%) 0.092 2.01 (0.77-4.91) 0.14 1.90 (0.81-4.44)
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Discussion
Prosthetic joint infection is a serious complication. Fortunately, under contemporary surgery 
aseptic conditions and the use of antibiotic prophylaxis, infection rates have lowered to residual
values. Nevertheless, there seems to be a worldwide trend to an increase in the incidence of 
this complication. Together with the ever-rising number of arthroplasties performed every year, 
it contributes to the increasing social and economic burden of infection [5;6]. 
Staphylococcus aureus is a major pathogen in this setting and it has been extensively shown 
that patients who carry it in their nasal flora are at increased risk for infection in a multitude of 
clinical scenarios [11]. In a cardiothoracic surgery study, it has been shown that SSI isolates
match those found in the patient’s nose in a significant proportion of cases suggesting the 
presence of an endogenous contamination pathway [12]. The association between nasal S. 
aureus carriage and increased risk of SSI has been extensively shown also in orthopedic 
surgery [10;16-19]. 
Our cohort’s prevalence of S. aureus carriers is comparable to previous descriptions in 
orthopedic populations that range from 20-30% MSSA and 2-4% MRSA carriers [17;18;20-22].
Interestingly, although we are in a setting where MRSA infections are common [7;23], the 
prevalence of MRSA carrier status was under 1%. It is possible that using more sensitive 
methods to detect carriers (e.g. polymerase chain reaction) would add to this prevalence but 
high level carriers are the ones at increased risk for infection and these patients are detected 
by standard microbiologic culture methods [18].
This highly prevalent and apparently modifiable risk factor has driven the interest on preopera-
tive S. aureus carriers screening and treatment protocols to potentially reduce infection rates. 
Mupirocin is the most frequently studied drug for the eradication of nasal S. aureus carriage 
and its eradication effectiveness over the short term has been convincingly demonstrated [24]. 
Notwithstanding, Kalmeijer et al. [25] in a double-blind, randomized, placebo-controlled study 
focusing on the effect of mupirocin nasal ointment in surgical site infections in orthopedic 
surgery found that it did not result in a significant difference in overall infection rate.  Also in the 
secondary outcomes (rate of SSI due to S. aureus and rate of endogenous S. aureus infection) 
no significant differences were found. 
A possible explanation for this, is that extranasal colonization must also be addressed to avoid 
failure in the prevention of SSI and the addition of whole-body chlorhexidine bathing seems 
to be important in this regard [26;27]. There seems to be enough scientific evidence that a 
combined nasal mupirocin/chlorhexidine bathing approach, similar to what was used in our 
study, leads to a significant reduction in overall SSI. In a paramount study by Bode et al. [28], 
S. aureus deep SSI was significantly lower in the treatment (0.9% - 4/504) than in the placebo 
group (4.4% - 16/413). 
Data on orthopedics and arthroplasty surgery specifically is not so convincing. Further analysis 
of Bode’s paper shows only 172 out of 808 surgical patients were orthopedics (no information
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regarding how many of those were total joint replacements is available). In this specific 
subgroup of patients there was no significant difference regarding S. aureus infections 
between treated and untreated carriers. Focusing exclusively on orthopedic trials using the 
same approach described in the present study (5 days immediately prior to surgery nasal 
mupirocin/chlorhexidine bathing) two major papers can be found. In 2010, Kim and co-workers 
[20]  enrolled over 7,000 patients before elective surgery. MSSA carriers were 22.6% of the 
cohort and 4.4% were MRSA carriers. Non carriers showed the lowest infection rate (0.14%) 
and MRSA carriers showed a significantly higher infection rate (0.97%). MSSA carriers showed 
a not significant difference (0.19%) compared to non carriers. Comparing the overall infection 
rate during the study period to an historic control group of over 5,000 patients, the authors 
found a significant improvement (0.19% vs. 0.45% respectively) thus favoring preoperative
S. aureus carrier’s treatment. Eligible procedures were arthroplasty but also spine and sports 
medicine and unfortunately no information regarding specifically total joint replacement 
patients either on the study population or the historical control group was given. 
A year later, Rao et al. [22] reported their results of a prospective cohort study of 3,724 total 
joint arthroplasty patients. A total of 1,285 out of 1,440 patients operated by three participating 
surgeons were screened. There were 22% MSSA and 3% MRSA carriers. All positive nasal 
cultures received preoperative treatment and infection rate was 0.0% (0/321). Enrolled patients 
were compared to a concurrent control group of 2,284 patients operated by non participating 
surgeons where 19 infections were present. The authors assumed a similar proportion of 25% 
S. aureus carriage among the later group and calculate 571 patients would be culture positive. 
They found that if all 19 infections had occurred in the nasal carriers, the infection rate would have 
been 3.3% (19/571) (RR=1.03, 95%CI [1.02-1.05]) thus advocating the value of preoperative
treatment. This methodology is debatable as it assumes non carriers in this concurrent control 
group would account for no infections. A secondary analysis found the overall infection rate 
in all patients decreased from 20 (2.7%) in 741 historic control patients to 17 (1.2%) in 1440 
patients enrolled in the intervention period (OR=2.32, 95%CI [1.21-4.46]). As such, both 
previous studies major conclusions are drawn by comparing to their respective historical 
controls which may lead to false conclusions as many other variables may be in play.
The major limitation of our study is that it should be considered underpowered to show a possible
small advantage in preoperatively decolonizing S. aureus carriers. The fact that S. aureus 
eradication was not confirmed before surgery may also be considered a relevant limitation. 
No information regarding patient compliance was objectively gathered and local mupirocin 
resistance data is not available. However, the proposed treatment has been previously shown 
to be effective [18;24;29]. Another important issue is that practical flaws led to uneven groups 
of treated and untreated carriers. The author’s choice not to perform an intent-to-treat but 
rather an actual treated vs. untreated analysis is also debatable from a methodological point of 
view. Also not having the clonal relationship between nasal and infecting strain is a limitation. 
This limits our ability to make a detailed analysis on the origin (endogenous or exogenous) of 
every S. aureus PJI.
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All things considered, although there seems to be enough evidence that nasal carriage of S. 
aureus at the time of surgery is a risk factor for SSI also in orthopedic surgery, there is no definitive
evidence regarding total joint replacement specifically [30;31]. A major multicenter paper 
focusing mainly on arthroplasties and including almost 4,000 patients found that in most 
cases of S. aureus SSI, either an endogenous origin could not be demonstrated or preoperative
nasal colonization retrieved a strain that was different from the infecting pathogen [16]. This 
lack of causal relation between nasal S. aureus and PJI pathogen is similar to our finding 
that at least 10 out of 14 cases of S. aureus PJI may have had an exogenous source. On the 
other hand a recent multicenter study performed in American hospitals  involving over 30,000 
hip or knee arthroplasties found a modest, but statistically significant decrease in S. aureus 
infections among hip or knee arthroplasties after an intervention very similar to ours (difference
per 10,000 operations, -17 [95% CI, -39 to 0]; RR, 0.48 [95% CI, 0.29 to 0.80])[32]. 
Nevertheless, patients during the intervention period were younger, had lower Charlson 
comorbidity index scores, and were less likely to have a history of MRSA carriage (all of which 
known risk factors for infection) than those during the pre-intervention period. Furthermore, 
and perhaps the major limitation of this finding is that patients were followed up for no more 
than 90 days after their operations which is admittedly a short period for PJI. 
As such, the authors believe that currently available evidence is not enough to definitively
recommend S. aureus screening and decolonization as an effective strategy to prevent 
infection in total joint arthroplasty. A necessarily huge trial addressing the real worth of S. 
aureus screening and decolonization as well as it cost-effectiveness in the particular field of 
total joint arthroplasty is still missing. Assuming S. aureus carriage and PJI rates similar to the 
present study, over 10,000 patients would have to be screened and followed for up to one year.
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Abstract
Objective(s): Autologous labeled leukocytes combined with sulfur colloid bone marrow scan 
is the current nuclear medicine gold standard for the diagnosis of prosthetic joint infection. The 
goal of this study is to assess the diagnostic accuracy of a new nuclear medicine modality for 
detecting infection in this context.
Methods: Twenty-seven suspicious hip and knee arthroplasties were enrolled prospectively
and underwent nuclear medicine testing using 99mTc-Sulesomab and 99mTc-nanocolloids 
sequentially. These results were then crossed with final diagnosis to determine the test(s) 
diagnostic accuracy. 
Results: Isolated 99mTc-Sulesomab scan shows 100% sensitivity (0.40-1) and negative 
predictive value (0.31-1) but only 20% specificity (0.05-0.48). Combining it with 99mTc-nanocol-
loids bone marrow scan increases specificity (0.75-1) and positive predictive value (0.40-1) to 
100%. Furthermore, the combined test has less equivocal readings and higher inter-reader 
agreement: kappa test value 0.59 vs. 0.44. 
Conclusions: The results support the hypothesis that these technically simpler and ready-to-use 
products may be an alternative to autologous labeled leukocytes/sulfur colloid marrow scan.    
Keywords
Prosthetic Joint Infection; Diagnosis; Labeled leucocytes; Bone marrow imaging.
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Introduction
Periprosthetic infection is probably the most devastating complication of total joint arthroplasty.
Despite recent advances in prophylaxis its prevalence is on the rise [1]. Treatment of an 
infected implant is quite different from treatment of an aseptic loosening and it is thus crucial 
to differentiate between them. 
The diagnosis of prosthetic joint infection poses numerous challenges particularly when it 
presents as a low-grade chronic affliction with no signs and symptoms other than unexplained 
pain or stiffness [2]. There is no diagnostic test that is 100% accurate in this setting. Currently, 
isolation of organisms and histological analysis from intraoperative samples seem to be the 
best way to definitively confirm the diagnosis of infection [3]. However, preoperative diagnosis
is forced to rely on clinical suspicion as well as careful scrutiny of laboratory and imaging 
modalities. 
Combined indium [111In]-labeled autologous leukocyte and complementary technetium [99mTc]- 
sulfur colloid bone marrow imaging, with an accuracy of 95% or greater, is the current imaging
modality of choice for diagnosing prosthetic joint infection[4].  Although this technique is 
reliable, in vitro leukocyte labeling raises technical difficulties that limit its widespread use[5] 
and sulfur colloid is increasingly difficult to obtain. Therefore, valid alternatives are needed. 
The study hypothesis is that autologous leukocyte labeling and sulfur colloid can successfully
be replaced for 99mTc-Sulesomab (antigranulocyte antibody) and 99mTc-colloidal rhenium 
sulphide (nanocolloids) respectively. 
The aim of the present study is to assess the diagnostic accuracy of 99mTc-Sulesomab alone 
and in combination with 99mTc-nanocolloids bone marrow imaging in the diagnosis of infection 
in painful total joint arthroplasties. A secondary goal was to estimate inter-reader concordance 
of both interpretations.
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Patients and Methods
Participants
This study prospectively included patients with total hip or knee arthroplasty suspected of 
having deep infection. Patients were elected for nuclear medicine testing for having joint pain 
or unexplained stiffness and abnormal erythrocyte sedimentation rate (ESR) >22.5mm/h 
or C-reactive protein (CRP) >13.5mg/L[6]. Final decision of whether or not to proceed with 
revision surgery was based on clinical, laboratory as well as nuclear medicine results. Data 
collection was planned in advance and started at the time of nuclear medicine testing forward. 
In the absence of a true gold standard for the definitive diagnosis of prosthetic joint infection
the following criteria were used: at least two intraoperative positive cultures for the same 
organism(s) or positive intraoperative histological findings (i.e. at least five neutrophils in each 
of three 400x high-power microscopic fields[3]) even in the absence of culture growth. Negative
intraoperative findings or instead favorable clinical and laboratory follow-up of at least one year 
in non-operated patients was used as criteria for absence of infection.  
Imaging Protocol
Nuclear medicine study protocol starts with a 20 mCi 99mTc-Sulesomab (LeukoScan®, 
Immunomedics Inc., USA) intravenous injection. Images are acquired at two and four hours 
timeline.   If this scan is negative no further test is performed (figure 1). If this scan shows any 
periprosthetic activity, the bone marrow scan is performed after intravenous injection of 20 
mCi of colloidal rhenium sulphide (Nanocis®, Electra-Box Pharma, Finland), with a minimum 
72 hours interval to avoid confounding persistent 99mTc-Sulesomab activity. These images are 
acquired for five minutes at 30, 60 and 120 minutes timeline. Both scans are acquired in a 
double detector gamma-chamber equipped with high resolution collimators in a 256x256 matrix. 
Image Interpretation
The rationale behind combined leukocyte/bone marrow scan is the fact that both leukocyte and 
nanocolloids accumulate in marrow regardless of its location, whereas leukocyte accumulate 
in infection but nanocolloids does not. The study is positive for infection when there is activity
on the sulesomab scan without corresponding activity on the bone marrow scan (i.e. the 
images are spatially incongruent) as shown in figure 2. Any other pattern is negative for
infection (figures 1 and 3).
Test reading was done by the nuclear medicine doctor (IA) and the orthopedic surgeon 
(RS) together using the four and two hour images of the sulesomab and nanocolloids scan 
respectively. The interpretation was done accessing clinical and laboratory information but 
(naturally) there was no previous knowledge of definitive diagnosis criteria. In order to appreciate
inter-observer concordance three different observers (RS, IA and FF) were retrospectively 
asked to blindly review each scan and classify them as positive, negative or equivocal.
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Statistical Analysis
Sensitivity and specificity as well as negative and positive predictive value of both tests 
were determined using the prospective nuclear medicine and orthopedic surgeon collective 
interpretations made during the study period. Blinded retrospective interpretations were used 
to estimate isolated Sulesomab and Sulesomab/Nanocolloids scans inter-reader agreement 
by applying the kappa test[7].
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Fig. 1b Right total hip replacement with obvious osteolysis around the 
stem and negative sulesomab scan excluding 
Fig. 2b Left total knee replacement showing increased uptake in the 
sulesomab scan in two different anatomic areas with no correspon-
dence in the bone marrow scan in the lateral tibial area (red arrows) 
indicative of infection.
Fig. 3b Right total knee replacement showing increased uptake in the 
sulesomab scan with a congruent pattern in the bone marrow scan 
(green arrows) pointing to aseptic loosening
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Results
Twenty-seven patients were recruited between February/2008 and February/2010. There were 
25 total knee and two total hip replacements. Three of them were men and 24 women with 
an average age of 65 years old. Mean time from index surgery was 29.7 months. Laboratory 
results revealed an average ESR of 29.1 [4-81] and CRP of 18.51 [1.7-48.6]. Nineteen patients 
(2 hips and 17 knees) were included in the diagnostic accuracy analysis. 
Methicillin-resistant S. epidermidis in two cases, methicillin-resistant and methicillin-sensitive 
S. aureus in one case each were the bacteria isolated in the four positive cases that underwent 
surgery. The negative cases were classified as aseptic loosening since no microorganism was 
isolated and histological findings were negative. One positive and seven negative results were 
excluded for not meeting the criteria for definitive diagnosis (figure 4). The positive case had 
severe medical conditions that ill-advise revision surgery.  Out of the five negative sulesomab 
scan cases, only two underwent revision surgery. Two of the other three were excluded for 
not meeting the clinical and laboratory follow-up criteria for negativity.  The same was true for 
five of the six negative combined sulesomab/bone marrow scan that did not undergo surgery. 
The patients not operated on constitute a heterogeneous group of patients whose symptoms 
improved or were not serious enough to require revision surgery once infection was ruled out. 
As such no final diagnosis can be reached.
Table I shows a cross-tabulation of the reference diagnosis criteria with the isolated 99mTc-Sule-
somab scan and combined 99mTc-Sulesomab/99mTc-nanocolloids bone marrow scan results. 
Isolated 99mTc-Sulesomab scan sensitivity was 100% as was the negative predictive value. 
Combined 99mTc-Sulesomab/99mTc-nanocolloids bone marrow scan showed 100% specificity 
and positive predictive value. Table II displays diagnostic accuracy of both tests.
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27 Suspicious 
TJR
22 positive
Sulesomab scan
5 negative
Sulesomab scan
5 positive 
Sulesomab/
Nanocolloids scan
4 patients 
revision surgery
1 patient no
surgery (included)
4 positive cultures 
and/or histology 
results
11 negative cultures
and histology results
6 patients 
no surgery
1 favorable 
follow-up
> 1 year
5 patients 
not meeting criteria
 (excluded)
17 negative 
Sulesomab/
Nanocolloids scan
11 patients 
revision surgery
2 negative cultures
and histology results
3 patients 
no surgery
1 favorable 
follow-up
> 1 year
2 patients 
not meeting criteria
 (excluded)
2 patients 
revision surgery
Fig. 4b Flow diagram of every suspicious total joint replacements entered in the study and final outcome or reasons for exclusion.
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Table I.A Scan results crossed with definitive diagnosis of both tests.
Infection
Present Absent Total
Isolated Sulesomab
Positive 4 12 16
Negative 0 3 3
Total 4 15 19
Present Absent Total
Sulesomab/Nanocolloids
Positive 4 0 4
Negative 0 15 15
Total 4 15 19
Table II.A Diagnostic accuracy results (95% confidence interval) of both tests.
Sensitivity Specificity NPP PPP
Isolated Sulesomab 100% (0.40-1) 20% (0.05-0.48) 100% (0.31-1) 25% (0.08-0.53)
Sulesomab/Nanocolloids 100% (0.40-1) 100% (0.75-1) 100% (0.75-1) 100% (0.40-1)
NPP negative predictive value; PPP positive predictive value.
The inter-reader agreement as estimated by the kappa test can be seen in table III. In the 
isolated sulesomab scan it averaged 0.44 for the three pairs of readers and in the combined 
sulesomab/marrow scan it averaged 0.59. 
Table III.A A Kappa test results (95% confidence interval) for the three pairs of readers.
Pair A-B Pair A-C Pair B-C
Isolated Sulesomab 0.50 (0.12-0.88) 0.52 (0.02-1) 0.31 (0-0.77)
Sulesomab/Nanocolloids 0.55 (0.09-1) 0.72 (0.36-1) 0.50 (0-1)
The number of equivocal readings was lower in the combined test as can be seen in table IV.
Table IV.A Blinded interpretation of isolated and combined scans by the three readers.
Observer A Observer B Observer C
Isolated Sulesomab
Positive 14 11 17
Equivocal 2 6 1
Negative 3 2 1
Sulesomab/Nanocolloids
 Positive 4 2 3
 Equivocal 1 1 1
 Negative 14 16 15
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Discussion
Diagnosing a chronic low grade prosthetic joint infection and differentiating it from aseptic 
loosening is a crucial and often complex job. Currently there is no preoperative diagnostic 
modality that offers perfect sensitivity or specificity and therefore the orthopedic surgeon is 
forced to base his decision on the collective interpretation of different test modalities.  Nuclear 
medicine studies are the imaging modality of choice in this context and combined 111In-labeled 
leukocyte/99mTc-sulfur colloid marrow is the gold standard with a diagnostic accuracy of more 
than 90% for both hip and knee[4, 8-10]. Despite reliable results, autologous leukocyte labeling 
and imaging is a laborious and technically demanding procedure[11]. Its inherent complexity 
limits its widespread use as not all centers have the means to employ it. Sulfur colloid is also 
a increasingly difficult product to obtain in Europe nowadays and therefore there is a need to 
study valid alternatives. 
Sulesomab is an antigranulocyte antibody (Fab fragment of the immunoglobulin G antibody 
against the glycoprotein cross-reactive antigen-90) and as such accumulates not only in sites of 
increased concentration of granulocytes in the inflamed tissue surrounding infected prosthesis
but also in the bone marrow as a result of phagocytosis by the reticuloendothelial cells[12]. 
Nanocolloids are small particles that, after intravenous injection, are phagocytosed by 
macrophages and distributed throughout the body in the reticuloendothelial system thus 
targeting bone marrow[13]. Both products are available as simple ready-to-use kits. The 
present study hypothesis is that they can effectively replace autologous labeled leukocytes 
and sulfur colloid bone marrow scan in the diagnosis of infected total joint replacements.
Antigranulocyte scintigraphy with monoclonal antibodies (especially sulesomab) is increasingly
being used in the diagnostic evaluation of suspected infection of prosthetic joint replacements. 
Sulesomab scan sensitivity and specificity in this context is around 80%[12]. Sensitivity is highly 
related with the criteria used for image interpretation. Interpreting even slight 99mTc-Sulesomab
activity as positive raises the test sensitivity simultaneously lowering its specificity[14]. Other 
authors have shown that it is possible to increase specificity of the isolated sulesomab scan by 
implementing a dual-time acquisition protocol consisting of early four hour and delayed 20-24 
hour imaging[15, 16]. Since this test was used as an initial screening in the present study, the 
authors chose to interpret any periprosthetic activity in the early four-hour scan as positive. This 
fact probably explains the high sensitivity and negative predictive value (and conversely very 
low specificity) found. The explanation for the isolated sulesomab scan lack of specificity lays 
on the fact that these antibodies also target reticuloendothelial cells present in bone marrow.
Hence, its increased uptake around orthopedic implants may be due to the presence of 
localized expansion of hematopoietically active marrow and not translate real periprosthetic 
inflammation/infection[12]. Exactly why hematopoietically active marrow develops around joint 
prostheses is unknown[5]. The goal of adding a bone marrow scan is to compensate for this 
phenomenon. Although nanocolloids have been used isolated for the diagnosis of orthopedic
infections [17], we believe it should be used as an alternative to conventional sulfur colloid 
scintigraphy since they target the same bone marrow compartment [13]. Nanocolloids will 
accumulate in the reticuloendothelial cells present in the normal hematopoietically active marrow
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but not in periprosthetic osteomyelitis. Infection and subsequent bone metabolism changes
destroy bone marrow phagocytes consequently inhibiting nanocolloids uptake [5]. This 
represents the base of the combined scan interpretation criteria. Any activity in the sulesomab
scans without corresponding activity in the marrow scans will constitute a positive test for 
infection. Our results suggest both sulesomab and nanocolloids are valid surrogates for 
autologous labeled leucocytes and sulfur colloid respectively. The combined scan reached a 
very good diagnostic accuracy. 
When assessing the accuracy of a diagnostic test it is important to establish its reliability as it 
respects to agreement between observers. The results demonstrate that combined sulesomab/ 
nanocolloids scan has a lower number of equivocal interpretations than isolated sulesomab 
(respectively 3 and 9 out of independent 57 readings each). The inter-reader agreement is also 
higher (average 0.59 vs. 0.44) when interpreting the combined scan. These findings suggest 
the combined scan is easier to read and more reproducible.
The relatively low number of patients recruited is one of the major limitations of this study as 
it precludes more statistically powerful findings. The fact that these are the first such cases 
performed at our institution also hampers a more concordant test reading as they reflect the 
initial learning curve of the authors. Lastly the criteria we used to define prosthetic joint infection
diagnosis (intraoperative microbiological and histological testing) is widely accepted in the 
orthopedic community but even these tests have been demonstrated to fail in establishing a 
correct diagnosis[3, 18].  Other tests such as preoperative synovial fluid differential cell count 
and culture or sonication of the removed implant can be of assistance but their discussion is 
beyond the scope of this paper[19, 20]. Notwithstanding, this study suggests that combined 
sulesomab/nanocolloids scan can be a very helpful tool in diagnosing prosthetic joint infection 
in selected cases and considering clinical and laboratory data together. An isolated negative
sulesomab scan is helpful in excluding infection. The studied methodology seems a valid 
alternative to labelled leucocytes/sulphur colloid bone marrow imaging although it needs 
validation at a larger scale. The fact that it is technically easier to perform might possibly allow 
a more widespread use.
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Abstract
Aims: The aims of this study were to increase the diagnostic accuracy of the analysis
of synovial fluid in the differentiation of prosthetic joint infection (PJI) by the addition of 
inexpensive biomarkers such as the levels of C-reactive protein (CRP), adenosine deaminase 
(ADA), alpha-2-macrogloblulin (α2M) and procalcitonin.
Patients and Methods: Between January 2013 and December 2015, synovial fluid and 
removed implants were requested from 143 revision total joint arthroplasties. A total of 55 
patients met inclusion criteria of the receipt of sufficient synovial fluid, tissue samples and 
removed implants for analysis.
The diagnosis of PJI followed the definition from a recent International Consensus Meeting 
to create two groups of patients; septic and aseptic. Using receiver operating characteristic 
curves we determined the cutoff values and diagnostic accuracy for each marker.
Results: There were 23 PJIs and 32 patients with aseptic loosening. The levels of total 
leucocyte count, proportion of polymorphonuclear leucocytes (PMNs), CRP, ADA and α2M 
in the synovial fluid were all significantly higher in those with a PJI than in those with aseptic 
loosening. The levels of procalcitonin were comparable in the two groups.
Cutoff values for the optimal performance in the diagnosis of infection were: total leucocyte 
count > 1463 cells/μL (sensitivity (Sens) = 100%, specificity (Spec) = 71.9%, positive predictive 
value (PPV) = 71.9%, negative predictive value (NPV) = 100%); proportion of PMNs > 81% 
(Sens = 78.3%, Spec = 75.0%, PPV = 69.2%, NPV = 82.8%); CRP > 6.7mg/L (Sens = 78.3%, 
Spec = 93.8%, PPV = 90.0%, NPV = 85.7%); ADA > 61U/L (Sens = 78.3%, Spec = 96.9%, PPV 
= 94.7%, NPV = 86.1%) and α2M > 958 mg/L (Sens = 47.8%, Spec = 96.9%, PPV = 91.7%, 
NPV = 72.1%).
The addition of a raised level of CRP or ADA to the total leukocyte count increased the 
specificity: total leukocyte count > 1463cells/μL and CRP > 6.7mg/L (Sens = 78.3%, Spec = 
100%, PPV = 100%, NPV = 86.5%) or with ADA > 61U/L (Sens = 78.3%, Spec = 96.9%, PPV 
= 94.7%, NPV = 86.1%). 
Conclusion: The total leucocyte count in the synovial fluid offers great negative predictive 
value in the diagnosis of PJI and the addition of more specific markers such as CRP and ADA 
improves the positive predictive value. Thus the addition of simple and inexpensive markers 
to the measurement of the leucocyte count in the synovial fluid may reduce the number of 
equivocal results which demand more expensive investigation.
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Introduction
A common and severe complication of total joint arthroplasty is periprosthetic joint infection 
(PJI).1 There is however no single, accurate test which may be used to make this diagnosis. 
A recent International Consensus Meeting agreed on diagnostic criteria, but stated that in 
patients with less virulent organisms, infection could exist even with negative criteria.2 Definitive
diagnosis currently relies on a combination of different markers in the serum and synovial 
fluid and, most of all, adequate intra- operative sampling for microbiological testing.2-5 The
preoperative work-up should include a history and physical examination, then blood tests 
including erythrocyte sedi- mentation rate (ESR) or C-reactive protein (CRP), as a preoperative
diagnosis of PJI can determine the operative plan for the patient.
If there is a high probability of infection, aspiration of the joint is mandatory.2,6 Synovial fluid is 
then available for tests including microbiological study and leucocyte count. Microbiological 
examination is lengthy and offers a signif- icant proportion of false-negatives.7 The leucocyte 
count is also an imperfect marker as several different thresholds have been proposed in the 
literature and the measurement may be influenced by the presence of an inflammatory arthritis 
or the recent use of antibiotics.8-10 These diagnostic limitations have driven the search for the 
more accurate interpretation of synovial fluid and the development of alternative biomarkers, 
some of which are prohibitively expensive.11-13
The hypothesis of this study was that the diagnostic accuracy of pre-operative aspiration of a 
potentially infected joint could be increased with more simple, readily available and inexpensive
synovial fluid biomarkers. We compared the concentrations of CRP, adenosine deaminase 
(ADA), alpha-2-macrogloblulin (α2M) and procalcitonin in the synovial fluid between infected 
and aseptic cases, and analysed the performance and optimal cutoff values of these markers. 
We investigated whether the addition of these tests to the standard synovial fluid leucocyte 
count may improve the pre-operative diagnostic performance for PJI.
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Patients and Methods
The inclusion criteria for this prospective study were potentially all patients undergoing revision 
total hip (THA) or knee (TKA) arthroplasty (either single-stage for presumed aseptic or first-
stage for known infected prosthesis) at our institution between January 2013 and December 
2015. All surgeons who undertake arthroplasties were asked to collect intra-operative synovial 
fluid aspirates and at least four periprosthetic tissue samples from each patient for analysis 
of biomarkers and microbiological testing. Removed implants were sent for sonication and 
subsequent microbi- ological study. If sufficient synovial fluid was available, it was also sent for 
measurement of the standard leucocyte and differential counts. We excluded those cases with 
insufficient synovial fluid or tissue samples, or those whose implants were not sent for sonica-
tion. We also excluded patients who developed a PJI within four weeks of the initial procedure, 
and those with a haematogenous infection within four weeks of the development of symptoms, 
as these were considered to be acute presentations.
We recorded the pre-operative diagnosis (septic or aseptic, hip or knee), gender, age, joint, 
history of comorbid inflammatory conditions, pre-operative antibiotic treat- ment (not including
the prophylactic peri-operative dose) and the microorganisms which were isolated. When 
available, the pre-operative ESR and CRP were also documented.
Patients who met the inclusion criteria were prospectively evaluated, and the definitive 
diagnosis was classified as periprosthetic infection or aseptic loosening on the basis of the 
recent International Consensus Meeting definition of PJI (Table I).2 Post-operatively, tissue 
cultures were incu- bated for up to fourteen days and sonication of removed implants followed 
a standardised, previously validated protocol.3
Table IV.A International Consensus Meeting Definition of Periprosthetic Joint Infection 
1) Two positive periprosthetic cultures with phenotypically identical organisms, or
2) A sinus tract communicating with the joint, or
3) Having three of the following minor criteria:
Elevated serum CRP and ESR
Elevated synovial fluid WBC count OR ++ change on leukocyte esterase test strip
Elevated synovial fluid PMN percentage
A single positive culture
Positive histological analysis of periprosthetic tissue
CRP C-reactive protein, ESR erythrocyte sedimentation rate, WBC white blood cell; PMN polymorphonuclear neutrophil.
Synovial fluid samples were collected intra-operatively. A plain tube was used for biochemical 
studies (CRP, ADA, α2M and procalcitonin) and a tube with tri-potassium salts of ethylene-
diaminetetraacetic acid was used for cytological study. When insufficient synovial fluid was 
available for all tests, the analysis of biochemical biomarkers was favoured.
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Cytological examination of the synovial fluid was performed immediately on reception of the 
fluid in the labora- tory. The total cell count was measured with a haemocytometer (Neubauer
improved, BRAND GMBH + CO KG, Wertheim, Germany) and the differential count with 
a Leishman stained smear obtained by cytocentrifugation (Shandon Cytospin 3, Thermo 
Electron Corp., Waltham, Massachusetts). In order to compensate for pos- sible contamination 
of the synovial fluid with blood, both total white blood cell and polymorphonuclear neutrophil 
(PMN) counts were adjusted for by the amount of blood present in the fluid using a previously 
validated formula: WBCadjusted = WBCobserved − [(WBCblood × RBCfluid/ RBCblood)] predicted
In order to decrease the viscosity of the synovial fluid for biochemical analysis, it was diluted in 
a proportion of 9:1 with a solution of hyaluronidase (0.025 g/L in a phosphate buffer). The final 
results were obtained following multiplication by the dilution factor.
The level of CRP in the synovial fluid was measured using a high sensitivity immunonephelo-
metric assay (hsCRP, Siemens Healthcare Diagnostics, Marburg, Ger- many) on a Dimension
Vista 500 AutoAnalyzer (Siemens Healthcare Diagnostics) that is able to offer a 0.16 mg/L 
detection limit. ADA was measured using an enzymatic col- orimetric assay (ITC Diagnostics,
IZASA, Barcelona, Spain) adapted to the AutoAnalyzer Cobas Integra 800 (Roche 
Diagnostics, Mannheim, Germany). The level of α2M in the synovial fluid was measured using 
an immuno-nephelometric assay (A2MAC, Siemens Healthcare Diagnostics) on a Dimension
Vista 500 AutoAnalyzer (Siemens Healthcare Diagnostics). The level of procalcitonin was 
measured using an electroluminescence immunoassay (Elecsys BRAHMS PCT, Roche 
Diagnostics) on a Cobas e411 AutoAnalyzer (Roche Diagnostics) that is able to offer a 0.02 
ng/mL detection limit.
The study had institutional ethical approval and all patients provided informed consent.
Statistical Analysis
Categorical variables are expressed as counts (percentage) and frequency distributions 
were compared with the chi-squared test. For small cell counts, Fisher’s exact test was used. 
Continuous variables were expressed as mean values (interquartile range). Differences were 
tested with the Mann-Whitney U test for non-normally distributed variables.
Optimal cutoff values were determined using receiver operating characteristic (ROC) curve 
analysis. These curves were generated and the areas under the curve were com- pared to 
determine the most appropriate cutoff. More cut- off values were determined using the 
Youden’s index method,15 which maximises the difference between sensitivity and specificity. 
Specificity and predictive values of the tests were estimated. Using selected cutoff values, 
multiple combinations were created, with the aim of improving the ability to confirm or exclude
the diagnosis of PJI. The statistical tests were two-tailed and we considered p-values of 
< 0.05 as statistically significant. Data were analysed using the software Stata (version 14.0; 
StataCorp, College Station, Texas).
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Results
A total of 143 revision THAs or TKAs were performed dur- ing the study period. We excluded
88 patients in whom syn- ovial fluid was either not collected or was insufficient, or where 
microbiological sampling was insufficient with less than four tissue samples being obtained or 
an implant not being received for sonication. A total of 55 patients met the inclusion criteria; 21 
with a pre-operative assumed diagnosis of PJI and 34 with aseptic loosening.
In two patients with a preoperative diagnosis of aseptic failure, the diagnosis was ultimately 
re-classified as infected, since two or more phenotypically identical organisms were isolated 
from intra-operative samples (one with two positive tissue cultures and one with one positive 
tissue culture and positive sonication). Micro-organisms were isolated in a single sample in 
five other patients but they did not meet other minor criteria for infection. The demographic and 
clinical information of the patients (including unadjusted leukocyte and differential counts) are 
shown in Table II. 
Table II.C Demographic and clinical information according to the presence of infection.
Infection cases Aseptic failures p value
n=23 n=32
Age*  68.0 (61-76) 65.3 (62-71) 0.154
Female gender 14 (61%) 25 (78%) 0.231
Hip:Knee ratio 8:15 7:25 0.201
History	of	inflammatory	conditions	 0 (0%) 3 (9.4%) 0.257
Previous antibiotic therapy 3 (13%) 0 (0%) 0.068
ESR* (mm/h) 60.2 (36-82)† 27.5 (11-25) ‡ 0.0001
CRP* (mg/L) 65.1 (18-98)† 11.8 (2-9) ‡ <0.0001
Total leukocyte count* (cells/μL) 33,790 (14,000-60,000)§ 384 (41-666) ‡ <0.0001
Proportion of PMN* 84% (80-96)§ 30% (11-43) ‡ <0.0001
ESR Erythrocyte sedimentation rate; CRP C-reactive protein; PMN Polymorphonuclear neutrophils.
* expressed as mean (interquartile range); † available in 19 cases; § available in 17 cases; ‡ available in 24 cases 
Synovial fluid final results (including leukocyte and differential counts adjusted for blood in the 
fluid) are expressed in Table III. It is noteworthy that in those with a PJI there was a significant 
increase in the total leucocyte count, the percentage of PMNs and the concentrations of CRP, 
ADA and α2M in the synovial fluid compared with aseptic cases. The levels of procalcitonin 
were comparable in the two groups.
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Table III.C Synovial fluid analysis results according to the presence of infection*.
Infection cases Aseptic revisions p value
n=23 n=32
Adjusted Total leukocyte count (cells/μL) 34,443 (9,532-61,368)§ 347 (37-544)¶ <0.0001
Adjusted proportion of PMN 85% (80-97)§ 28% (10-42) ¶ <0.0001
C-reactive protein (mg/L) 31.7 (7.96 -24.72) 1.02  (0.33- 0.82) <0.0001
Adenosine Deaminase (U/L) 126.1 (67-118) 35.7 (19-42) <0.0001
α-2-Macroglobulin	(mg/L) 895.3 (124-1332) 365.0 (127-505) 0.009
Procalcitonin (ng/mL) 0.050 (0.022 -0.060) 0.034 (0.022 – 0.041) 0.650
*expressed as mean (interquartile range); 1) Mann-Whitney test; § available in 17 cases; ¶ available in 24 cases; PMN polymorphonuclear 
neutrophils.
ROC curves obtained for each parameter are shown in Figure 1. and optimised threshold 
values in Table IV. In some instances, two different cutoff values were found with different 
characteristics but a similar combined diagnostic accuracy. Regarding the proportion of PMN, 
we found the optimal cutoff value to be around 78% to 81%, but it is also noteworthy that the 
65% cutoff for the proportion of PMNs, commonly described in the literature,9 performs almost 
as well as the proposed values.
A search for synergic combined interpretation was made (Table V), considering associations
where either one or other of the markers were positive, to increase the sensitivity, or 
alternatively, where both markers were positive, to increase specificity. A total leucocyte count 
of > 1463 cell/μL had a 100% negative predictive value and no other marker was able to 
increase its sensitivity. A close alternative was the association of a PMN proportion of > 
81% with either CRP > 6.7 mg/L or ADA > 61 U/L, which both also exhibited a high negative 
predictive value. It was possible to increase the positive predictive value of the testing of 
synovial fluid greatly when combining the differential leucocyte count and other parameters by 
choosing more specific cutoff values, especially CRP > 6.7 mg/L and ADA > 61 U/L.
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Fig 1C Graphs showing a)receiver operating characteristic (ROC) curve and area under curve (AUC) for total leucocyte count (area under ROC 
curve = 0.9967); b) ROC curve and AUC for proportion of polymorphonuclear leucocytes (area under ROC curve = 0.9750); c) ROC curve and AUC 
for C-reactive protein (area under ROC curve = 0.9411); d) ROC curve and AUC for adenosine deaminase (area under ROC curve = 0.8563); e) 
ROC curve and AUC for alpha-2-macrogloblunin (area under ROC curve = 0.6948); f) ROC curve and AUC for procalcitonin (area under ROC curve 
= 0.5025).
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Table IV.C Proposed ROC cutoff values with ideal performance for each test.
Proposed
cutoff(s) Sensitivity Specificity
Positive 
Predictive 
Value
Negative 
Predictive 
Value
Adjusted Total leukocyte count (cells/μL)
1,463
2,064
100%
91.3%
71.9%
75%
71.9%
72.4%
100%
85.3%
Adjusted proportion of PMN
78%
81%
87.0%
78.3%
71.9%
75.0%
69.0%
69.2%
88.5%
82.8%
C-reactive protein (mg/L)
1.6
6.7
8.0
91.3%
78.3%
73.9%
87.5%
93.8%
96.9%
84.0%
90.0%
94.4%
93.3%
85.7%
83.8%
Adenosine Deaminase (U/L) 61 78.3% 96.9% 94.7% 86.1%
α-2-Macroglobulin	(mg/L)
810
958
60.9%
47.8%
90.6%
96.9%
82.4%
91.7%
76.3%
72.1%
Table V.C Diagnostic accuracy of selected test(s) values and respective combinations.
Sensitivity
(95%CI)
Specificity
(95%CI)
Positive 
Predictive 
Value 
(95%CI)
Negative 
Predictive 
Value 
(95%CI)
One of the test(s) positive
Leukocyte count > 1,463 or CRP > 6.7 mg/L
100.0% 
(100.0 to 100.0)
65.6% 
(53.1 to 78.2)
67.6% 
(55.3 to 80.0)
100.0% 
(100.0 to 100.0)
Leukocyte count > 1,463 or ADA > 61
100.0%
(100.0 to 100.0)
71.9% 
(60.0 to 83.8)
71.9% 
(60.0 to 83.8)
100.0% 
(100.0 to 100.0)
PMN> 81% or CRP > 6.7 mg/L
95.6%
(90.3 to 100.0)
68.8% 
(56.5 to 81.0)
68.8% 
(56.5 to 81.0)
95.6% 
(90.3 to 100.0)
PMN> 81% or ADA > 61 U/L
91.3%
(83.9 to 98.8)
75.0% 
(63.6 to 86.4)
72.4% 
(60.6 to 84.2)
92.3% 
(85.3 to 99.4)
Both test(s) positive
Leukocyte count > 1,463 and PMN> 81%
78.3% 
(67.4 to 89.2)
75.0% 
(63.6 to 86.4
69.2% 
(57.0 to 81.4)
82.8% 
(72.8 to 92.7)
Leukocyte count > 1,463 and CRP > 6.7 mg/L
78.3% 
(67.4 to 89.2)
100.0% 
(100.0 to 100.0)
100.0% 
(100.0 to 100.0)
86.5% 
(77.4 to 95.5)
Leukocyte count > 1,463 and ADA > 61 U/L
78.3% 
(67.4 to 89.2)
96.9% 
(92.3 to 100.0)
94.7% 
(88.8 to 100.0)
86.1% 
(77.0 to 95.2)
PMN> 81% and CRP > 6.7 mg/L
60.9% 
(48.0 to 73.8)
100.0% 
(100.0 to 100.0)
100.0% 
(100.0 to 100.0)
78.0% 
(67.1 to 89.0)
PMN> 81% and ADA > 61 U/L
65.2% 
(52.6 to 77.8)
96.9% 
(92.3 to 100.0)
93.8% 
(87.3 to 100.0)
79.5% 
(68.8 to 90.2)
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Discussion
Several different tests can be performed on synovial fluid in the pursuit of a diagnosis of PJI. 
Microbiological culture is the only test that can identify the pathogen, but it has limited diagnostic
accuracy16,17 and takes several days to pro- duce a result. Leucocyte esterase reagent strips 
are readily available and can be informative. A normal result practically excludes infection,
whilst a bluntly positive test is suggestive of infection.18-20 The results are equivocal in 
many patients, either because of blood and debris in the fluid which make the reagent strip 
unreadable, or because of an intermediate result.21
In recent years, the total leucocyte and differential counts have formed the basis of the analysis
of synovial fluid, with sensitivity and specificity for PJI around or > 90%. Nevertheless, proposed
thresholds vary significantly between different authors, and the counts may be influenced by 
other factors especially the recent use of antibiotics.8-10 In order to overcome these limitations,
several different synovial fluid markers have been investigated. They can be divided in two 
categories: cytokines, and markers with antimicro- bial functions, such as synovial CRP and 
α-defensin.22 Of the cytokines, interleukin (IL)-6 is probably the most studied,12,23 but this 
requires complex and costly laboratory processing which is not widely available. To date, 
only the α-defensin test has been made commercially available as a quick test specifically 
designed for the diagnosis of PJI and it has shown promising results, although this test may 
be prohibitively expensive.24-27 A cost-effective approach could be to limit its use to patients 
with an equivocal leucocyte count, but there is a lack of evidence regarding its accuracy in this 
specific cohort.
We mainly wished to consider markers which were inex- pensive and routinely performed in 
our own and other lab- oratories in other clinical circumstances. We chose to focus on CRP, 
ADA, α2M and procalcitonin, as well as the leucocyte count. Not surprisingly, the leucocyte
count had a good diagnostic performance. Although the literature proposes a range of 
thresholds from 1100 to 17009,28,29 to > 3000 cells/μL2,8,10, it has consistently been shown to be 
a powerful tool to which every new biomarker must be com- pared. The serum level of CRP 
has also long been consid- ered a useful parameter in musculoskeletal and prosthetic joint 
infections. However, because it is produced by the liver in response to a variety of inflammatory 
stimuli, it is not specific to PJI and may be normal in low-grade PJI.30,31 There is some evidence 
that measuring the CRP directly from the synovial fluid can improve its accuracy. Zamani et 
al32 pioneered the evaluation of the ability of the CRP to differentiate between inflammatory 
and non-inflammatory arthritis. Parvizi et al33 applied the same enzyme-linked immuno sorbent 
assay methodology to measure the CRP in synovial fluid and differentiate between infected 
and unin- fected revision TKAs. Others have studied the use of less complex standard assay 
equipment currently available at most hospitals, to measure the CRP in synovial fluid and all 
found that the level in patients with aseptic loosening was significantly lower than in those 
with a PJI.31-34 However, the proposed cutoff values (ranging from 1.8 mg/L to 9.5 mg/L) and 
respective diagnostic accuracy varied between the studies.35-38 Our results suggest that the 
adoption of a low threshold may be helpful in the exclusion of infection and a high threshold may 
be indicative of infection. More studies are needed to clarify the optimum diagnostic criteria.
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Adenosine is a purine nucleoside with anti-inflammatory and tissue protective properties.38 It 
has been proposed that the measurement of the levels of ADA in different tissues, especially
in serous body fluids, may help to identify activation of the immune system.38 There is much 
evidence that the levels of ADA in pleural, pericardial, peritoneal and cerebrospinal fluid can 
distinguish a tuberculous infection from inflammatory conditions accurately. There is also 
some evidence that the level of ADA in synovial fluid may help in differentiating septic from 
rheumatoid and crystal- induced joint arthritis as well as monitoring disease activity within the 
joint.32,39,40 However, to the best of our knowledge, there are no studies on the value of the 
levels of ADA in synovial fluid in the diagnosis of PJI. We found that levels of ADA in the 
synovial fluid of > 61 U/L offer reasonably good diagnostic accuracy.
The primary function of α2M is the rapid inhibition of excess proteinases released during tissue 
injury. Proteinases are liberated by neutrophils at the site of inflammation but they may also be 
secreted by exogenous sources such as pathogens.41 Jacovides et al11 showed that the level 
of α2M was significantly higher in PJIs than in aseptic failures. They were able to set a cutoff at 
0.26 mg/mL (260 mg/L) with 89.5% diagnostic accuracy. The mean synovial fluid concentration
of α2M in our aseptic group was higher than this level (365 mg/L). Although we did confirm 
that the level of α2M was significantly increased in infected cases, our optimal cutoff is much 
higher, and this was the second worst performing marker in our study, with a diagnostic 
accuracy of < 80%.
The level of procalcitonin in the synovial fluid was the poorest performing indicator which we 
analysed. The level of procalcitonin in the serum has been extensively studied as a diagnostic 
and prognostic indicator of systemic sepsis and has been shown to differentiate sepsis from 
a systemic inflammatory response.42 It has also been studied for the diagnosis of bone and 
joint infection, including PJI,43-45 without success. The measurement of levels of procalcitonin 
in synovial fluid have previously been proposed as a method of distinguishing PJI from aseptic 
loosening. Saeed et al46 reported that these levels were significantly higher in septic arthritis 
than in nonseptic arthritis and suggested that it could be a valuable tool, but their patients were 
a heterogenous group with prosthetic and native joints. In our cohort, we were not able to show 
a significantly higher level of procalcitonin in the synovial fluid in patients with a PJI compared 
with those with aseptic loosening.
This study has limitations. The levels of ESR and/or CRP in the serum were not available 
in some patients. It was not possible to obtain enough synovial fluid to perform a differential 
leucocyte count in some patients. This may have affected the correct final diagnosis. The strict 
microbiological sampling requirements in the inclusion criteria precluded the results being
analysed in many patients. However, it has been shown that the sensitivity of testing for 
PJI is improved by the use of several periprosthetic tis- sue samples and sonication of the 
implants.3,47 Positive sonication findings were classified as a minor criterion for PJI if no other 
tissue culture grew in accordance. If sonication and at least one tissue culture grew the same 
organism, then it was classified as an infection. In all, two patients with negative tissue cultures 
had positive results from sonication. In the five patients in whom micro-organisms were isolated
in a single sample (either tissue or sonication), there was enough supporting information to 
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classify them as aseptic. Another possible source of error was the method of diluting synovial 
fluid for biochemical analysis due to its viscosity.
We believe that the total leucocyte count is very informative and remains the first step in the 
diagnosis of a PJI. We found that when a lower cutoff is used a very high negative predictive 
value is to be expected and conversely a higher threshold offers better positive predictive 
value. We believe a lower cutoff is beneficial as it allows confident exclusion of infection. A 
positive leucocyte count can be further considered with the combined interpretation of other 
specific but simple and inexpensive markers, such as CRP and adenosine deaminase.
The diagnosis of PJI by the examination of the synovial fluid of the affected joint relies mostly 
on the leucocyte count, however simple and inexpensive markers such as the levels of CRP 
and ADA increase the diagnostic accuracy, namely specificity. Further research is needed to 
confirm these findings and to establish their role in the presence of confounding variables such 
as metallosis or inflammatory arthritis.
Take Home Message
• Adding simple and inexpensive markers to synovial fluid traditional leukocyte count 
examination may reduce the number of equivocal synovial fluid results requiring more 
expensive investigation.
• Pre-operative diagnostic accuracy for PJI can be greatly enhanced in a relatively simple way, 
as leukocyte count, CRP and ADA measurement technology is widely available, allowing for 
straightforward translation.
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Abstract
Study Goal: Treating prosthetic joint infections is complex and the results of debridement with 
implant retention are often unpredictable. Our hypothesis is that it is possible to offer a good 
chance for success as long as simple patient selection and treatment guidelines are met. The 
goal of this paper is to present the results of prospectively applying these principles over the 
past few years in our institution. 
Material and Methods: This is a prospective clinical study including patients with prosthetic 
joint infection treated since January/2012 and a 12 months’ minimum follow-up after treatment 
discontinuation. Only patients with a stable prosthesis with no signs of loosening, good soft 
tissues and short duration of symptoms were candidates to debridement with implant retention. 
Surgery was performed by the same surgeon and it always included mobile parts exchange. 
Whenever possible, antibiotic therapy included agents effective against bacteria within the 
biofilm.  
Results: Twenty-four patients (15 knees and 9 hips) with a mean age of 65 years were included. 
One patient was excluded from the analysis of results as a result of unrelated death. There 
were three cases of treatment failure, resulting in an overall success rate of 87% (20/23) with 
an average 30 months’ follow-up after discontinuing antibiotic therapy.
Conclusion: Following a predetermined treatment protocol allows for good results in the 
treatment of prosthetic joint infections even when choosing to preserve the implant.
Keywords
Hip Prosthesis; Knee Prosthesis; Prosthesis-Related Infections; Cohort Studies; Prospective 
Studies; Prosthesis Retention; Therapeutic Irrigation; Anti-Bacterial Agents/therapeutic use; 
Treatment Outcome
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Introduction
Infection is one of the most frequent and feared complications after total joint arthroplasty. The 
enormous difficulties of its treatment often involve multiple surgeries and hospital stays with a 
significant impact on the patient’s quality of life and even mortality (1).
Despite all the awareness and investing in prophylaxis it has been getting in the past few 
years, there is actually a worldwide trend to increasing prevalence and associated costs (2, 3). 
If we also consider the growing number of arthroplasties being performed every year, we can 
easily reach the conclusion that this is a complication that every orthopedic surgeon must learn 
how to recognize and deal with.
Surgical debridement and implant retention (DAIR) is an appealing treatment alternative for 
prosthetic joint infection (PJI). For the surgeon, it is technically less demanding than revision 
surgery and for the patient it is easier to recover from (4). 
However, there is massive controversy in the literature regarding its real efficacy. Success 
rates vary between 0% and 90%, with an average around 50% both for hips and knees (5, 
6). Furthermore, it has been suggested that failure of debridement as first-line treatment may 
compromise the success of ensuing revision surgery. It is therefore relevant to adequately 
choose the best therapeutic strategy in each case (7).
Multiple factors influence the outcome of this treatment choice. However, the authors believe 
that considering simple criteria for adequate patient selection and some basic principles for 
correct surgical and medical treatment, it is possible to offer a good chance for eradication of 
infection. Thus, the goal of this paper is to present the protocol adopted by the authors as well 
as the results of its implementation over the past few years.
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Material and Methods
This is a prospective study that started in January/2012 and focuses on patients with a 
prosthetic joint infection diagnosis treated by the first author. Clinical and demographic 
variables as well as treatment and clinical and laboratory follow-up information are collected
into an institutional database. This database is duly approved by the Institution’s Ethic 
Committee and the National Committee on Data Protection. 
The results of all patients treated up to September/2015 with a 12-month’s minimum follow-up
after antibiotic therapy discontinuation will be presented. The authors believe this is the 
minimal acceptable requirement as this is the time frame where most failures occur430,489. 
Selection Criteria
In order to be considered as candidates for surgical debridement with implant retention, 
patients should meet the following conditions: 1) stable prosthesis with no signs of loosening; 
2) good soft tissues with no sinus tract and; 3) duration of symptoms under four weeks. These 
criteria were determined after previous analysis of our experience and literature review (10).
Surgical Approach Protocol
Recognizing the specificities inherent to each joint and specific clinical case, debridement 
obeys a systematic and constant order.
The first step is to excise the previous incision. If the fascia is closed, a superficial debridement 
is performed gathering samples for microbiology. Once this layer is macroscopically clean a 
needle is used to perform a joint tap and collect uncontaminated synovial fluid for analysis 
and only then is the arthrotomy performed. After the arthrotomy, all mobile parts are removed 
(i.e. liner, femoral head and modular neck, etc.) in order to improve exposure and allow for the 
cleansing of all prosthetic interfaces. A total synovectomy as well as excision of all devitalized
tissues and hematomas or collections are also performed thus improving exposure as well 
as debridement. At this stage, a minimum of five samples for culture are taken preferably for 
macroscopically unhealthy tissues and/or those in contact with the prosthesis. After rigorous
debridement of all suspicious tissues as well as suture remnants a copious lavage is 
performed. The first washout is made with 3L of chlorohexidine solution and another one is 
made with 3L of normal saline.  After this, the wound is temporarily closed allowing the entire 
team to leave reprep and change surgical clothes.  With a new set of surgical instruments an 
additional wash using 1L of saline is made before implant new mobile parts to replace the 
ones that were removed. Usually one single intra-articular drain is used and the wound is 
closed by layers as tightly as possible using a technique similar to primary surgery (fascial and 
subcutaneous absorbable sutures and skin staples).
A single debridement is usually performed and only if the clinical scenario requires it 
(persistent drainage for instances) is a second debridement performed. If failure of the second 
debridement occurs alternative treatment options including prosthesis removal are strongly 
considered, especially when facing a patient with major risk factors for failure such as medical 
comorbidities or difficult to treat pathogens.
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Medical Approach Protocol
When facing a suspected prosthetic joint infection, antibiotic therapy is not started before 
surgery unless in cases of clinical emergency such as imminent sepsis. In the overwhelming
majority of cases, antibiotic therapy should start after culture sample gathering, after 
tourniquet release in knees. Empirical antibiotic therapy starts in the operating room with 
extended gram-positive and gram-negative coverage. During the entire study period, our 
protocol was vancomycin with a carbapenem (11). Once definitive microbiology results are 
available it is adjusted accordingly.
The switch from intravenous to oral therapy does not follow any predetermined time period 
but rather a conjugation of favorable clinical response (e.g. no wound drainage, diminishing 
inflammatory blood parameters) and the availability of effective and good oral bioavailability 
alternatives.
Outpatient oral antibiotic therapy extends for three and six months for hips and knees 
respectively. Antibiotics are discontinued after the time period defined for each case regardless
of inflammatory parameters. Whenever possible, antibiotic regimen includes drug(s) with 
activity against slow-growing bacteria in the biofilm. Specifically, rifampicin for staphylococci 
(always in combination) and ciprofloxacin for gram-negative infections.
Important	Definitions
PJI cases included in this study were classified according to a previous proposal (10) as: 
a) Postoperative Acute Infections as those who occur in the first three months after implant 
surgery and is usually characterized by an acute inflammatory clinical picture with persistent 
wound drainage that may or may not have macroscopic purulent appearance and; b) Acute 
Hematogenous Infections that are usually characterized by an acute inflammatory clinical 
picture appearing in a previously well-functioning and asymptomatic joint in the setting of a 
document or presumed bacteremia.
Outpatient antibiotic therapy regimen was classified as: a) Optimal Regimen if it included 
rifampicin for staphylococci infections, ciprofloxacina for gram-negative infections or both in 
cases of mixed polymicrobial flora and; b) Subptimal Regimen if these conditions were not met 
either for unfavorable resistance profile or patient adverse reactions that forced interrupting 
adequate therapy before the completion of recommended time period.
Success was determined according to the Delphi international consensus (12) as: a) failed 
infection eradication, characterized by a fistula, drainage, pain or infection recurrence caused by 
the same organism strain; b) subsequent surgical intervention for infection after reimplantation
surgery; or c) PJI-related mortality. Results with a minimum 12 months’ follow-up after 
antibiotic discontinuation success rate as defined by the authors will be presented. Results 
with a minimum of two years after the last surgery, as recommended in the aforementioned 
consensus (12), will also be specified.
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Statistical Analysis
Given the relatively reduced sample size a descriptive analysis of the results was made not 
searching for statistical correlations that would be clearly not significant.
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Results
Twenty-four patients with infection of a total hip (THA) or total knee (TKA) arthroplasty, in which 
debridement with implant retention was chosen as initial treatment, were included in this study. 
Table I summarizes main clinical and demographics information. Table II shows corresponding 
microbiologic findings.
Table I.D Clinical and demographic information of the study population.
Total 
n=24
Age * 65.2 (24-83)
Female gender 17 (71%)
Joint
Hip 9 (38%)
Knee 15 (62%)
ASA	score	≥3 10 (42%)
Relevant Comorbidities
Obesity (BMI>30) 12 (50%)
Diabetes 7 (29%)
Immunosuppression 2 (8%)
Liver failure 2 (8%)
Type of infection
Acute postoperative 18 (75%)
Acute Hematogenous 6 (25%)
Duration of symptoms until surgery (days) * 17.2 (6-28)
C reactive protein (mg/L) * 100.7 (1-364)
Erythrocyte sedimentation rate (mm/h) * 71.4 (20-104)
* average (minimum-maximum); ASA American Society of Anesthesiologists; BMI Body Mass Index.
These are consecutive unselected cases, from the first author clinical practice and most of 
them are primary prosthesis (12 TKA and six THA). Notwithstanding, infections after aseptic 
revision surgery were also included (one TKA and two THA) and even after two-stage revision 
surgery for previous infection (one knee and one hip). An infection of a knee mega-prosthesis 
after high grade osteoblastic osteosarcoma resection of the distal femur was also included. It 
is noteworthy that, according to the previously described protocol only acute postoperative and 
hematogenous infections with short duration of symptoms were included.
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Table II.D Microbiology findings among the study population.
Total
Number of infections n=24
Polymicrobial infections 8 (33.3%)
Culture Negatives 0 (0.0%)
Isolated microorganisms n=35
Gram positive 25 (71.4%)
Staphylococcus aureus 9 (25.7%)
MRSA 2 (5.7%)
MSSA 7 (20.0%)
Coagulase-negative staphylococci 10 (28.6%)
MR CoNS 7 (20.0%)
MS CoNS 3 (8.6%)
Other Gram positives 6 (17.1%)
Enterococcus spp. 3 (8.6%)
Streptococcus spp. 2 (5.7%)
Corynebacterium spp. 1 (2.9%)
Gram negative 10 (28.6%)
Enterobacteriaceae 9 (25.7%)
Enterobacter spp. 3 (8.6%)
Escherichia coli 3 (8.6%)
Proteus spp. 2 (5.7%)
Klebsiella spp. 1 (2.9%)
Pseudomonas spp. 1 (2.9%)
MR methicillin-resistant; MS methicillin-sensitive; SA Staphylococcus aureus; CoNS Coagulase-negative staphylococci.
Table III shows information regarding the different treatment variables considered. Only four 
cases (17%) needed a second debridement. Antibiotic therapy regimen was considered 
suboptimal in four cases: one polymicrobial infection including a ciprofloxacin-resistant Gram 
negative bacilli, one MRSA case that was also rifampicin-resistant, one case of methicillin-
resistant S. epidermidis in which a rifampicin induced decompensation of a known liver 
insufficiency occurred after seven days forcing its discontinuation and one other MRSA case 
with significant patient intolerance to the therapy with incoercible vomiting that led to irregular 
antibiotic(s) intake. Interestingly, there were no failures among these four cases. On the day 
of antibiotic therapy discontinuation, erythrocyte sedimentation rate was above 30 mm/h in 11 
cases and C reactive protein above 10mg/L in four cases. There were no significant differences
of the registered variables between success and failure cases.
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Table III.D Summary of treatment related variables.
Total
n=24
Average number of debridements 1.2  
Need for a repeated debridement 4 (17%)
Duration of hospital stay (days) * 23.8 (13.5-29.8)
Duration of IV antibiotic therapy (days) * 15.6 (11.0-18.8)
Duration of total antibiotic therapy (weeks) *
Hip 15.7 (12.9-14.6)
Knee 25.9 (22.7-26.7)
Antibiotic therapy regimen 
Optimal regimen 20 (83%)
Suboptimal regimen 4 (17%)
CRP at the end of antibiotic therapy* (mg/L) 6.6 (2.4-7.0)
ESR at the end of antibiotic therapy* (mm/h) 32.5 (14.0-50.0)
Follow-up time (months) 
Since surgery 35.2 (20.2-48.2)
Since the end of antibiotic therapy 30.0 (15.5-44.9)
* mean (interquartile range); IV intravenous; CRP C reactive protein; ESR erythrocyte sedimentation rate.
One patient died about one year after surgery and only six months after antibiotic 
discontinuation thus not reaching the minimum follow-up required. It was therefore excluded 
from final results analysis. However, it was not considered a treatment failure as she died of 
unrelated causes (i.e. acute myocardial ischemia) while she was completely asymptomatic 
of the operated joint and TKA was being considered for the other knee. One other patient 
died during the study period also for unrelated causes. However, because he died after more 
than four years after antibiotic discontinuation and had no signs of infection, it was included 
and considered a treatment success. As such, with a mean follow-up period of 30 months 
(minimum 12 months) after antibiotic therapy discontinuation, there were three treatment 
failures, with an overall success rate of 87% (20/23). If we consider the two years’ minimum 
follow-up after surgery, success rate was 85% (17/20). Table IV shows clinical information 
regarding the three failures. All of them were ultimately successfully treated with two-stage 
exchange surgery.
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Table IV.D Summary information concerning the three failures.
Relevant history Type and Joint age Infection clinical features Microbiology
Antibiotic 
Therapy Regimen Mode of Failure
69 years old 
women, Oral 
anticoagulation 
for AF
14 months 
old
primary TKA
Acute inflammatory/infectious 
arthritis after trauma and signif-
icant hematoma and cutaneous 
abrasion;
15 days’ during of symptoms 
(operated the same day she 
entered the ER)
Methicilin-
sensitive S. 
aureus
Empirical vanco-
mycin + imipenem 
after surgery
Early failure with extensive 
skin necrosis the first few 
days after debridement 
(fig.1) 
73 years old man, 
Morbidly obese 
(BMI=42), COPD
3 weeks old
primary TKA Persistent wound drainage
Methicilin-
sensitive S. 
aureus
3 months’ 
rifampicin 600mg 
qd + levofloxacin 
500 mg qd
De novo pain and femoral 
lithic lesions 15 months 
after antibiotic 
discontinuation (fig.2)
Prosthesis removal/spacer 
implantation 19 months 
after debridement
76 years old 
women,
Myelodysplastic 
syndrome with 
pancytopenia
3 weeks old
primary TKA Persistent wound drainage
Methicilin-
resistant S. 
epidermidis
6 months’ 
rifampicin 600mg 
id + linezolid 600 
mg bid (4 weeks) 
followed by 
clindamycin
 600 mg tid
Pain worsening 
immediately after antibiotic 
discontinuation
Prosthesis removal/spacer 
implantation 9 months after 
debridement
AF atrial fibrillation; ER emergency room; TKA total knee arthroplasty; THA total hip arthroplasty; BMI body mass index; COPD 
chronic obstructive pulmonary disease.
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Fig. 1d Clinical aspect of the surgical wound at: A) third postoperative 
day; B) tenth postoperative day; C) fifteenth postoperative day
Fig. 2d Radiographic appearance at 13 months after debridement 
(ESR and CRP were normal at this visit); B) radiographic appearance 5 
months later with obvious lytic lesions in the femur (withe arrows) and 
de novo peri acetabular radiolucent line
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Discussion
As the number of total joint arthroplasties continues to grow every year, and despite all the 
efforts around prophylaxis, prosthetic joint infections are becoming a more common problem.
Debridement with implant retention (DAIR) is an appealing treatment alternative but its 
success rate is very inconsistent with results in the literature varying from 0% to 90% (5, 6). 
Many variables may influence the final outcome. Some of them like patient comorbidities or 
responsible pathogen(s) virulence elude the control of the surgeon (8,13,14). Others such as 
correct patient selection, rigorous surgical debridement and selected antibiotic regimen are 
directly under the control of the medical team (9, 15-19).
Naturally, the first indispensable condition to go ahead with DAIR is that we face a stable 
prosthesis with no signs of loosening. In other words, a prosthesis worth saving. Inability to 
adequately close the wound and soft tissues or the presence of a sinus tract are also often 
considered absolute contra-indications as they exponentially increase the risk of treatment 
failure (17).
Short duration of symptoms seems to be a major criterion in choosing this treatment alternative 
with an ideal time threshold located somewhere between 3-4 weeks (8, 14, 17, 20-22). It is very 
important to distinguish between duration of symptoms and “joint age” or time elapsed since its 
implantation. Regardless of the time elapsed since the original surgery, acute infections may 
occur by hematogenous spread into previously asymptomatic joints. In these cases, DAIR is 
proven as effective as in postoperative infections (13, 15). In acute postoperative infections, 
our policy when facing a suspicious case is not to start antibiotics on its own. We believe it will 
mask the manifestations of infection that can be very subtle. We advocate tight clinical and 
laboratory surveillance with serial measurement od inflammatory parameters. If these 
parameters show an increasing trend or wound drainage persists after the tenth postoperative 
day we go ahead with a formal debridement.
A thorough surgical debridement is perhaps one of the most important and probably the 
most difficult variable to objectively assess.  The main goal of surgery is to lower as much as 
possible the bacterial load within the joint in order to facilitate the role of antibiotics and patient 
immune system. In this regard, mobile parts exchange seems very relevant. Not only does 
it increase exposure as it allows for cleansing of the prosthesis interfaces thus helping to 
fulfill the goal of surgery. It has been widely shown that mobile parts exchange increases the 
probability of success (23, 24).
A main determinant of success after DAIR is the type and specific characteristics of the 
bacteria causing the infection. Staphylococci infections, specifically S. aureus, have been 
frequently associated with worse outcomes (8, 13, 20). Naturally this variable cannot be 
influenced by the surgeon and is often not known when deciding to operate. However, antibiotic
regimen can and should be optimized. When choosing to perform a DAIR one must 
acknowledge the presence of bacterial biofilm remnants and whenever feasible drug(s) active
against slow growing bacteria in the biofilm should be chosen (19). Although a detailed 
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discussion of the more appropriate antibiotic(s) is beyond the scope of this paper, it is 
important to highlight the crucial role of rifampicin in staphylococci infections (9, 15) and 
ciprofloxacina in gram negative infections (16, 25). In our series, all three failures occurred in 
the 18 PJI cases where a staphylococcus sp. was found despite adequate antibiotic therapy.
The ideal duration of antibiotic therapy is a matter of open debate, although it is still 
recommended to extend treatment for at least three months in hips and six months in knees 
(26). Byren et al (8) showed not only that the risk infection relapse increases after antibiotic 
discontinuation but also that treatment longer than 180 days did not increase the likelihood of 
cure. These findings suggest that infections are either cured or not in this initial stage and that 
prolonging therapy only postpones the treatment failure. An issue often encountered in clinical 
practice is to use the monitoring of inflammatory parameters to decide when to discontinue 
therapy. It has been shown that this practice lacks real predictive value (27, 28).
It has been repeatedly shown that adopting a clear treatment concept based on scientific 
evidence leads to significant improvement in the results when compared to an ad hoc 
approach (29, 30). It is important to stress that such an improvement does not depend on 
significant technical breakthroughs but rather on the compliance to simple principles of patient 
selection and the strict adherence to predetermined treatment rules. The fact that failures in 
the treatment of prosthetic joint infections often occur on the medium/long term cause a false 
sense of immediate success among surgeons thus contributing to the perpetuation of the 
same mistakes and preconceived notions of the past.
Conclusion
The results of employing our protocol over the last few year have been encouraging. The 
current success rate of around 85% is located in the favorable end of the spectrum and 
compares very favorably with the 30% success rate of our previous 2008 study (10). We could 
thus prove that it is possible to improve ad reproduce the best results in the literature also in 
clinical daily practice as long as one adopts an evidence-based approach.
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Abstract
Study Goal: Revision surgery with implant removal, because it offers predictable results, is 
considered to be the gold standard in the treatment of prosthetic joint infections.  Our belief
is that a protocoled approach may offer better infection control as well as reduce patient 
morbidity. The goal of this paper is to present the results our management protocol and the 
results obtained with its implementation. 
Material and Methods: This is a prospective clinical study including patients with prosthetic
joint infection treated between January/2012 and December/2015 thus allowing a twelve 
months’ minimum follow-up. Prosthetic joint infection definition followed internationally 
established criteria and medical and surgical treatment was performed in a standardized way. 
Every patient underwent prosthesis removal and high-dose antibiotic spacer implantation.
Results: Twenty-nine patients (19 knees and e 10 hips) with a mean age of 67 years were 
included.  There were two related deaths. Infection eradication was achieved in all cases, 
although it was not possible to complete the second stage in two cases. Among the 25 patients 
who completed the second stage, the mean time interval between stages was 11 weeks. There 
were no cases of infection relapse at a mean 30 months’ follow-up. Overall success rate is 
86% (25/29).
Conclusion: Following a protocoled approach resulted in good results with significant 
reduction of morbidity between the two stages without compromising safety.
Keywords
Revision hip arthroplasty; Revision knee arthroplasty; Prosthesis-Related Infections; Cohort
Studies; Prospective Studies; 2-stage exchange; Anti-Bacterial Agents/therapeutic use; 
Treatment Outcome
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Introduction
Infection is one of the most dreadful complications after total joint arthroplasty. It is often the 
first or second cause for revision total knee arthroplasty (1, 2) and the third most common 
reason for revision total hip after aseptic loosening and instability (2, 3).
Despite all the awareness around it over the past few years, there is actually a worldwide trend 
to its increasing incidence along with associated economic burden (4).
Treating this complication is hard and arduous and it is therefore advisable that it is undertaken 
by an experienced multidisciplinary team (5). Nevertheless, it often leads to significant patient 
morbidity and mortality even when it is possible to eradicate infection (6). The presence of 
bacterial biofilme in prosthetic joint infections (PJI) is responsible for most of the difficulties. 
Bacteria become about 1,000 times more resistant to antibiotics and the host’s immune system
is unable to eradicate it (7). Most of the tissue destruction is caused by this “frustrated 
phagocytosis” and persistent inflammation around the implant (7). Currently once a mature 
biofilm is formed, there is no way to eradicate in vivo. A such the only alternative is to remove 
it by removing the prosthesis. 
In this regard, two-stage revision surgery is the most frequent treatment option worldwide 
although one-stage surgery may be indicated in specific circumstances (8, 9). Two-stage 
revision surgery consists in surgical debridement and removing the infected implant, with or 
without using a temporary cement spacer with high dose antibiotics, before implanting a new 
prosthesis in a second surgery. 
The purpose of this paper is to present the author’s two-stage management protocol for the 
treatment of PJI as well as the results of its implementation over the past few years. 
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Material and Methods
This is an ongoing prospective study that started in January/2012 and focuses on patients with 
prosthetic joint infections treated according to predetermined protocol. Several different clinical 
and demographic as well as treatment and laboratory follow-up variables are collected into an 
institutional database.  This database is duly approved by the Institution’s Ethic Committee and 
the National Committee on Data Protection.
Results concerning patients treated up to December/2015 will be presented so a minimum 12 
months’ follow-up after the second surgery is possible. Results with at least two years follow-up 
will also be presented as is suggested in an international multidisciplinary consensus (10).
Success of the procedure was defined accordingly to the previously mentioned consensus as: 
a) failed infection eradication, characterized by a fistula, drainage, pain or infection recurrence 
caused by the same organism strain; b) subsequent surgical intervention for infection after 
reimplantation surgery; or c) PJI-related mortality (10).
Selection	Criteria	and	Definitions
Every patient with chronic PJI or those with acute infections who do not meet predetermined 
criteria for debridement and implant retention surgery, specifically stable prosthesis with no 
signs of loosening and adequate soft tissues (e.g. sinus tract or inability to close the wound) 
are considered candidates to two-stage revision surgery. These criteria were defined after 
analyzing our previous experience and literature review (11).
Chronic infection diagnosis follows the definition and criteria proposed in a recent international 
consensus meeting on PJI (5) and are exposed in table I. 
Table I.E International Consensus Meeting Definition of Periprosthetic Joint Infection.
1) Two positive periprosthetic cultures with phenotypically identical organisms, or
2) A sinus tract communicating with the joint, or
3) Having three of the following minor criteria
Elevated serum CRP and ESR
Elevated synovial fluid WBC count OR ++ change on leukocyte esterase test strip
Elevated synovial fluid PMN percentage
A single positive culture
Positive histological analysis of periprosthetic tissue
CRP C-reactive protein, ESR erythrocyte sedimentation rate, WBC white blood cell; PMN polymorphonuclear neutrophil.
Erythrocyte sedimentation rate (ESR) is considered positive above 30mm/H and C-reactive 
protein above 10mg/L. Total leukocyte count in the synovial fluid above 3,000 cells/μL and 
polymorphonuclear neutrophil (PMN) proportion over 80% are also considered positives. 
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Sonication of the removed implant is routinely performed and subsequent microbiology findings
are interpreted as a single sample to be interpreted with the rest of the data. In our institution, 
histological analysis of periprosthetic tissue is not routinely performed.
Surgical Treatment Protocol
Recognizing the specificities inherent to each joint and specific clinical case, two-stage surgery 
obeys a systematic and constant order.
During the first surgery, all the implant is removed but also all and any inert material including 
bone cement, screws, etc. Furthermore, every ill looking sift tissue is meticulously debrided. 
If there is a sinus tract it must be completely excised. If it is not possible to include it in the 
approach of the joint, it must be removed separately. Although one should seek to preserve 
structures that are vital to the postoperative functional status (e.g. knee extensor mechanism), 
the priority is to cure the infection and as such, debridement must be as radical as possible.
Alongside complete synovectomy and removal of all devitalized soft tissues (e.g. muscle 
necrosis, collections, etc.) also all infected bone must be debrided. In the hip, it is in this stage 
that the socket size is evaluated and reamers are used to create an appropriate cavity for 
the chosen spacer head. During debridement, at least five representative tissue samples are 
gathered for culture, favoring macroscopically purulent tissues and/or those in intimate contact 
with the prosthesis specifically the pseudo-membrane that usually forms between the bone and the 
implant. A copious lavage is then performed. The first washout is made with 3L of chlorohexidine
 solution and another one is made with 3L of normal saline. After this, the wound is temporarily 
closed allowing the entire team to leave reprep and change surgical clothes. With a new set of 
surgical instruments an additional wash using 1L of saline is made before spacer implantation. 
Usually one single intra-articular drain is used and the wound is closed by layers as tightly as 
possible using a technique similar to primary surgery (fascial and subcutaneous absorbable 
sutures and skin staples).
Whenever possible, we prefer to use spacers instead of simple resection arthroplasty. 
Our first-choice is to use spacers that allow mixing the type and dosages of the selected 
antibiotic(s). Mixing antibiotics in the cement is performed on a separate table and starts by 
adding powder antibiotic(s) to the cement powder. Finally, the liquid is added and the mixture 
is performed without vacuum so as to increase the porosity and increase antibiotic elution. 
When the infecting organism is unknown we add 3-4g vancomycin and 1-2g meropenem to 
each 40g of bone cement with gentamicin (0.5g). In specific cases of resistant microorganisms 
or an history of adverse reactions, added antibiotics may be adjusted. Out of the ten cases of 
hip infection articulating spacers with metallic core reinforcement made using silicone molds 
and the fore mentioned mixture were used in eight (Fig. 1A). In one case of documented 
vancomycin allergy and methicillin-resistant staphylococcus infection, daptomycin was 
used as an alternative. The other case presented proximal femur bone loss and required a 
long-stemmed spacer so a commercially manufactured spacer containing gentamicin was 
used. In order to minimize pain and mechanical complications, the spacer is fixed to the bone 
using a coarse cementing technique (same antibiotics mixture) as not to hamper its removal
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in the second surgery. Among knee infections, articulating knee spacers made using silicone
molds were used in the first nine cases (Fig. 1B). In the nine most recent cases (since 
January/2014) were hand-made (Fig. 1C). In one case of previous revision for infection a static 
spacer was used for there was not enough bone stock. In the distal femur tumor mega-prosthesis,
a custom-made articulated spacer with vancomycin and tobramycin was specifically 
manufactured.
Specificities of the second surgery largely depend on the bone and ligamentous defects that 
result from the first stage. It is important to stress that, more than just removing the spacer this 
surgery should include a new debridement and several samples for culture should be taken 
again.
Medical Treatment Protocol
When facing a suspected prosthetic joint infection, antibiotic therapy should not start before 
surgery except in cases of manifest clinical emergence. In the overwhelming majority of cases 
antibiotics should start only after sample gathering for culture has ended, in the knee after 
the tourniquet is released. Empirical antibiotic therapy start still in the operating room and 
comprises wide spectrum antibiotics active against Gram positive and Gram negative 
microorganisms. During this study period, our protocol is to use vancomycin combined with 
a carbapenem (12). Once definitive microbiology results are available therapy is adjusted 
accordingly.
The switch form intravenous (IV) to oral therapy does not obey ay predetermined timeline 
but rather a conjugation of favorable clinical response (e.g. no wound drainage, diminishing 
inflammatory blood parameters) and the availability of effective and good oral bioavailability 
alternatives. Exceptionally it may be necessary to do the full period of IV therapy. Usually it 
lasts around six weeks but it may be necessary to prolong it in rare cases who require waiting 
for complete wound healing (e.g. muscle flaps) or associated other site infections require it. 
Deciding when to perform the second stage does not depend exclusively on the inflammatory 
parameters and even less so of their complete normalization. Usually the decision is made 
after a two weeks’ window period after antibiotics discontinuation. We decide to go ahead with 
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the second stage when the following conditions are met: a) inflammatory parameters steadying
or descending trend regardless of their absolute values; b) favorable soft tissues with nice 
wound healing and no local inflammatory signs; c) correction of the cause for infection if it is 
obvious (e.g. leg ulcer, urinary tract infection, etc.); d) general health status and comorbidities 
optimization (e.g. diabetes control, malnutrition, immunosuppression, etc).
In the second surgery, prophylactic antibiotics are not withheld and start before skin incision
and follows the same wide spectrum protocol described earlier. When definitive culture 
results are available, antibiotics are discontinued or adjusted to oral therapy if bacterial growth 
demands it.
Statistical Analysis
Given the relatively reduced sample size a descriptive analysis of the results was made not 
searching for statistical correlations that would be clearly not significant.
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Results
Twenty-nine patients with infected total hip (THA) or total knee (TJKA) arthroplasty, treated 
with two-stage revision surgery were included in this study. Table II shows the main clinical and 
demographic characteristics of the cohort. It is noteworthy that revision surgery was 
undertaken in three acute infections (two TKA and one THA) after failure of debridement and 
implant retention to control infection; one case of acute THA infection after revision surgery 
for recurrent instability and with two new dislocation episodes after surgery and; one acute 
postoperative TKA infection in which the prosthesis was found to be loose intraoperatively.
These are unselected, consecutive cases the majority concerning primary arthroplasties (15 
TKA and seven THA). Nevertheless, infections after aseptic loosening were also included (two 
TKA and three THA) and even one TKA case after previous revision for infection several years 
back. An infected tumor mega-prosthesis after resection of distal femur fibrosarcoma was 
also included. It is important to emphasize that 12 of the 29 cases had previously undergone 
treatment attempts with debridement and implant retention.
                 Table II.E Clinical and demographic information of the study population.
Total 
n=29
Age* 67.1 (30-84)
Female gender 14 (48%)
Joint
Hip 10 (34%)
Knee 19 (66%)
ASA	score	≥3 13 (45%)
Relevant comorbidities 
Diabetes 19 (66%)
Obesity (BMI>30) 14 (48%)
Inflammatory arthritis 2 (7%)
Chronic renal failure 2 (7%)
Type of infection 
Chronic 24 (83%)
Acute/Hematogenous 5 (17%)
Joint	age	at	the	first	stage	(months) * 34.2 (1-192)
                                            * mean (minimum-maximum); ASA American Society of Anesthesiologists; BMI Body Mass Index.
Table III displays information about microbiology findings. It is noteworthy that there was no 
growth in any sample taken during the first surgery in three cases. All those patients were 
under antibiotics (two in the setting of failed surgical debridement and one that had been 
prescribed even before any surgery for persistent wound drainage).
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                                Table III.E Microbiologic findings among the study population.
Number of infections n=29
Polymicrobial infections 9 (31.0%)
Culture Negative 3 (10.3%)
Isolated microorganisms n=38
Gram positive 31 (81.6%)
Staphylococcus aureus 7 (18.4%)
MRSA 1 (2.6%)
MSSA 6 (15.8%)
Coagulase-negative staphylococci 17 (44.7%)
MR CoNS 7 (18.4%)
MS CoNS 10 (26.3%)
Other Gram positive 7 (18.4%)
Streptococcus spp. 6 (15.8%)
Enterococcus spp. 1 (2.6%)
Gram negative 6 (15.8%)
Enterobacteriaceae 5 (13.2%)
Escherichia coli 2 (5.3%)
Enterobacter spp. 1 (2.6%)
Providencia spp. 1 (2.6%)
Serratia spp. 1 (2.6%)
Pseudomonas spp. 1 (2.6%)
Fungi 1 (2.6%)
Table IV shows information about treatment related variables. As would be expected, 
inflammatory parameters were high in the vast majority of cases. However, five out of 24 
patients in which it was measured, presented normal ESR below 30mm/H and in three patients 
CRP was below 10mg/L. In two cases, both markers were below diagnostic thresholds (one 
THA with chronic years long sinus tract and one TKA under antibiotic therapy for persistent 
wound drainage). In the first stage, a total of 146 culture samples were gathered, averaging 
about five samples in each case. There was growth in 96 (66%) of them. There was an overall 
improvement regarding inflammatory markers between both stages. Nevertheless, in six out 
of the 22 in which it was available, ESR was above 30mm/H and in eight patients CRP was 
above 10mg/L. In five cases, both were still high. During the second stage a total of 103 culture
samples (≈4 samples/patient) were taken and only three displayed bacterial growth. One 
isolated sample grew Propioniobacterium acnes in a patient with previous methicillin-resistant 
S. epidermidis infection and was therefore dismissed as contamination. In the second stage 
of the patient with the infected tumor megaprosthesis two samples had positive growth (a 
methicillin-sensitive S. aureus and a methicillin-resistant S. epidermidis). Since the first stage 
had shown methicillin-resistant S. epidermidis these findings were considered. The second 
stage consisted of a total femur arthroplasty after removing the proximal femur and the patient 
was prescribed a four-month period of rifampicin and levofloxacin. Up to now, with 13 months’ 
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follow-up after antibiotics discontinuation the patient remains pain free and with no other signs 
of infection relapse.
  Table IV.E Summary of treatment related variables.
Total
Presentation	at	the	first	stage	 n=29
C-reactive protein (mg/L) * 78.3 (25.1-122.7)
Erythrocyte sedimentation rate (mm/H) * 56.4† (35.0-81.0)
Microbiology samples: total number/ positive 146 / 96
Treatment n=27
Duration of hospital stay (days) * 22.4 (13.0-26.0)
Duration of IV antibiotic therapy (days) * 15.2 (9.8-15.3)
Total duration of antibiotic therapy (weeks) * 6.4 (5.9-6.7)
Presentation at the second stage n=25
Time interval between stages (weeks) * 11.2 (9.1-11.9)
C-reactive protein (mg/L) * 8.1 (1.9-12.0)
Erythrocyte sedimentation rate (mm/H) * 32.1‡ (23.0-44.0)
Microbiology samples: total number/ positive 103 / 3
  * mean (interquartile range); IV intravenous; † available in 24 cases; ‡ available in 22 cases.
In four cases the protocol was not completed. In two cases, there was PJI-related deaths and 
two other lacked desire for further surgery. A 76-years old man with THA infection underwent
the first stage while in septic shock and died during the first 24 hours with intravascular 
disseminated coagulation. A second death occurred in an 83-years old woman with severe 
heart failure, stage IV chronic renal failure and TKA infection that required a flap for wound 
closure after the first stage. She died of multi-organ failure while still in the hospital about one 
month after surgery. An 84-years old woman with infection after a THA performed for a femoral 
neck fracture, expressed the will of not undergoing further surgery after the first stage even 
though infection was seemingly eradicated. The spacer was ultimately removed for mechanical
reasons, after more than two years at a time that she was bedridden.  All samples taken for 
culture were negative at that point. The remaining case in which a second stage was not 
completed concerns a 73-years old woman with multiple previous surgery for recurrent hip 
instability. Despite a temporary cement tectoplasty (Fig. 2), a dislocation of the spacer 
occurred and after discussing the risks and limitations of all the options, the patient chose 
resection arthroplasty. 
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Again, in this surgery all culture samples were negative. There was another death during the 
study period but, because it was of unrelated causes, it occurred over 15 months after the 
second stage and the patient was asymptomatic of his hip, this case was included in the 
results and deemed a success.
As such, with a mean follow-up of 30 months (minimum 12 months) after the second stage the 
overall success rate is 86% (25/29). To the best of our knowledge, it was possible to eradicate 
infection in every case and there is still no infection relapse after the second stage. However, 
the truth is that treatment was not completed in four cases. If we consider a minimum two 
years’ follow-up after surgery, success rate is 83% (19/23).
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Fig. 2e A) radiographic appearance of THA after revision with structural allograft and restrictive sock for recurrent instability; B) intraoperative pho-
tograph depicting acetabular temporary reconstruction with cement tectoplasty (white arrow) without the spacer; C) radiographic appearance of the 
reconstruction after spacer implantation; D) clinical appearance of the postoperative rehabilitation showing (limited) functional ability of this solution.
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Discussion
Given the increasing prevalence of patients living with some type of arthroplasty and since 
infections may occur at any point in the life of a prosthesis, this is a growing problem for 
which the orthopedic community must be prepared (4, 13). It has been repeatedly shown that 
infection must be a part of the differential diagnosis of any painful arthroplasty as it may be 
present without obvious signs or symptoms and if actively looked for, it may be present in a 
significant proportion of cases thought to be aseptic, especially in the first years after surgery 
(14, 15).
Revision surgery with removal of the infected implant is considered to be the most reliable 
treatment alternative with the best success rates published between 80-90% (5, 16). Although 
revision surgery in a single stage is increasingly being advocated especially in selected cases 
(9, 17, 18), two-stage surgery is still the most common option worldwide (8). We believe this a 
technique with greater tolerance for error and it is maybe easier to adopt in less experienced 
centers. Still, the quality of surgery is crucial. Debridement must be rigorous and all infected 
foreign bodies as well as devitalized bone must be removed. Keeping infected bone as to not 
create additional difficulties in the eventual second stage reconstruction may seriously hamper 
the main goal of eradicating infection and thus prevent completing the desired final outcome.
Using an antibiotic loaded spacer, though it is not indispensable and may even be 
contraindicated in some cases (e.g. major acetabular bone defect), seems to be an important 
adjunct to infection eradication. It allows very high local drug(s) concentrations that would 
be impossible to obtain using systemic antibiotic therapy only (19). Using spacers that allow 
adding the most appropriate drug(s) in the desired dosages seem to increase the amount 
of antibiotics actually released within the joint (20). Nevertheless, there is no real clinical 
evidence of increased efficacy in eradicating infection between these spacers and 
commercially available ones (5). The use of an articulating spacer should be preferred over 
a static as it not only maintains some joint function between stages as it tends to offer better
functional results after revision surgery (5). Using articulated spacers is not without risks though 
and some precautions must be taken to minimize them (21, 22).
One of the most difficult decisions along this procedure is when to advance for the second stage. 
Traditionally, most surgeons prefer to wait for the normalization of inflammatory parameter
such as ESR and CRP. In our institution’s previous experience this lead to a time interval 
between stages of almost 11 months (11). Adopting the criteria previously described allowed 
reducing that interval to around two months without a negative impact in infection eradication, 
even with persistently elevated inflammatory parameters in a significant proportion of cases. 
In fact, it has been repeatedly shown that ESR and CRP are unreliable and note predictive 
of the real probability of cure. Therefore, this practice should be abandoned (23, 24). Even in 
preoperative diagnostic investigation, the negativity of these parameters is no guarantee of 
absent infection as is demonstrated in this and other studies (25).
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Prior administration of antibiotics is one of the main culprits for this and other difficulties in the 
diagnosis of prosthetic infection. In addition to masking laboratory findings, it will also influence 
the reliability of intraoperative cultures during revision surgery, which may not only compromise 
the diagnosis but also the result of treatment (26). In our series, all cases of negative cultures
occurred in patients under antibiotic therapy emphasizing the importance of withholding 
antibiotics prior to surgery and the gathering of appropriate samples whenever possible. 
Sampling should always include four or five representative tissue samples (5).
It has been consistently demonstrated that adopting a clear concept of treatment based on 
scientific evidence leads to a significant improvement in results when compared to an ad hoc 
approach (27, 28). It is important to emphasize that this improvement does not depend on 
significant technical innovations, but rather on applying simple principles and strict compliance
with the predetermined treatment rules. The adoption in our institution of a protocoled 
approach for the treatment of prosthetic infections in the last few years has led to very 
encouraging results allowing cure of infection in all patients. It is important to point out that they 
were obtained in an unselected cohort of cases that included circumstances with increased risk 
of failure such as persistent infection after surgical debridement (including a tumor prosthesis) 
or after previous revision for infection (29, 30). Nevertheless, it is important to emphasize that 
in four out of 29 cases (14%) the treatment was not completed and the second stage was not 
possible. This is a number often overlooked in the literature when discussing the success of 
the two-stage approach and is probably its greatest weakness. Still, current results compare 
very favorably with the 56% of patients who ended up with arthrodesis or resection arthroplasty 
in our previous analysis even after excluding mortality as a cause of failure (11).
Conclusion
The overall success rate, at around 85%, is at the favorable end of the spectrum in the 
literature. This improvement was achieved while at the same time significantly reducing 
morbidity between both stages and not compromising safety as proven by the absence of 
recurrent infection after the second stage. These findings confirm that it is possible to 
reproduce the best results of the literature also in our daily clinical practice and also highlight 
the advantages of a protocol approach based on scientific evidence.
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Naturally, a lot of issues and controversies remain unanswered in this vast field of prosthetic 
joint infections. Improving clinical multidisciplinary collaborative efforts but also cooperation 
between clinicians and basic research scientists and even industry and regulatory agencies is 
key in providing better PJI management in the future.
Prophylaxis
Due to the presence of an implant, a very small number of bacteria reaching the wound is 
enough to cause relevant infection making prevention of PJI extremely demanding. Most 
traditional prophylactic strategies (e.g. skin decontamination, OR asepsis, etc.) aim to reduce 
the number of bacteria reaching the wound via the surrounding environment, the so called 
exogenous contamination. Notwithstanding its remarkable importance, a second route for 
bacterial seeding into the joint is has been recently recognized. The host itself harbors a huge 
number of bacteria that, in the right circumstances, may become pathogenic. This so called 
endogenous contamination and its real weight are yet to be fully understood. 
In trying to understand the potential role of asymptomatic urinary tract colonization we 
performed research in the subject that raised a lot of interest warranting an editorial 
commentary by Duncan619 and correspondence with Uçkay et al.620,621 To the best of our 
knowledge, it remains up to now the largest prospective survey of its kind. Adjusting for known 
risk factors in a multivariate model, ASB independently raised the risk of PJI >3-fold. However, 
preoperative treatment of ASB did not influence it and among patients who had both ASB and 
PJI, the causative organisms did not match at all. Our findings advise against this common 
practice with associated costs, possible side effects of unnecessary antibiotic therapy (i.e. 
adverse drug reactions, altering native flora, contributing to antimicrobial resistance) and 
most of all, no apparent efficacy. Several questions remain unanswered though. If ASB is an 
independent risk factor for PJI but no causal relation seems to exist, does ASB itself constitute 
a real threat or is it just a surrogate marker of vulnerability? If so, are the same mechanisms 
that facilitate urinary tract colonization involved in facilitating joint infection? Remarkably, a 
significantly higher proportion of Gram negative bacteria PJI was found in ASB patients 
suggesting there is maybe some kind of specific susceptibility. Would it be possible to 
mitigate this inherent risk by the use of different perioperative antibiotic prophylaxis? 
Prospective randomized trials are needed to answer these questions. Until such trials can be 
completed, preoperative screening for ASB should be avoided, apart from careful research 
protocols.
III.  CONCLUSION AND FUTURE DEVELOPMENTS
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Staphylococcus aureus carriers are another pool of patients with well-known increased risk 
of infection. There is enough evidence that an endogenous route of joint contamination does 
occur as there is a significant proportion of patients who develop PJI with bacterial clones 
similar to those in previously isolated in the nares103. As such, it is currently recommended to 
treat known nasal carriers. However, implementing a screening and targeted decolonization
strategy in daily practice is complicated. A too long period between outpatient screening 
and surgery increases the risk of misclassification but on the other hand, results need to be 
communicated in time, patients need to be reconvened and instructed towards appropriate 
therapy. This is both labor and time consuming. Another problem regards the sensitivity of 
nasal swab to detect carriers. Molecular PCR-based screening techniques may be more fast 
and allow more flexibility than traditional widely available cultures but not only are they more 
expensive but have also been shown to have limited sensitivity622. It has also been shown that 
screening multiple body site is much more accurate and using nasal swabs as a surrogate 
may at best identify only two thirds of true MRSA carriers623. Whether the same is true for 
MSSA remains unknown. In addition, though the endogenous route is clearly supported by the 
evidence, the exogenous S. aureus contamination pathway may still be preponderant in some 
settings such as our own where at least 10 out of 14 cases of S. aureus PJI may have had an 
exogenous source109. As such, we remain skeptic about the real worth and cost-effectiveness 
of implementing a screening and targeted decolonization strategy. An universal decolonization 
protocol would have the advantage of easy and less resource-consuming implementation, no 
carrier would be left untreated due to screening sensitivity issues or timely identification and 
treatment problems and it would probably be less expensive as costs with screening outweigh 
treatment. The chief concern with universal decolonization is that unnecessary treatment
may promote mupirocin resistance spread. Although it has been suggested that universal 
decolonization seems to be associated with an equally low risk of mupirocin resistance in S. 
aureus, a better option would be to find adequate alternatives for mupirocin nasal ointment624.
Povidone-iodine-based skin and nasal antiseptic has already been shown to be just as 
effective as mupirocin with the added advantage of fast acting. Significant reductions in the 
number of S. aureus colony forming units were found after just one hour of treatment and 
extending up to 12 hours625. There is some evidence that universal treatment with such 
products may lead to similar infection rates as screening and selective mupirocin treatment
of carriers with significant cost savings and ease of implementation626. Larger studies 
investigating this alternative strategy are needed.
Alongside minimizing wound contamination, prophylaxis emphasis is also on optimizing the 
host’s ability to fight bacteria that manage to get to the joint. Perioperative antibiotics are a 
chief component of such strategy and further research is needed on the otimal institutional-
specific regimen (according to resident flora) or even patient-specific regimens according to 
known risk factors such as S. aureus carrier or ASB status.
One other major component of this equation is the prosthesis itself. Once it is implanted the 
so-called “race for the surface” begins between the bacteria and the host tissues627. According 
to this model, when the host cells colonize the implant surface first, the probability of attachment 
of bacterial cells is very low and vice versa. The speed at which the biofilm develops on the 
prosthesis depends on the number and kind of bacteria reaching it, the immune state of the 
Prophylaxis, Diagnosis and Treatment of Prosthetic Joint Infections  Conclusion and Future Development
187
patient but also the characteristics of the implant surface. Surface characteristics of a 
biomaterial such as roughness, hydrophobicity, and electrostatic charge are in play628 but also 
a number of potential receptors for bacterial adhesive ligands offered by the protein film that 
covers an implant immediately after its placement into the host body629. As a result, there is 
a strong need for intrinsic implant surface antibacterial functionality to overcome the implant-
induced defects in local immune response and prevent bacteria from quickly adhering to 
the implant and produce a protective biofilm barrier. The research on new biomaterials or 
alternative implant coatings is currently a major research topic. This goal can be achieved in 
several different ways. 
Romano et al.630 proposed a classification of antibacterial coatings according to their strategy 
of action. Passive surface finishing/modification of an existing biomaterial that results in a 
substantial change of its susceptibility to bacterial colonization would constitute a first group. 
Several different anti-adhesive surface modifications have been proposed, but only a few 
will probably be suitable for clinical use. Most of them seem to offer limited antibacterial and 
anti-biofilm activity and their use in prosthetic joints specifically is further limited by a potential 
interference with osteointegration. 
Active surface finishing/modification is a separate group. Coatings included in this class, 
feature pharmacologically active pre-incorporated antibacterial agents, like antibiotics, 
antiseptics, metal ions, or other organic and inorganic molecules. A well-known example that 
is already being extensively used especially in tumor megaprosthesis is silver ion coating631. 
Silver is however, cytotoxic to bone cells preventing the coating of the intra-medullary part 
of the prosthesis and costly, thus limiting its use to a small number of cases. Other metallic 
ions such as zinc for instances, also have potent antibacterial effects on a wide spectrum of 
bacterial species632,633. However, potential toxic side effects of these metals remain a strong 
concern. Non-metal elements such as iodine, chlorhexidine or selenium have also shown 
great promise. Of these, povidone-iodine is probably the most interesting and there is already 
data of its efficacy in the clinical setting631. Another path is to use organic compounds with 
antibacterial properties of which using antibiotics is by far the most studied alternative. A large 
number of studies have investigated the efficacy of surfaces coated with covalently linked 
antibiotics630. In fact, despite the theoretical advantages of non-eluting systems, this concept 
is limited by the fragility of the coatings and killing activity potential of bacteria which might not 
be directly adjacent to the implant. To overcome these issues, combinations of antibiotics with 
other compounds such as porous hydroxyapatite or biodegradable polymers634 that control 
antibiotic elution have been proposed. To avoid the risk of drug resistance, some antiseptic
agents such as chlorhexidine or even antimicrobial peptides or cytokines are being explored. 
Antimicrobial peptides (ex. chitosan) are a new class of antibiotics with very interesting 
features. They are highly active against a broad spectrum of microorganisms, highly selective
towards microorganisms and not mammalian cells, present fast killing even at low concentra-
tions and most importantly, they have a much lower tendency to induce resistance635. Long-term 
impact of permanently coated implants with antibiotics and other organic compounds, does 
raise concerns regarding possible induction of bacterial resistance, local or systemic toxicity 
and possible detrimental effects on implant osteointegration. In addition, regulatory issues 
apart, its large-scale application seems very challenging in the foreseeable future. 
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Perioperative antibacterial local carriers or coatings would be a better way to overcome such 
challenges. Instead of pre-manufactured surface modifications, that require the use of specific 
implants, a different approach would be to provide a traditional implant with an antibacterial
carrier or coating at the time of surgery. Such a universal coating would allow the use of 
different, already existing, implants and biomaterials making it a versatile solution. Traditional 
antibiotic-loaded PMMA, bone grafts or even bone substitutes636 are examples of such a way 
to deliver implant protection but are associated with several already discussed limitations. 
Biocompatible antibiotic delivering hydrogels represent a possible alternative solution with 
demonstrable in vitro efficacy634,637. Resistance to press fit insertion of uncemented prosthesis, 
favorable elution kinetics and lack of adverse osteointegration effect are key to assuring in 
vivo efficacy as it has already been hinted638,639. A hypothetically better alternative that would 
reduce the risk of drug resistance would be to apply the same principle in delivering alternative 
antibacterial agents such as antiseptics or antimicrobial peptides.
In addition to innovative device technologies, another possible future approach to prevent 
PJI would be through vaccination and immunization against common pathogens or biofilm 
antigens640.
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Diagnosis
PJI diagnosis is often a difficult and laborious task. The matrix-enclosed sessile biofilm 
bacteria elicit a much lower and more localized inflammatory response than an equivalent
number of planktonic bacteria would. This limited inflammatory response often eludes 
traditional clinical and laboratory diagnostic criteria. In addition, biofilm-mode bacteria are 
often in a slow-growing phase thus diminishing the sensitivity of traditional bacterial isolation 
and culturing methods.
 
The fact remains that presently, there is no bullet proof, gold standard definition of infection. 
In current clinical practice, PJI diagnosis must rely on the combined interpretation of different 
diagnostic modalities that must be thoroughly and systematically considered along with sound 
clinical judgment. Synovial fluid investigation seems to be the best available preoperative tool. 
A number of different tests should be performed once a sample is collected. 
However, in correctly understanding how to interpret existing literature, one must be aware of a 
major predicament. Often, especially in acute infections, prosthetic joint infection presentation
is quite clear cut (i.e. major elevation of inflammatory parameters, obvious local wound signs, 
purulence around the prosthesis, etc.). The real struggle is differentiating between certain 
chronic low-grade infections depicting pain alone from other types of aseptic failure. In fact, 
most studies about diagnostic performance of a particular test compare aseptic failures to 
all infected cases regardless of type of infection. This small detail may be contributing to 
overestimation of the real diagnostic worth of each test in the real clinical practice dilemma of 
aseptic vs. chronic low grade infection distinction.
We focused on optimizing the interpretation of synovial fluid examination in this specific setting. 
That is why we focused exclusively on chronic painful total joint replacements requiring revision 
surgery and excluded acute infections. The goal was to investigate simple, inexpensive and 
widely available tests that could easily make the transition into every day management such 
as leukocyte differential counts, high sensitivity C-reactive protein or adenosine deaminase. 
We were able to prove the added practical value of such strategy but a number of different 
issues demand us to continue with further research. Should synovial CRP and ADA threshold 
values be different in each specific joint? What is the accuracy of these markers in patients with 
inflammatory arthritis? Will the levels of these markers be useful in determining optimal timing 
for the second stage? It is also conceivable that these biomarkers prove its usefulness in other 
settings such as differentiating septic from non-septic acute native joint arthritis. 
Notwithstanding, intraoperative culture samples are still a critical step in reaching a definitive 
diagnosis. Correct multiple tissue sample gathering and processing have greatly enhanced 
our ability to detect pathogens over the last few years and should be regarded as the first line 
intervention in those seeking to improve. More expensive and labor intensive strategies such 
as sonication and other biofilm disruption techniques that are already available seem to be 
especially important in cases where bacterial load is lower, previous cultures are negative 
and/or previous antibiotic treatment has been initiated. New molecular-based techniques of 
bacterial identification should be viewed mainly as investigational tools at least in the near 
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future. Not only because of cost and availability but also because of struggles in accurately 
interpreting some findings. These highly sensitive techniques have raised interesting 
questions and defy the limits of pathogen mediated vs. real aseptic prosthesis failure. Palmer 
et al.641 using molecular diagnostics were able to show a significant proportion of patients with 
knee osteoarthritis and no signs of infection, undergoing primary arthroplasty, have confirmed 
bacterial biofilms present where traditional cultures have been negative. Are all joints really
sterile and therefore should all encountered bacteria be viewed as potentially pathogenic 
or are modern diagnostic techniques too sensitive and lack specificity? Ultimately currently 
accepted definitions of PJI may be in need of revision. Staats et al.642 performed a 
retrospective matched-pair analysis in 98 patients who had undergone revision surgery after 
total joint arthroplasty. They found that in the group of 49 patients with less than three minor 
criteria (insufficient to consider them infected), long-term implant survival was significantly
inferior than the group of 49 patients with absolutely no positive criteria. 
While many of the characteristics of biofilm implant-related infections have now been well 
characterized, challenges remain for translating this paradigm shift into clinically meaningful 
diagnostic benefits. A promising research path based on serological detection of elevated 
levels of antibody to microbial antigens, specifically “anti-biofilm” antigens is underway640,643. 
Recently, it has been demonstrated that noninvasive detection of serum antibodies is able to 
diagnose PJI in the clinical setting644,645. Artini et al.644 demonstrated that an enzyme-linked 
immunosorbent assay (ELISA) designed to detect IgM serum antibodies to staphylococcal 
slime polysaccharide antigens showed promising results (95% specificity; 90% sensitivity) in 
detecting delayed orthopedic joint prosthesis infections due to staphylococci. Marmor et al.645 
went a step further and tried to use a multiplex immunoassay that measured serum IgG with 
antigens from three Staphylococcus species, Streptococcus agalactiae and Propionibacterium
acnes. However, compared to traditional cultures of intraoperative samples it has shown 
limited sensitivity and specificity with authors acknowledging limitations regarding bacterial 
species not included in the assay, cross reactivity between antigens from species in the same 
genus and naturally inherent limitations of the fact that sole detection of IgG’s may not provide
accurate information soon after the onset of infection. There are even others trying to come 
up with lateral flow immunoassays that would rapidly and inexpensively diagnose biofilm 
infections by detecting host antibodies against these biofilm-upregulated antigens in different 
biologic samples such as serum or synovial fluid640. Antibodies against biofilm surface proteins, 
have also been shown to accumulate rapidly in the site of infection and it is conceivable that 
this fact could be used to accurately diagnose infection if such antibodies can be conjugated 
with some kind of marker (e.g. radionuclide)640.
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Treatment
Selecting the best treatment alternative for each specific situation is possibly the most 
challenging decision in PJI management. Accurately classifying each case taking into account
major variables that influence outcome such as type and duration of infection, specific 
pathogen but also host characteristics would be ideal. Although numerous classification 
systems exist for PJI, a flawless classification system is still lacking. An ideal classification 
system would be comprehensive, and at the same time simple enough to use in clinical 
practice. It would help guide correct treatment choice and hold intrinsic prognostic value.
It is critical to acknowledge the biofilm paradigm as it conveys extreme implications in the 
treatment of PJI. For a number of known and probably several not yet fully understood 
mechanisms, bacteria within the biofilm are resistant to antibiotic levels up to 1,000 times 
higher than their planktonic counterparts627. In addition, biofilms are resistant to the host 
immune system as it has been shown that antibodies fail to penetrate them and even 
activated phagocytes cannot kill bacteria in biofilms627. Costerton et al.42 suggested that much 
of the tissue damage in chronic biofilm infections is caused by this “frustrated phagocytosis”
and persistent inflammation around the implant. It is critical to acknowledge that, up to 
nowadays, once a mature biofilm is formed there are no effective ways to eliminate it in vivo. 
It is therefore logical that the success of debridement and implant retention depends largely on 
the short duration of infection before treatment. Nevertheless, biofilm forms and matures in the 
first hours and days after bacteria reaching the implant and therefore the use of antimicrobials 
effective in disrupting biofilm and/or killing bacteria within it is decisive. Further research is 
needed regarding potential adjuvants for intraoperative biofilm disruption. Chlorhexidine and 
acetic acid are examples of such strategies that are already being used but they offer limit-
ed efficacy. Adequate postoperative anti-biofilm antibiotic therapy is also a cornerstone for 
successful implant retention. Presently, rifampicin and ciprofloxacin to some degree are the 
only effective therapy and alternative drug(s) are desperately needed. Antimicrobial peptides 
are also a possible therapeutic tool if an effective delivery methodology can be devised. If in vivo 
biofilm disruption therapy becomes real, the need for revision surgery would greatly diminish.
For the time being it is crucial to adequately select cases in which DAIR is likely to succeed
since patients who have undergone DAIR and failed, often undergo multiple subsequent 
surgical procedures adding morbidity and cost to the process. Gardner et al.590 reported a 
failure rate of 42% in 19 patients treated with revision TKA after failed DAIR. A multicenter 
retrospective study, focusing on 83 patients undergoing two-stage revision knee surgery after 
failed previous DAIR procedures, found a 34% failure rate591. Comparing such results with 
traditionally higher success rates of the two-stage revision approach, the authors suggested 
failed DAIR procedures could lead to prohibitively high failure rates of two-stage reimplantation
thus recommending caution in its use591. However, more recent findings seem to call into 
question this concern,  Brimmo589 et al. retrospectively looked at 750 patients who had 
undergone 2-stage revision, 57 (7.6%) of them after undergoing DAIR within 2 years before 
revision and 693 as initial PJI treatment. Even after adjusting for multiple variables a lower risk 
of failure (albeit not statistically significant) was found in the group with failed previous DAIR 
suggesting it may not be as detrimental as previously supposed.
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Notwithstanding, in an effort to accurately predict the probability of success thus helping 
decide on the best course of treatment, some authors have tried to come out with prognostic
preoperative scores429,434. Data on prospectively applying these tools or even including 
pathogen specific indications and analyzing its implications are however still missing. In the 
future, such tools may prove to be of major importance. 
There is still open debate around a number of other issues. What is the best management for 
persistent postoperative wound leakage? It is our personal belief that every suspicious wound 
should be viewed as infected until proven otherwise. As such, we advocate a formal DAIR 
procedure following all of the previously described steps especially deep debridement and 
culture samples gathering that will dictate the correct of treatment in each case (i.e. prolonged 
antibiotic therapy or not). Whether a single or multiple debridements should be performed is 
also doubtful. Our current practice is to try a second debridement only when it is necessary. If 
it fails, especially in a patient with risk factors such as medical comorbidities, polymicrobial or 
“high risk” pathogen infections, strong consideration is given to another treatment alternative 
such as revision surgery or excision arthroplasty depending on the patient’s general health 
status.
Once a mature biofilm is formed in a chronic infection, the only currently viable alternative is to 
surgically eradicate it by removing the implant as well as all foreign material and dead tissues 
that can potentially host it. Whether this exchange revision surgery should be performed in a 
single or two-stage procedure has been the topic of discussion for many years now. There is a 
recent trend towards favoring one-stage exchange. If successful, it offers obvious benefits to 
the patient. In fact, at least in selected cases, it seems to offer favorable infection eradication 
rates. It is nevertheless important to stress that: 1) infection eradication rates after two-stage 
have consistently shown to be good despite including those difficult to treat cases that are 
often excluded from the one stage approach and, 2) routine unselected one-stage approach 
has yet to prove similar worth. On the other hand, in addition to patient morbidity throughout 
treatment, a major handicap of the two-stage approach concerns patients not completing the 
second stage. The proportion of patients who do not actually complete the second stage is a 
very important and often over-looked problem. In our experience, it accounted for all treatment
failures (four out of 29 patients) and recent studies suggest the proportion of patients who 
fail to undergo subsequent reimplantation may be as high as one-third519-521. The scant 
available information regarding this specific cohort of patients may have been contributing to 
overestimation of the success of the two-step exchange as others have also noticed520.
As such, debate seems to have moved on definitively from whether one- or two-stage revision 
surgery is better, to which are the specific circumstances that dictate the best course of action. 
One of the most widely adopted algorithms for selecting circumstances-adapted treatment 
including the choice between one- and two-stage exchange is the one proposed by Zimmerli 
et al.247 in 2004. There is reiterated evidence that strictly following these patient selection 
algorithms seems to offer favorable results501,646,647. The best way to prove the actual 
significance of such selection criteria or even finding new ones would be to conduct 
unselecting randomized controlled trials and this work has already started648. Still, it is also 
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our belief that the two-stage approach is perhaps more forgiving and tolerant to error. We also 
believe that before embarking in one-stage exchange surgery one should gain experience in 
prosthetic joint infection surgery and management, understand the biofilm and its implications 
in optimal surgical but also medical/antibiotic therapy as well as assemble a multidisciplinary 
dedicated team.
A number of other unanswered questions demand continuing research. What is the optimal 
antibiotic regimen and is there a role for of resorbable local antibiotic delivery biomaterials 
in both DAIR and exchange surgery? When a two-stage approach is preferred, what is the 
optimal timing for reimplantation and what the proper serum or synovial tests to determine
it should be? Is there a role and what are the indications for antibiotic therapy after 
reimplantation surgery? 
Interpreting existing literature is also hampered by a widespread heterogeneity on reported 
clinical outcomes, the most important fact being different definitions of success. In an attempt
to overcome this issue and uniform outcome reports, an international consensus was 
developed with the goal to create a consensus multidimensional definition for success after PJI 
treatment649. The consensus definition of a successfully treated PJI is: (1) infection eradication, 
characterized by a healed wound without fistula, drainage, or pain, and no infection recurrence 
caused by the same organism strain; (2) no subsequent surgical intervention for infection 
after reimplantation surgery; and (3) no occurrence of PJI-related mortality649. Future research 
should comply as much as possible with this common ground in order to facilitate discussion 
and outcome comparison.
Still, we believe definition of successful PJI treatment must progress past looking solely at 
infection eradication or associated mortality. As knowledge evolves and the number of patients
where successful infection eradication becomes greater, other variables such as functional
outcomes after completion of treatment, re-revision rates for causes other than infection 
(i.e. instability, aseptic loosening, etc.) and health-related quality of life must be considered. 
Optimizing treatment costs are also an important matter especially in this era of worldwide 
financial concerns. In the future, one of the major challenges is to define the role of DAIR, 
one-stage or two-stage revision surgery in view of this perspective.
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